diff --git a/indication_paths.json b/indication_paths.json
index 8c8cacc13..de0051d44 100644
--- a/indication_paths.json
+++ b/indication_paths.json
@@ -102795,7 +102795,6 @@
     ]
   },
   {
-    "comments": "MESH:C000608451 may have been deprecated; no longer in MESH.",
     "directed": true,
     "graph": {
       "_id": "DB09087_MESH_D010437_1",
@@ -102807,24 +102806,14 @@
     },
     "links": [
       {
-        "key": "subclass of",
-        "source": "MESH:D000534",
-        "target": "MESH:D000891"
-      },
-      {
-        "key": "subclass of",
+        "key": "negatively regulates",
         "source": "MESH:D000534",
-        "target": "MESH:D001252"
-      },
-      {
-        "key": "negatively correlated with",
-        "source": "MESH:D000891",
         "target": "GO:0006954"
       },
       {
-        "key": "negatively correlated with",
-        "source": "MESH:D001252",
-        "target": "MESH:D005744"
+        "key": "negatively regulates",
+        "source": "MESH:D000534",
+        "target": "GO:0001696"
       },
       {
         "key": "positively correlated with",
@@ -102833,7 +102822,7 @@
       },
       {
         "key": "positively correlated with",
-        "source": "MESH:D005744",
+        "source": "GO:0001696",
         "target": "MESH:D010437"
       }
     ],
@@ -102848,19 +102837,9 @@
         "name": "alum"
       },
       {
-        "id": "MESH:D000891",
-        "label": "ChemicalSubstance",
-        "name": "Anti-Infective Agents, Local"
-      },
-      {
-        "id": "MESH:D001252",
-        "label": "ChemicalSubstance",
-        "name": "Astringents"
-      },
-      {
-        "id": "MESH:D005744",
-        "label": "ChemicalSubstance",
-        "name": "Gastric Acid"
+        "id": "GO:0001696",
+        "label": "BiologicalProcess",
+        "name": "gastric acid secretion"
       },
       {
         "id": "GO:0006954",
@@ -102879,7 +102858,7 @@
     ]
   },
   {
-    "comments": "MESH:C000608451 may have been deprecated; no longer in MESH. The disease is denotated as Indigestion in the original file before curation. Note that the majority of cases no cause can be attributed to leading to the disease. When a cause can indeed be determined, the majority of cases will be due to gastroesophageal reflux and gastritis (https://en.wikipedia.org/wiki/Indigestion#Cause).",
+    "comment": "The disease is also known as Indigestion as per in the original file before curation. Note that in the majority of cases no cause can be attributed to leading to the disease. When a cause can indeed be determined, the majority of cases will be due to gastroesophageal reflux and gastritis (https://en.wikipedia.org/wiki/Indigestion#Cause).",
     "directed": true,
     "graph": {
       "_id": "DB09087_MESH_D004415_1",
@@ -102891,24 +102870,14 @@
     },
     "links": [
       {
-        "key": "subclass of",
-        "source": "MESH:D000534",
-        "target": "MESH:D000891"
-      },
-      {
-        "key": "subclass of",
+        "key": "negatively regulates",
         "source": "MESH:D000534",
-        "target": "MESH:D001252"
-      },
-      {
-        "key": "negatively correlated with",
-        "source": "MESH:D000891",
         "target": "GO:0006954"
       },
       {
-        "key": "negatively correlated with",
-        "source": "MESH:D001252",
-        "target": "MESH:D005744"
+        "key": "negatively regulates",
+        "source": "MESH:D000534",
+        "target": "GO:0001696"
       },
       {
         "key": "positively correlated with",
@@ -102917,16 +102886,16 @@
       },
       {
         "key": "positively correlated with",
-        "source": "MESH:D005744",
+        "source": "GO:0001696",
         "target": "HP:0002020"
       },
       {
-        "key": "positively correlated with",
+        "key": "manifestation of",
         "source": "HP:0002020",
         "target": "MESH:D004415"
       },
       {
-        "key": "positively correlated with",
+        "key": "manifestation of",
         "source": "HP:0005263",
         "target": "MESH:D004415"
       }
@@ -102942,19 +102911,9 @@
         "name": "alum"
       },
       {
-        "id": "MESH:D000891",
-        "label": "ChemicalSubstance",
-        "name": "Anti-Infective Agents, Local"
-      },
-      {
-        "id": "MESH:D001252",
-        "label": "ChemicalSubstance",
-        "name": "Astringents"
-      },
-      {
-        "id": "MESH:D005744",
-        "label": "ChemicalSubstance",
-        "name": "Gastric Acid"
+        "id": "GO:0001696",
+        "label": "BiologicalProcess",
+        "name": "gastric acid secretion"
       },
       {
         "id": "HP:0005263",
@@ -103131,7 +103090,7 @@
     ]
   },
   {
-    "comments": "Esomeprazole is the s-isomer of Omeprazole, both are a proton pump inhibitor class of drug and the mechanism of action for both is similar. Weve annotated the path for the S isomer only as it seems this isomer is metabolized more slowly than omeprazole and therefore it will act for longer and more effectively (https://onlinelibrary.wiley.com/doi/pdf/10.1046/j.1365-2036.17.s1.1.x).",
+    "comment": "Esomeprazole is the s-isomer of Omeprazole, both are a proton pump inhibitor class of drug and the mechanism of action for both is similar. Weve annotated the path for the S isomer only as it seems this isomer is metabolized more slowly than omeprazole and therefore it will act for longer and more effectively (https://onlinelibrary.wiley.com/doi/pdf/10.1046/j.1365-2036.17.s1.1.x).",
     "directed": true,
     "graph": {
       "_id": "DB00736_MESH_D005764_1",
@@ -103218,7 +103177,7 @@
     ]
   },
   {
-    "comments": "Esomeprazole is the s-isomer of Omeprazole, both are a proton pump inhibitor class of drug and the mechanism of action for both is similar. Weve annotated the path for the S isomer only as it seems this isomer is metabolized more slowly than omeprazole and therefore it will act for longer and more effectively (https://onlinelibrary.wiley.com/doi/pdf/10.1046/j.1365-2036.17.s1.1.x). This disease is denoted as Peptic reflux disease in the original file.",
+    "comment": "Esomeprazole is the s-isomer of Omeprazole, both are a proton pump inhibitor class of drug and the mechanism of action for both is similar. Weve annotated the path for the S isomer only as it seems this isomer is metabolized more slowly than omeprazole and therefore it will act for longer and more effectively (https://onlinelibrary.wiley.com/doi/pdf/10.1046/j.1365-2036.17.s1.1.x). This disease is denoted as Peptic reflux disease in the original file.",
     "directed": true,
     "graph": {
       "_id": "DB00736_MESH_D004942_1",
@@ -103255,7 +103214,7 @@
         "target": "HP:0002020"
       },
       {
-        "key": "positively correlated with",
+        "key": "manifestation of",
         "source": "HP:0004791",
         "target": "MESH:D004942"
       },
@@ -103312,7 +103271,7 @@
     ]
   },
   {
-    "comments": "Esomeprazole is the s-isomer of Omeprazole, both are a proton pump inhibitor class of drug and the mechanism of action for both is similar. Weve annotated the path for the S isomer only as it seems this isomer is metabolized more slowly than omeprazole and therefore it will act for longer and more effectively (https://onlinelibrary.wiley.com/doi/pdf/10.1046/j.1365-2036.17.s1.1.x). This disease is denoted as Peptic reflux disease in the original file.",
+    "comment": "Esomeprazole is the s-isomer of Omeprazole, both are a proton pump inhibitor class of drug and the mechanism of action for both is similar. Weve annotated the path for the S isomer only as it seems this isomer is metabolized more slowly than omeprazole and therefore it will act for longer and more effectively (https://onlinelibrary.wiley.com/doi/pdf/10.1046/j.1365-2036.17.s1.1.x). This disease is denoted as Peptic reflux disease in the original file.",
     "directed": true,
     "graph": {
       "_id": "DB00736_MESH_D015043_1",
@@ -103349,12 +103308,12 @@
         "target": "HP:0002588"
       },
       {
-        "key": "positively correlated with",
+        "key": "manifestation of",
         "source": "HP:0002588",
         "target": "MESH:D015043"
       },
       {
-        "key": "positively correlated with",
+        "key": "manifestation of",
         "source": "HP:0004398",
         "target": "MESH:D015043"
       }
@@ -103408,7 +103367,7 @@
     ]
   },
   {
-    "comments": "Esomeprazole is the s-isomer of Omeprazole, both are a proton pump inhibitor class of drug and the mechanism of action for both is similar. Weve annotated the path for the S isomer only as it seems this isomer is metabolized more slowly than omeprazole and therefore it will act for longer and more effectively (https://onlinelibrary.wiley.com/doi/pdf/10.1046/j.1365-2036.17.s1.1.x). This disease is denoted as Peptic reflux disease in the original file.",
+    "comment": "Esomeprazole is the s-isomer of Omeprazole, both are a proton pump inhibitor class of drug and the mechanism of action for both is similar. Weve annotated the path for the S isomer only as it seems this isomer is metabolized more slowly than omeprazole and therefore it will act for longer and more effectively (https://onlinelibrary.wiley.com/doi/pdf/10.1046/j.1365-2036.17.s1.1.x). This disease is denoted as Peptic reflux disease in the original file.",
     "directed": true,
     "graph": {
       "_id": "DB00736_MESH_D010437_1",
@@ -103471,11 +103430,7 @@
     "reference": [
       "https://go.drugbank.com/drugs/DB00736#mechanism-of-action",
       "https://en.wikipedia.org/wiki/Esomeprazole",
-      "https://en.wikipedia.org/wiki/Omeprazole#Mechanism_of_action",
-      "https://en.wikipedia.org/wiki/Esophagitis#Causes",
-      "https://en.wikipedia.org/wiki/Esophagitis#Medications",
-      "https://en.wikipedia.org/wiki/Zollinger%E2%80%93Ellison_syndrome#Treatment",
-      "https://en.wikipedia.org/wiki/Zollinger%E2%80%93Ellison_syndrome#Pathophysiology"
+      "https://en.wikipedia.org/wiki/Omeprazole#Mechanism_of_action"
     ]
   },
   {
@@ -103564,7 +103519,7 @@
     ]
   },
   {
-    "comments": "The disease is denoted as Sore throat symptom in the original file.",
+    "comment": "The disease is also known as Sore throat symptom as per the original file.",
     "directed": true,
     "graph": {
       "_id": "DB06742_MESH_D010612_1",
@@ -103576,34 +103531,29 @@
     },
     "links": [
       {
-        "key": "increases abundance of",
+        "key": "negatively regulates",
         "source": "MESH:D000551",
-        "target": "MESH:D011663"
-      },
-      {
-        "key": "produced by",
-        "source": "MESH:D011663",
-        "target": "MESH:D056809"
+        "target": "GO:0038060"
       },
       {
-        "key": "part of",
-        "source": "MESH:D056809",
-        "target": "UBERON:0000065"
+        "key": "positively correlated with",
+        "source": "GO:0038060",
+        "target": "GO:0006954"
       },
       {
-        "key": "location of",
-        "source": "UBERON:0000065",
-        "target": "MESH:D010612"
+        "key": "positively correlated with",
+        "source": "GO:0006954",
+        "target": "HP:0033050"
       },
       {
         "key": "negatively regulates",
         "source": "MESH:D000551",
-        "target": "GO:0038060"
+        "target": "Pfam:PF06512"
       },
       {
         "key": "positively correlated with",
-        "source": "GO:0038060",
-        "target": "MESH:D007249"
+        "source": "Pfam:PF06512",
+        "target": "GO:0006954"
       },
       {
         "key": "increases abundance of",
@@ -103620,33 +103570,18 @@
         "source": "HP:0031602",
         "target": "HP:0033050"
       },
-      {
-        "key": "negatively regulates",
-        "source": "MESH:D000551",
-        "target": "Pfam:PF06512"
-      },
       {
         "key": "positively correlated with",
         "source": "Pfam:PF06512",
-        "target": "MESH:D010146"
-      },
-      {
-        "key": "positively correlated with",
-        "source": "Pfam:PF06512",
-        "target": "MESH:D007249"
-      },
-      {
-        "key": "positively correlated with",
-        "source": "MESH:D010146",
-        "target": "HP:0033050"
+        "target": "HP:0012531"
       },
       {
         "key": "positively correlated with",
-        "source": "MESH:D007249",
+        "source": "HP:0012531",
         "target": "HP:0033050"
       },
       {
-        "key": "positively correlated with",
+        "key": "manifestation of",
         "source": "HP:0033050",
         "target": "MESH:D010612"
       }
@@ -103658,29 +103593,14 @@
         "label": "Drug",
         "name": "ambroxol"
       },
-      {
-        "id": "MESH:D011663",
-        "label": "ChemicalSubstance",
-        "name": "Pulmonary Surfactants"
-      },
-      {
-        "id": "MESH:D056809",
-        "label": "Cell",
-        "name": "Alveolar Epithelial Cells"
-      },
-      {
-        "id": "UBERON:0000065",
-        "label": "GrossAnatomicalStructure",
-        "name": "respiratory tract"
-      },
       {
         "id": "GO:0038060",
         "label": "BiologicalProcess",
         "name": "nitric oxide-cGMP-mediated signaling pathway"
       },
       {
-        "id": "MESH:D010146",
-        "label": "BiologicalProcess",
+        "id": "HP:0012531",
+        "label": "PhenotypicFeature",
         "name": "Pain"
       },
       {
@@ -103699,13 +103619,13 @@
         "name": "Sodium ion transport-associated"
       },
       {
-        "id": "MESH:D007249",
-        "label": "PhenotypicFeature",
-        "name": "Inflammation"
+        "id": "GO:0006954",
+        "label": "BiologicalProcess",
+        "name": "inflammatory response"
       },
       {
         "id": "HP:0033050",
-        "label": "BiologicalProcess",
+        "label": "PhenotypicFeature",
         "name": "Pharyngalgia"
       },
       {
@@ -103722,7 +103642,7 @@
     ]
   },
   {
-    "comments": "Tolvaptan is also known as aquaretic (https://en.wikipedia.org/wiki/Aquaretic). Note that hyponatremia corresponds to the state where water content is relatively large for the sodium content available (https://pubmed.ncbi.nlm.nih.gov/19322975/), which is possibly due to increased water reabsorption. There are different types of hyponatremia, and medications like tolvaptan should only be used in those patients with high volume or normal volume hyponatremia (https://en.wikipedia.org/wiki/Hyponatremia#Medications).",
+    "comment": "Tolvaptan is also known as aquaretic (https://en.wikipedia.org/wiki/Aquaretic). Note that hyponatremia corresponds to the state where water content is relatively large for the sodium content available (https://pubmed.ncbi.nlm.nih.gov/19322975/), which is possibly due to increased water reabsorption. There are different types of hyponatremia, and medications like tolvaptan should only be used in those patients with high volume or normal volume hyponatremia (https://en.wikipedia.org/wiki/Hyponatremia#Medications).",
     "directed": true,
     "graph": {
       "_id": "DB06212_MESH_D007010_1",
@@ -103789,7 +103709,7 @@
     ]
   },
   {
-    "comments": "This disease is denoted as Syndrome of inappropriate vasopressin secretion in the original file. Tolvaptan is also known as aquaretic (https://en.wikipedia.org/wiki/Aquaretic). Note that hyponatremia corresponds to the state where water content is relatively large for the sodium content available (https://pubmed.ncbi.nlm.nih.gov/19322975/), which is possibly due to increased water reabsorption.",
+    "comment": "This disease is also known as Syndrome of inappropriate vasopressin secretion as per the original file. Tolvaptan is also known as aquaretic (https://en.wikipedia.org/wiki/Aquaretic). Note that hyponatremia corresponds to the state where water content is relatively large for the sodium content available (https://pubmed.ncbi.nlm.nih.gov/19322975/), which is possibly due to increased water reabsorption.",
     "directed": true,
     "graph": {
       "_id": "DB06212_MESH_D007177_1",
@@ -103860,7 +103780,7 @@
     ]
   },
   {
-    "comments": "This disease is denoted as Polycystic kidney disease adult type in the original file. Tolvaptan is also known as aquaretic (https://en.wikipedia.org/wiki/Aquaretic). Note that hyponatremia corresponds to the state where water content is relatively large for the sodium content available (https://pubmed.ncbi.nlm.nih.gov/19322975/), which is possibly due to increased water reabsorption.",
+    "comment": "This disease is also known as Polycystic kidney disease adult type as per the original file. Tolvaptan is also known as aquaretic (https://en.wikipedia.org/wiki/Aquaretic). Note that hyponatremia corresponds to the state where water content is relatively large for the sodium content available (https://pubmed.ncbi.nlm.nih.gov/19322975/), which is possibly due to increased water reabsorption.",
     "directed": true,
     "graph": {
       "_id": "DB06212_MESH_D016891_1",
@@ -103897,7 +103817,7 @@
         "target": "HP:0000107"
       },
       {
-        "key": "positively correlated with",
+        "key": "manifestation of",
         "source": "HP:0000107",
         "target": "MESH:D016891"
       },
@@ -104019,7 +103939,7 @@
     ]
   },
   {
-    "comments": "In Parkinson's disease, there is imbalance between levels of acetylcholine and dopamine, where increased levels of acetylcholine and degeneration of dopaminergic pathways are observed. Therefore, muscarinic antagonists such as biperiden block central cholinergic activity and balancing out neurotransmitters in the brain (https://en.wikipedia.org/wiki/Muscarinic_antagonist#Effects). Anticholinergic drugs may also be prescribed to improve bladder dysfunction (https://pubmed.ncbi.nlm.nih.gov/20370804/).",
+    "comment": "In Parkinson's disease, there is imbalance between levels of acetylcholine and dopamine, where increased levels of acetylcholine and degeneration of dopaminergic pathways are observed. Therefore, muscarinic antagonists such as biperiden block central cholinergic activity and balancing out neurotransmitters in the brain (https://en.wikipedia.org/wiki/Muscarinic_antagonist#Effects). Anticholinergic drugs may also be prescribed to improve bladder dysfunction (https://pubmed.ncbi.nlm.nih.gov/20370804/).",
     "directed": true,
     "graph": {
       "_id": "DB00810_MESH_D010300_1",
@@ -104043,6 +103963,11 @@
       {
         "key": "positively correlated with",
         "source": "GO:0007271",
+        "target": "HP:0100022"
+      },
+      {
+        "key": "manifestation of",
+        "source": "HP:0100022",
         "target": "MESH:D010300"
       }
     ],
@@ -104066,6 +103991,11 @@
         "label": "BiologicalProcess",
         "name": "synaptic transmission, cholinergic"
       },
+      {
+        "id": "HP:0100022",
+        "label": "PhenotypicFeature",
+        "name": "Abnormality of movement"
+      },
       {
         "id": "MESH:D010300",
         "label": "Disease",
@@ -104077,7 +104007,7 @@
     ]
   },
   {
-    "comments": "The disease is denoted as Postencephalitic parkinsonism in the original file. This disease is believed to be caused by a viral infection, leading to clinical parkinsonism (https://en.wikipedia.org/wiki/Postencephalitic_parkinsonism) and anti-Parkinson drugs may be helpful in treating the symptoms (https://en.wikipedia.org/wiki/Encephalitis_lethargica). For example, muscarinic antagonists can allow dopamine levels to rebalance, which can help relieve some Parkinsonian symptoms e.g. involuntary movements. Anticholinergic drugs may also be prescribed to improve bladder dysfunction (https://pubmed.ncbi.nlm.nih.gov/20370804/).",
+    "comment": "The disease is denoted as Postencephalitic parkinsonism in the original file. This disease is believed to be caused by a viral infection, leading to clinical parkinsonism (https://en.wikipedia.org/wiki/Postencephalitic_parkinsonism) and anti-Parkinson drugs may be helpful in treating the symptoms (https://en.wikipedia.org/wiki/Encephalitis_lethargica). For example, muscarinic antagonists can allow dopamine levels to rebalance, which can help relieve some Parkinsonian symptoms e.g. involuntary movements. Anticholinergic drugs may also be prescribed to improve bladder dysfunction (https://pubmed.ncbi.nlm.nih.gov/20370804/).",
     "directed": true,
     "graph": {
       "_id": "DB00810_MESH_D010301_1",
@@ -104104,7 +104034,7 @@
         "target": "HP:0100022"
       },
       {
-        "key": "manifestation of",
+        "key": "positively correlated with",
         "source": "HP:0100022",
         "target": "HP:0001300"
       },
@@ -104155,7 +104085,7 @@
     ]
   },
   {
-    "comments": "The disease is denoted as Parkinsonism in the original file. Muscarinic antagonists can allow dopamine levels to rebalance, which can help relieve some Parkinsonian symptoms e.g. involuntary movements. Anticholinergic drugs may also be prescribed to improve bladder dysfunction (https://pubmed.ncbi.nlm.nih.gov/20370804/).",
+    "comment": "The disease is also known as Parkinsonism as per the original file. Muscarinic antagonists can allow dopamine levels to rebalance, which can help relieve some Parkinsonian symptoms e.g. involuntary movements. Anticholinergic drugs may also be prescribed to improve bladder dysfunction (https://pubmed.ncbi.nlm.nih.gov/20370804/).",
     "directed": true,
     "graph": {
       "_id": "DB00810_MESH_D020734_1",
@@ -104224,7 +104154,7 @@
     ]
   },
   {
-    "comments": "The disease is denoted as Extrapyramidal disease in the original file.",
+    "comment": "The disease is also known as Extrapyramidal disease as per the original file.",
     "directed": true,
     "graph": {
       "_id": "DB00810_MESH_D001480_1",
@@ -110495,7 +110425,7 @@
     ]
   },
   {
-    "comments": "The drug is no longer FDA approved (https://en.wikipedia.org/wiki/Tocolytic#Types_of_agents).",
+    "comment": "The drug is no longer FDA approved (https://en.wikipedia.org/wiki/Tocolytic#Types_of_agents).",
     "directed": true,
     "graph": {
       "_id": "DB00867_MESH_D007752_1",
@@ -110973,7 +110903,7 @@
     ]
   },
   {
-    "comments": "There seems to be no evidence linking sulfacetamide as treatment for Amebic infection. Sulfacetamide is an antibacterial type of drug (https://www.kegg.jp/entry/D05947) and it seems the drug has some anti-inflammatory role. Since the disease could lead to inflammation and ulceration of the colon perhaps there could be an anti-inflammation hypothesis but the drug is mainly available as eye drops and lotions (https://en.wikipedia.org/wiki/Sulfacetamide#Available_forms), and therefore unavailable to treat the intestinal tract in such formats. Note there are few amoeba species that may cause skin or eye issues (https://en.wikipedia.org/wiki/Acanthamoeba_keratitis), in which case sulfacetamide could potentially be an indication, albeit no evidence to prove this assumption has been found in databases or literature.",
+    "comment": "There seems to be no evidence linking sulfacetamide as treatment for Amebic infection. Sulfacetamide is an antibacterial type of drug (https://www.kegg.jp/entry/D05947) and it seems the drug has some anti-inflammatory role. Since the disease could lead to inflammation and ulceration of the colon perhaps there could be an anti-inflammation hypothesis but the drug is mainly available as eye drops and lotions (https://en.wikipedia.org/wiki/Sulfacetamide#Available_forms), and therefore unavailable to treat the intestinal tract in such formats. Note there are few amoeba species that may cause skin or eye issues (https://en.wikipedia.org/wiki/Acanthamoeba_keratitis), in which case sulfacetamide could potentially be an indication, albeit no evidence to prove this assumption has been found in databases or literature.",
     "directed": true,
     "graph": {
       "_id": "DB00634_MESH_D000562_1",
@@ -110985,13 +110915,13 @@
     },
     "links": [
       {
-        "key": "decreases activity of",
+        "key": "negatively regulates",
         "source": "MESH:D013409",
-        "target": "MESH:D007249"
+        "target": "GO:0006954"
       },
       {
-        "key": "positively correlated with",
-        "source": "MESH:D007249",
+        "key": "caused by",
+        "source": "GO:0006954",
         "target": "MESH:D000562"
       }
     ],
@@ -111003,9 +110933,9 @@
         "name": "sulfacetamide"
       },
       {
-        "id": "MESH:D007249",
+        "id": "GO:0006954",
         "label": "BiologicalProcess",
-        "name": "Inflammation"
+        "name": "inflammatory response"
       },
       {
         "id": "MESH:D000562",
@@ -111018,7 +110948,7 @@
     ]
   },
   {
-    "comments": "The action of the drug on 5-HT2 receptors is of an inverse agonist (https://en.wikipedia.org/wiki/Inverse_agonist). The dopamine neurons are located in the mesolimbic dopaminergic system (BTO:0005591), which is a component pathway of the medial forebrain bundle (UBERON:0001910)(https://en.wikipedia.org/wiki/Medial_forebrain_bundle#Anatomy).",
+    "comment": "The action of the drug on 5-HT2 receptors is of an inverse agonist (https://en.wikipedia.org/wiki/Inverse_agonist). The dopamine neurons are located in the mesolimbic dopaminergic system (BTO:0005591), which is a component pathway of the medial forebrain bundle (UBERON:0001910)(https://en.wikipedia.org/wiki/Medial_forebrain_bundle#Anatomy).",
     "directed": true,
     "graph": {
       "_id": "DB08922_MESH_D012559_1",
@@ -111125,27 +111055,27 @@
         "target": "HP:0000741"
       },
       {
-        "key": "positively correlated with",
+        "key": "manifestation of",
         "source": "HP:0100543",
         "target": "MESH:D012559"
       },
       {
-        "key": "positively correlated with",
+        "key": "manifestation of",
         "source": "HP:0030213",
         "target": "MESH:D012559"
       },
       {
-        "key": "positively correlated with",
+        "key": "manifestation of",
         "source": "HP:0012154",
         "target": "MESH:D012559"
       },
       {
-        "key": "positively correlated with",
+        "key": "manifestation of",
         "source": "HP:0002465",
         "target": "MESH:D012559"
       },
       {
-        "key": "positively correlated with",
+        "key": "manifestation of",
         "source": "HP:0000741",
         "target": "MESH:D012559"
       },
@@ -114963,7 +114893,7 @@
     ]
   },
   {
-    "comments": "Disease is denoted Infection by Onchocerca volvulus in the original file.",
+    "comment": "Disease is also known as Infection by Onchocerca volvulus as per the original file.",
     "directed": true,
     "graph": {
       "_id": "DB00602_MESH_D009855_2",
@@ -114990,8 +114920,13 @@
         "target": "GO:0060081"
       },
       {
-        "key": "in taxon",
+        "key": "negatively regulates",
         "source": "GO:0060081",
+        "target": "GO:0099565"
+      },
+      {
+        "key": "in taxon",
+        "source": "GO:0099565",
         "target": "NCBITaxon:6282"
       },
       {
@@ -115022,6 +114957,11 @@
         "label": "BiologicalProcess",
         "name": "membrane hyperpolarization"
       },
+      {
+        "id": "GO:0099565",
+        "label": "BiologicalProcess",
+        "name": "chemical synaptic transmission, postsynaptic"
+      },
       {
         "id": "NCBITaxon:6282",
         "label": "OrganismTaxon",
@@ -115036,11 +114976,11 @@
     "reference": [
       "https://en.wikipedia.org/wiki/Ivermectin#Mechanism_of_action",
       "https://go.drugbank.com/drugs/DB00602#mechanism-of-action",
-      "https://en.wikipedia.org/wiki/Strongyloidiasis#Treatment"
+      "https://en.wikipedia.org/wiki/Onchocerciasis#Ivermectin"
     ]
   },
   {
-    "comments": "Disease is denoted Infection by Strongyloides in the original file.",
+    "comment": "Disease is denoted Infection by Strongyloides in the original file.",
     "directed": true,
     "graph": {
       "_id": "DB00602_MESH_D013322_1",
@@ -115067,8 +115007,13 @@
         "target": "GO:0060081"
       },
       {
-        "key": "in taxon",
+        "key": "negatively regulates",
         "source": "GO:0060081",
+        "target": "GO:0099565"
+      },
+      {
+        "key": "in taxon",
+        "source": "GO:0099565",
         "target": "NCBITaxon:6248"
       },
       {
@@ -115099,6 +115044,11 @@
         "label": "BiologicalProcess",
         "name": "membrane hyperpolarization"
       },
+      {
+        "id": "GO:0099565",
+        "label": "BiologicalProcess",
+        "name": "chemical synaptic transmission, postsynaptic"
+      },
       {
         "id": "NCBITaxon:6248",
         "label": "OrganismTaxon",
@@ -115117,7 +115067,7 @@
     ]
   },
   {
-    "comments": "Balsalazide is a prodrug and it releases mesalazine in the large intestine, the active site of ulcerative colitis (https://en.wikipedia.org/wiki/Balsalazide https://en.wikipedia.org/wiki/Mesalazine#Chemistry).",
+    "comment": "Balsalazide is a prodrug and it releases mesalazine in the large intestine, the active site of ulcerative colitis (https://en.wikipedia.org/wiki/Balsalazide https://en.wikipedia.org/wiki/Mesalazine#Chemistry).",
     "directed": true,
     "graph": {
       "_id": "DB01014_MESH_D003093_1",
@@ -115129,14 +115079,19 @@
     },
     "links": [
       {
-        "key": "produces",
+        "key": "has metabolite",
         "source": "MESH:C038637",
         "target": "MESH:D019804"
       },
       {
         "key": "decreases activity of",
         "source": "MESH:D019804",
-        "target": "MESH:D011451"
+        "target": "UniProt:P35354"
+      },
+      {
+        "key": "decreases activity of",
+        "source": "MESH:D019804",
+        "target": "UniProt:P23219"
       },
       {
         "key": "decreases activity of",
@@ -115161,7 +115116,7 @@
       {
         "key": "positively correlated with",
         "source": "GO:0007249",
-        "target": "MESH:D007249"
+        "target": "GO:0006954"
       },
       {
         "key": "decreases activity of",
@@ -115181,17 +115136,7 @@
       {
         "key": "positively correlated with",
         "source": "REACT:R-HSA-1169091",
-        "target": "MESH:D007249"
-      },
-      {
-        "key": "positively regulates",
-        "source": "UniProt:P37231",
-        "target": "GO:0060249"
-      },
-      {
-        "key": "located in",
-        "source": "GO:0060249",
-        "target": "UBERON:0001155"
+        "target": "GO:0006954"
       },
       {
         "key": "participates in",
@@ -115200,27 +115145,32 @@
       },
       {
         "key": "participates in",
-        "source": "MESH:D011451",
+        "source": "UniProt:P35354",
+        "target": "REACT:R-HSA-2162123"
+      },
+      {
+        "key": "participates in",
+        "source": "UniProt:P23219",
         "target": "REACT:R-HSA-2162123"
       },
       {
         "key": "positively correlated with",
         "source": "REACT:R-HSA-2162123",
-        "target": "MESH:D007249"
+        "target": "GO:0006954"
       },
       {
         "key": "positively correlated with",
         "source": "REACT:R-HSA-2142691",
-        "target": "MESH:D007249"
+        "target": "GO:0006954"
       },
       {
         "key": "located in",
-        "source": "MESH:D007249",
+        "source": "GO:0006954",
         "target": "UBERON:0001052"
       },
       {
         "key": "located in",
-        "source": "MESH:D007249",
+        "source": "GO:0006954",
         "target": "UBERON:0001155"
       },
       {
@@ -115243,13 +115193,18 @@
       },
       {
         "id": "MESH:D019804",
-        "label": "Drug",
+        "label": "ChemicalSubstance",
         "name": "Mesalamine"
       },
       {
-        "id": "MESH:D011451",
-        "label": "GeneFamily",
-        "name": "Prostaglandin-Endoperoxide Synthases"
+        "id": "UniProt:P23219",
+        "label": "Protein",
+        "name": "Prostaglandin G/H synthase 1"
+      },
+      {
+        "id": "UniProt:P35354",
+        "label": "Protein",
+        "name": "Prostaglandin G/H synthase 2"
       },
       {
         "id": "UniProt:P09917",
@@ -115276,11 +115231,6 @@
         "label": "BiologicalProcess",
         "name": "I-kappaB kinase/NF-kappaB signaling"
       },
-      {
-        "id": "GO:0060249",
-        "label": "BiologicalProcess",
-        "name": "anatomical structure homeostasis"
-      },
       {
         "id": "REACT:R-HSA-2142691",
         "label": "Pathway",
@@ -115297,9 +115247,9 @@
         "name": "Activation of NF-kappaB in B cells"
       },
       {
-        "id": "MESH:D007249",
+        "id": "GO:0006954",
         "label": "BiologicalProcess",
-        "name": "Inflammation"
+        "name": "inflammatory response"
       },
       {
         "id": "UBERON:0001052",
@@ -115513,7 +115463,7 @@
     ]
   },
   {
-    "comments": "Imatinib also modulates other protein targets and is an indication for other malignancies (https://en.wikipedia.org/wiki/Imatinib#Medical_uses).",
+    "comment": "Imatinib also modulates other protein targets and is an indication for other malignancies (https://en.wikipedia.org/wiki/Imatinib#Medical_uses).",
     "directed": true,
     "graph": {
       "_id": "DB00619_MESH_D015466_1",
@@ -115682,7 +115632,7 @@
     ]
   },
   {
-    "comments": "The disease is denoted Chronic eosinophilic leukemia in the original file. The malignancy is driven by FIP1L1-PDGFRA fusion genes (https://en.wikipedia.org/wiki/FIP1L1#FIP1L1-PDGFRA_fusion_genes).",
+    "comment": "The disease is also known as Chronic eosinophilic leukemia as per the original file. The malignancy is driven by FIP1L1-PDGFRA fusion genes (https://en.wikipedia.org/wiki/FIP1L1#FIP1L1-PDGFRA_fusion_genes).",
     "directed": true,
     "graph": {
       "_id": "DB00619_MESH_C580364_1",
@@ -115696,11 +115646,11 @@
       {
         "key": "decreases activity of",
         "source": "MESH:D000068877",
-        "target": "MESH:D017479"
+        "target": "UniProt:P16234"
       },
       {
         "key": "positively regulates",
-        "source": "MESH:D017479",
+        "source": "UniProt:P16234",
         "target": "GO:0048008"
       },
       {
@@ -115727,9 +115677,9 @@
         "name": "imatinib"
       },
       {
-        "id": "MESH:D017479",
-        "label": "GeneFamily",
-        "name": "Receptors, Platelet-Derived Growth Factor"
+        "id": "UniProt:P16234",
+        "label": "Protein",
+        "name": "Platelet-derived growth factor receptor alpha"
       },
       {
         "id": "GO:0048008",
@@ -115762,7 +115712,7 @@
     ]
   },
   {
-    "comments": "The disease is denoted Idiopathic hypereosinophilic syndrome in the original file. Treatment with imatinib is indicated for patients who have a tyrosine kinase fusion protein (https://en.wikipedia.org/wiki/Hypereosinophilic_syndrome#Diagnosis), a PDGFRA-FIP1L1 chimera, where PDGR is an oncogene (https://en.wikipedia.org/wiki/Oncogene#Classification).",
+    "comment": "The disease is also known as Idiopathic hypereosinophilic syndrome as per the original file. Treatment with imatinib is indicated for patients who have a PDGFRA-FIP1L1 chimera, where PDGR, a tyrosine kinase (https://en.wikipedia.org/wiki/Hypereosinophilic_syndrome#Diagnosis) and an oncogene (https://en.wikipedia.org/wiki/Oncogene#Classification) is fused with FIP1L1, giving rise to a PDGFRA-FIP1L1 chimera.",
     "directed": true,
     "graph": {
       "_id": "DB00619_MESH_D017681_1",
@@ -115776,11 +115726,6 @@
       {
         "key": "decreases activity of",
         "source": "MESH:D000068877",
-        "target": "MESH:D015514"
-      },
-      {
-        "key": "derives from",
-        "source": "MESH:D015514",
         "target": "UniProt:P16234"
       },
       {
@@ -115806,11 +115751,6 @@
         "label": "Drug",
         "name": "imatinib"
       },
-      {
-        "id": "MESH:D015514",
-        "label": "GeneFamily",
-        "name": "Oncogene Proteins, Fusion"
-      },
       {
         "id": "UniProt:P16234",
         "label": "Protein",
@@ -115840,7 +115780,7 @@
     ]
   },
   {
-    "comments": "The majority of Gastrointestinal stromal tumor patients have mutations on the KIT or PDGFRA genes (95% of all patients).",
+    "comment": "The majority of Gastrointestinal stromal tumor patients have mutations on the KIT or PDGFRA genes (95% of all patients).",
     "directed": true,
     "graph": {
       "_id": "DB00619_MESH_D046152_1",
@@ -115968,7 +115908,7 @@
     ]
   },
   {
-    "comments": "The majority of Dermatofibrosarcoma tumours have two genes fused due to a translocation involving the collagen gene (COL1A1) and platelet-derived growth factor (PDGF) genes.",
+    "comment": "The majority of dermatofibrosarcoma tumours have two genes fused due to a translocation involving the collagen gene (COL1A1) and the platelet-derived growth factor (PDGF). The latter can be further subdivided giving rise to PDGFA, for example, which is an oncogene.",
     "directed": true,
     "graph": {
       "_id": "DB00619_MESH_D018223_1",
@@ -115982,26 +115922,21 @@
       {
         "key": "decreases activity of",
         "source": "MESH:D000068877",
-        "target": "MESH:D050506"
-      },
-      {
-        "key": "derives from",
-        "source": "MESH:D050506",
-        "target": "MESH:D010982"
+        "target": "UniProt:P16234"
       },
       {
         "key": "positively regulates",
-        "source": "MESH:D010982",
+        "source": "UniProt:P16234",
         "target": "GO:0030154"
       },
       {
         "key": "positively regulates",
-        "source": "MESH:D010982",
+        "source": "UniProt:P16234",
         "target": "GO:0008283"
       },
       {
         "key": "positively regulates",
-        "source": "MESH:D010982",
+        "source": "UniProt:P16234",
         "target": "MESH:D002470"
       },
       {
@@ -116028,14 +115963,9 @@
         "name": "imatinib"
       },
       {
-        "id": "MESH:D050506",
-        "label": "GeneFamily",
-        "name": "Mutant Chimeric Proteins"
-      },
-      {
-        "id": "MESH:D010982",
-        "label": "GeneFamily",
-        "name": "Platelet-Derived Growth Factor"
+        "id": "UniProt:P16234",
+        "label": "Protein",
+        "name": "Platelet-derived growth factor receptor alpha"
       },
       {
         "id": "GO:0030154",
@@ -116184,11 +116114,11 @@
       {
         "key": "decreases activity of",
         "source": "MESH:D014700",
-        "target": "MESH:D020746"
+        "target": "UniProt:Q13936"
       },
       {
         "key": "positively regulates",
-        "source": "MESH:D020746",
+        "source": "UniProt:Q13936",
         "target": "GO:0060402"
       },
       {
@@ -116202,7 +116132,7 @@
         "target": "HP:0033533"
       },
       {
-        "key": "positively correlated with",
+        "key": "affects risk for",
         "source": "HP:0033533",
         "target": "HP:0032263"
       },
@@ -116220,9 +116150,9 @@
         "name": "verapamil"
       },
       {
-        "id": "MESH:D020746",
-        "label": "GeneFamily",
-        "name": "Calcium Channels, L-Type"
+        "id": "UniProt:Q13936",
+        "label": "Protein",
+        "name": "Voltage-dependent L-type calcium channel subunit alpha-1C"
       },
       {
         "id": "GO:0060402",
@@ -116271,21 +116201,21 @@
       {
         "key": "decreases activity of",
         "source": "MESH:D014700",
-        "target": "MESH:D020746"
+        "target": "UniProt:Q13936"
       },
       {
         "key": "positively regulates",
-        "source": "MESH:D020746",
+        "source": "UniProt:Q13936",
         "target": "GO:0061337"
       },
       {
         "key": "positively correlated with",
         "source": "GO:0061337",
-        "target": "MESH:D006339"
+        "target": "GO:0060047"
       },
       {
         "key": "positively correlated with",
-        "source": "MESH:D006339",
+        "source": "GO:0060047",
         "target": "HP:0001692"
       },
       {
@@ -116302,9 +116232,9 @@
         "name": "verapamil"
       },
       {
-        "id": "MESH:D020746",
-        "label": "GeneFamily",
-        "name": "Calcium Channels, L-Type"
+        "id": "UniProt:Q13936",
+        "label": "Protein",
+        "name": "Voltage-dependent L-type calcium channel subunit alpha-1C"
       },
       {
         "id": "GO:0061337",
@@ -116312,9 +116242,9 @@
         "name": "cardiac conduction"
       },
       {
-        "id": "MESH:D006339",
+        "id": "GO:0060047",
         "label": "BiologicalProcess",
-        "name": "Heart Rate"
+        "name": "heart contraction"
       },
       {
         "id": "HP:0001692",
@@ -116349,11 +116279,11 @@
       {
         "key": "decreases activity of",
         "source": "MESH:D014700",
-        "target": "MESH:D020746"
+        "target": "UniProt:Q13936"
       },
       {
         "key": "positively regulates",
-        "source": "MESH:D020746",
+        "source": "UniProt:Q13936",
         "target": "GO:0060402"
       },
       {
@@ -116364,11 +116294,11 @@
       {
         "key": "positively correlated with",
         "source": "GO:0042310",
-        "target": "MESH:D017202"
+        "target": "HP:0033401"
       },
       {
-        "key": "positively correlated with",
-        "source": "MESH:D017202",
+        "key": "manifestation of",
+        "source": "HP:0033401",
         "target": "MESH:D054058"
       }
     ],
@@ -116380,9 +116310,9 @@
         "name": "verapamil"
       },
       {
-        "id": "MESH:D020746",
-        "label": "GeneFamily",
-        "name": "Calcium Channels, L-Type"
+        "id": "UniProt:Q13936",
+        "label": "Protein",
+        "name": "Voltage-dependent L-type calcium channel subunit alpha-1C"
       },
       {
         "id": "GO:0060402",
@@ -116395,9 +116325,9 @@
         "name": "vasoconstriction"
       },
       {
-        "id": "MESH:D017202",
+        "id": "HP:0033401",
         "label": "PhenotypicFeature",
-        "name": "Myocardial Ischemia"
+        "name": "Tissue ischemia"
       },
       {
         "id": "MESH:D054058",
@@ -116426,11 +116356,11 @@
       {
         "key": "decreases activity of",
         "source": "MESH:D014700",
-        "target": "MESH:D020746"
+        "target": "UniProt:Q13936"
       },
       {
         "key": "positively regulates",
-        "source": "MESH:D020746",
+        "source": "UniProt:Q13936",
         "target": "GO:0060402"
       },
       {
@@ -116441,11 +116371,11 @@
       {
         "key": "positively correlated with",
         "source": "GO:0042310",
-        "target": "MESH:D017202"
+        "target": "HP:0033401"
       },
       {
-        "key": "positively correlated with",
-        "source": "MESH:D017202",
+        "key": "manifestation of",
+        "source": "HP:0033401",
         "target": "MESH:D000787"
       }
     ],
@@ -116457,9 +116387,9 @@
         "name": "verapamil"
       },
       {
-        "id": "MESH:D020746",
-        "label": "GeneFamily",
-        "name": "Calcium Channels, L-Type"
+        "id": "UniProt:Q13936",
+        "label": "Protein",
+        "name": "Voltage-dependent L-type calcium channel subunit alpha-1C"
       },
       {
         "id": "GO:0060402",
@@ -116472,9 +116402,9 @@
         "name": "vasoconstriction"
       },
       {
-        "id": "MESH:D017202",
+        "id": "HP:0033401",
         "label": "PhenotypicFeature",
-        "name": "Myocardial Ischemia"
+        "name": "Tissue ischemia"
       },
       {
         "id": "MESH:D000787",
@@ -116491,7 +116421,7 @@
     ]
   },
   {
-    "comments": "The disease is denoted as Prinzmetal angina in the original file.",
+    "comment": "The disease is also known as Prinzmetal angina as per the original file.",
     "directed": true,
     "graph": {
       "_id": "DB00661_MESH_D000788_1",
@@ -116505,11 +116435,11 @@
       {
         "key": "decreases activity of",
         "source": "MESH:D014700",
-        "target": "MESH:D020746"
+        "target": "UniProt:Q13936"
       },
       {
         "key": "positively regulates",
-        "source": "MESH:D020746",
+        "source": "UniProt:Q13936",
         "target": "GO:0060402"
       },
       {
@@ -116520,11 +116450,11 @@
       {
         "key": "positively correlated with",
         "source": "GO:0042310",
-        "target": "MESH:D017202"
+        "target": "HP:0033401"
       },
       {
-        "key": "positively correlated with",
-        "source": "MESH:D017202",
+        "key": "manifestation of",
+        "source": "HP:0033401",
         "target": "MESH:D000788"
       }
     ],
@@ -116536,9 +116466,9 @@
         "name": "verapamil"
       },
       {
-        "id": "MESH:D020746",
-        "label": "GeneFamily",
-        "name": "Calcium Channels, L-Type"
+        "id": "UniProt:Q13936",
+        "label": "Protein",
+        "name": "Voltage-dependent L-type calcium channel subunit alpha-1C"
       },
       {
         "id": "GO:0060402",
@@ -116551,9 +116481,9 @@
         "name": "vasoconstriction"
       },
       {
-        "id": "MESH:D017202",
+        "id": "HP:0033401",
         "label": "PhenotypicFeature",
-        "name": "Myocardial Ischemia"
+        "name": "Tissue ischemia"
       },
       {
         "id": "MESH:D000788",
@@ -220835,5 +220765,1550 @@
       "https://en.wikipedia.org/wiki/Factor_VIII",
       "https://en.wikipedia.org/wiki/Coagulation"
     ]
+  },
+  {
+    "comment": "Withdrawn. Tridihexethyl is no longer available in the US market.",
+    "directed": true,
+    "graph": {
+      "_id": "DB00505_MESH_D010437_1",
+      "disease": "Peptic ulcer",
+      "disease_mesh": "MESH:D010437",
+      "drug": "Tridihexethyl",
+      "drug_mesh": "MESH:C005386",
+      "drugbank": "DB:DB00505"
+    },
+    "links": [
+      {
+        "key": "decreases activity of",
+        "source": "MESH:C005386",
+        "target": "UniProt:P20309"
+      },
+      {
+        "key": "participates in",
+        "source": "UniProt:P20309",
+        "target": "GO:0001699"
+      },
+      {
+        "key": "increases abundance of",
+        "source": "GO:0001699",
+        "target": "MESH:D005744"
+      },
+      {
+        "key": "positively regulates",
+        "source": "MESH:D005744",
+        "target": "InterPro:IPR034162"
+      },
+      {
+        "key": "positively correlated with",
+        "source": "InterPro:IPR034162",
+        "target": "MESH:D010437"
+      }
+    ],
+    "multigraph": true,
+    "nodes": [
+      {
+        "id": "MESH:C005386",
+        "label": "Drug",
+        "name": "Tridihexethyl"
+      },
+      {
+        "id": "UniProt:P20309",
+        "label": "Protein",
+        "name": "Muscarinic acetylcholine receptor M3"
+      },
+      {
+        "id": "GO:0001699",
+        "label": "BiologicalProcess",
+        "name": "Acetylcholine-induced gastric acid secretion"
+      },
+      {
+        "id": "MESH:D005744",
+        "label": "ChemicalSubstance",
+        "name": "Gastric acid"
+      },
+      {
+        "id": "InterPro:IPR034162",
+        "label": "GeneFamily",
+        "name": "Pepsin catalytic domain"
+      },
+      {
+        "id": "MESH:D010437",
+        "label": "Disease",
+        "name": "Peptic ulcer"
+      }
+    ],
+    "reference": [
+      "https://go.drugbank.com/drugs/DB00505"
+    ]
+  },
+  {
+    "comment": "Withdrawn. Tridihexethyl is no longer available in the US market.",
+    "directed": true,
+    "graph": {
+      "_id": "DB00505_MESH_D013276_1",
+      "disease": "Gastric ulcer",
+      "disease_mesh": "MESH:D013276",
+      "drug": "Tridihexethyl",
+      "drug_mesh": "MESH:C005386",
+      "drugbank": "DB:DB00505"
+    },
+    "links": [
+      {
+        "key": "decreases activity of",
+        "source": "MESH:C005386",
+        "target": "UniProt:P20309"
+      },
+      {
+        "key": "participates in",
+        "source": "UniProt:P20309",
+        "target": "GO:0001699"
+      },
+      {
+        "key": "increases abundance of",
+        "source": "GO:0001699",
+        "target": "MESH:D005744"
+      },
+      {
+        "key": "positively regulates",
+        "source": "MESH:D005744",
+        "target": "InterPro:IPR034162"
+      },
+      {
+        "key": "positively correlated with",
+        "source": "InterPro:IPR034162",
+        "target": "MESH:D013276"
+      }
+    ],
+    "multigraph": true,
+    "nodes": [
+      {
+        "id": "MESH:C005386",
+        "label": "Drug",
+        "name": "Tridihexethyl"
+      },
+      {
+        "id": "UniProt:P20309",
+        "label": "Protein",
+        "name": "Muscarinic acetylcholine receptor M3"
+      },
+      {
+        "id": "GO:0001699",
+        "label": "BiologicalProcess",
+        "name": "Acetylcholine-induced gastric acid secretion"
+      },
+      {
+        "id": "MESH:D005744",
+        "label": "ChemicalSubstance",
+        "name": "Gastric acid"
+      },
+      {
+        "id": "InterPro:IPR034162",
+        "label": "GeneFamily",
+        "name": "Pepsin catalytic domain"
+      },
+      {
+        "id": "MESH:D013276",
+        "label": "Disease",
+        "name": "Gastric ulcer"
+      }
+    ],
+    "reference": [
+      "https://go.drugbank.com/drugs/DB00505"
+    ]
+  },
+  {
+    "directed": true,
+    "graph": {
+      "_id": "DB00733_MESH_D062025_1",
+      "disease": "Organophosphate poisoning",
+      "disease_mesh": "MESH:D062025",
+      "drug": "pralidoxime",
+      "drug_mesh": "MESH:C028797",
+      "drugbank": "DB:DB00733"
+    },
+    "links": [
+      {
+        "key": "increases activity of",
+        "source": "MESH:C028797",
+        "target": "UniProt:P22303"
+      },
+      {
+        "key": "positively regulates",
+        "source": "UniProt:P22303",
+        "target": "GO:0006581"
+      },
+      {
+        "key": "decreases abundance of",
+        "source": "GO:0006581",
+        "target": "MESH:D000109"
+      },
+      {
+        "key": "contributes to",
+        "source": "MESH:D000109",
+        "target": "GO:0032224"
+      },
+      {
+        "key": "occurs in",
+        "source": "GO:0032224",
+        "target": "MESH:D062025"
+      }
+    ],
+    "multigraph": true,
+    "nodes": [
+      {
+        "id": "MESH:C028797",
+        "label": "Drug",
+        "name": "Pralidoxime"
+      },
+      {
+        "id": "UniProt:P22303",
+        "label": "Protein",
+        "name": "Acetylcholinesterase"
+      },
+      {
+        "id": "GO:0006581",
+        "label": "BiologicalProcess",
+        "name": "Acetylcholine catabolic process"
+      },
+      {
+        "id": "MESH:D000109",
+        "label": "ChemicalSubstance",
+        "name": "Acetylcholine"
+      },
+      {
+        "id": "GO:0032224",
+        "label": "BiologicalProcess",
+        "name": "Positive regulation of synaptic transmission, cholinergic"
+      },
+      {
+        "id": "MESH:D062025",
+        "label": "Disease",
+        "name": "Organophosphate poisoning"
+      }
+    ],
+    "reference": [
+      "https://go.drugbank.com/drugs/DB00733",
+      "https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1420/",
+      "https://en.wikipedia.org/wiki/Organophosphate_poisoning#Signs_and_symptoms"
+    ]
+  },
+  {
+    "comment": "Trioxsalen is a psoralen derivative that has been used in combination with UV light to treat vitiligo, but has been discontinued by its manufacturer.",
+    "directed": true,
+    "graph": {
+      "_id": "DB04571_MESH_D014820_1",
+      "disease": "Vitiligo",
+      "disease_mesh": "MESH:D014820",
+      "drug": "trioxsalen",
+      "drug_mesh": "MESH:D014307",
+      "drugbank": "DB:DB04571"
+    },
+    "links": [
+      {
+        "key": "disrupts",
+        "source": "MESH:D014307",
+        "target": "MESH:D004247"
+      },
+      {
+        "key": "participates in",
+        "source": "MESH:D004247",
+        "target": "GO:0006915"
+      },
+      {
+        "key": "treats",
+        "source": "GO:0006915",
+        "target": "MESH:D014820"
+      }
+    ],
+    "multigraph": true,
+    "nodes": [
+      {
+        "id": "MESH:D014307",
+        "label": "Drug",
+        "name": "Trioxsalen"
+      },
+      {
+        "id": "MESH:D004247",
+        "label": "ChemicalSubstance",
+        "name": "DNA"
+      },
+      {
+        "id": "GO:0006915",
+        "label": "BiologicalProcess",
+        "name": "Apoptotic process"
+      },
+      {
+        "id": "MESH:D014820",
+        "label": "Disease",
+        "name": "Vitiligo"
+      }
+    ],
+    "reference": [
+      "https://go.drugbank.com/drugs/DB04571",
+      "https://en.wikipedia.org/wiki/Vitiligo"
+    ]
+  },
+  {
+    "comment": "The exact mechanism of action of ingenol mebutate in actinic keratosis is unknown.",
+    "directed": true,
+    "graph": {
+      "_id": "DB05013_MESH_D055623_1",
+      "disease": "Actinic keratosis",
+      "disease_mesh": "MESH:D055623",
+      "drug": "ingenol mebutate",
+      "drug_mesh": "MESH:C486592",
+      "drugbank": "DB:DB05013"
+    },
+    "links": [
+      {
+        "key": "increases activity of",
+        "source": "MESH:C486592",
+        "target": "UniProt:Q05655"
+      },
+      {
+        "key": "positively correlated with",
+        "source": "UniProt:Q05655",
+        "target": "GO:0004697"
+      },
+      {
+        "key": "increases activity of",
+        "source": "MESH:C486592",
+        "target": "UniProt:P17252"
+      },
+      {
+        "key": "positively correlated with",
+        "source": "UniProt:P17252",
+        "target": "GO:0004697"
+      },
+      {
+        "key": "positively regulates",
+        "source": "GO:0004697",
+        "target": "GO:0070265"
+      },
+      {
+        "key": "positively regulates",
+        "source": "GO:0004697",
+        "target": "GO:0001788"
+      },
+      {
+        "key": "treats",
+        "source": "GO:0070265",
+        "target": "MESH:D055623"
+      },
+      {
+        "key": "treats",
+        "source": "GO:0001788",
+        "target": "MESH:D055623"
+      }
+    ],
+    "multigraph": true,
+    "nodes": [
+      {
+        "id": "MESH:C486592",
+        "label": "Drug",
+        "name": "Ingenol mebutate"
+      },
+      {
+        "id": "UniProt:Q05655",
+        "label": "Protein",
+        "name": "Protein kinase C delta type"
+      },
+      {
+        "id": "GO:0004697",
+        "label": "MolecularActivity",
+        "name": "Protein kinase C activity"
+      },
+      {
+        "id": "UniProt:P17252",
+        "label": "Protein",
+        "name": "Protein kinase C alpha type"
+      },
+      {
+        "id": "GO:0070265",
+        "label": "BiologicalProcess",
+        "name": "Necrotic cell death"
+      },
+      {
+        "id": "GO:0001788",
+        "label": "BiologicalProcess",
+        "name": "Antibody-dependent cellular cytotoxicity"
+      },
+      {
+        "id": "MESH:D055623",
+        "label": "Disease",
+        "name": "Actinic keratosis"
+      }
+    ],
+    "reference": [
+      "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4257954/",
+      "https://en.wikipedia.org/wiki/Actinic_keratosis",
+      "https://go.drugbank.com/drugs/DB05013"
+    ]
+  },
+  {
+    "directed": true,
+    "graph": {
+      "_id": "DB05311_MESH_D054179_1",
+      "disease": "Hereditary angioneurotic edema",
+      "disease_mesh": "MESH:D054179",
+      "drug": "ecallantide",
+      "drug_mesh": "MESH:C511194",
+      "drugbank": "DB:DB05311"
+    },
+    "links": [
+      {
+        "key": "decreases activity of",
+        "source": "MESH:C511194",
+        "target": "UniProt:P03952"
+      },
+      {
+        "key": "increases abundance of",
+        "source": "UniProt:P03952",
+        "target": "MESH:D001920"
+      },
+      {
+        "key": "contributes to",
+        "source": "MESH:D001920",
+        "target": "GO:0043117"
+      },
+      {
+        "key": "contributes to",
+        "source": "MESH:D001920",
+        "target": "GO:0006954"
+      },
+      {
+        "key": "contributes to",
+        "source": "GO:0043117",
+        "target": "HP:0000969"
+      },
+      {
+        "key": "contributes to",
+        "source": "GO:0006954",
+        "target": "HP:0012531"
+      },
+      {
+        "key": "manifestation of",
+        "source": "HP:0000969",
+        "target": "MESH:D054179"
+      },
+      {
+        "key": "manifestation of",
+        "source": "HP:0012531",
+        "target": "MESH:D054179"
+      }
+    ],
+    "multigraph": true,
+    "nodes": [
+      {
+        "id": "MESH:C511194",
+        "label": "Drug",
+        "name": "Ecallantide"
+      },
+      {
+        "id": "UniProt:P03952",
+        "label": "Protein",
+        "name": "Plasma kallikrein"
+      },
+      {
+        "id": "MESH:D001920",
+        "label": "ChemicalSubstance",
+        "name": "Bradykinin"
+      },
+      {
+        "id": "GO:0043117",
+        "label": "BiologicalProcess",
+        "name": "Positive regulation of vascular permeability"
+      },
+      {
+        "id": "GO:0006954",
+        "label": "BiologicalProcess",
+        "name": "Inflammatory response"
+      },
+      {
+        "id": "HP:0000969",
+        "label": "PhenotypicFeature",
+        "name": "Edema"
+      },
+      {
+        "id": "HP:0012531",
+        "label": "PhenotypicFeature",
+        "name": "Pain"
+      },
+      {
+        "id": "MESH:D054179",
+        "label": "Disease",
+        "name": "Hereditary angioneurotic edema"
+      }
+    ],
+    "reference": [
+      "https://go.drugbank.com/drugs/DB05311#BE0002440",
+      "https://en.wikipedia.org/wiki/Kinin%E2%80%93kallikrein_system"
+    ]
+  },
+  {
+    "directed": true,
+    "graph": {
+      "_id": "DB06590_MESH_D011018_1",
+      "disease": "Pneumococcal pneumonia",
+      "disease_mesh": "MESH:D011018",
+      "drug": "ceftaroline fosamil",
+      "drug_mesh": "MESH:C515501",
+      "drugbank": "DB:DB06590"
+    },
+    "links": [
+      {
+        "key": "has metabolite",
+        "source": "MESH:C515501",
+        "target": "CHEBI:70729"
+      },
+      {
+        "key": "decreases activity of",
+        "source": "CHEBI:70729",
+        "target": "InterPro:IPR001460"
+      },
+      {
+        "key": "positively regulates",
+        "source": "InterPro:IPR001460",
+        "target": "GO:0009252"
+      },
+      {
+        "key": "contributes to",
+        "source": "GO:0009252",
+        "target": "GO:0009273"
+      },
+      {
+        "key": "in taxon",
+        "source": "GO:0009273",
+        "target": "NCBITaxon:1313"
+      },
+      {
+        "key": "causes",
+        "source": "NCBITaxon:1313",
+        "target": "MESH:D011018"
+      }
+    ],
+    "multigraph": true,
+    "nodes": [
+      {
+        "id": "MESH:C515501",
+        "label": "Drug",
+        "name": "Ceftaroline fosamil"
+      },
+      {
+        "id": "CHEBI:70729",
+        "label": "ChemicalSubstance",
+        "name": "Ceftaroline"
+      },
+      {
+        "id": "InterPro:IPR001460",
+        "label": "GeneFamily",
+        "name": "Penicillin-binding protein, transpeptidase"
+      },
+      {
+        "id": "GO:0009252",
+        "label": "BiologicalProcess",
+        "name": "Peptidoglycan biosynthetic process"
+      },
+      {
+        "id": "GO:0009273",
+        "label": "BiologicalProcess",
+        "name": "Peptidoglycan-based cell wall biogenesis"
+      },
+      {
+        "id": "NCBITaxon:1313",
+        "label": "OrganismTaxon",
+        "name": "Streptococcus pneumoniae"
+      },
+      {
+        "id": "MESH:D011018",
+        "label": "Disease",
+        "name": "Pneumococcal pneumonia"
+      }
+    ],
+    "reference": [
+      "https://go.drugbank.com/drugs/DB06590",
+      "https://en.wikipedia.org/wiki/Ceftaroline_fosamil#Chemistry"
+    ]
+  },
+  {
+    "directed": true,
+    "graph": {
+      "_id": "DB06590_MESH_D013203_1",
+      "disease": "Infection due to Staphylococcus aureus",
+      "disease_mesh": "MESH:D013203",
+      "drug": "Ceftaroline fosamil",
+      "drug_mesh": "MESH:C515501",
+      "drugbank": "DB:DB06590"
+    },
+    "links": [
+      {
+        "key": "has metabolite",
+        "source": "MESH:C515501",
+        "target": "CHEBI:70729"
+      },
+      {
+        "key": "decreases activity of",
+        "source": "CHEBI:70729",
+        "target": "InterPro:IPR001460"
+      },
+      {
+        "key": "positively regulates",
+        "source": "InterPro:IPR001460",
+        "target": "GO:0018104"
+      },
+      {
+        "key": "positively regulates",
+        "source": "GO:0018104",
+        "target": "GO:0009273"
+      },
+      {
+        "key": "has output",
+        "source": "GO:0009273",
+        "target": "GO:0005618"
+      },
+      {
+        "key": "occurs in",
+        "source": "GO:0005618",
+        "target": "NCBITaxon:1280"
+      },
+      {
+        "key": "causes",
+        "source": "NCBITaxon:1280",
+        "target": "MESH:D013203"
+      }
+    ],
+    "multigraph": true,
+    "nodes": [
+      {
+        "id": "MESH:C515501",
+        "label": "Drug",
+        "name": "Ceftaroline fosamil"
+      },
+      {
+        "id": "CHEBI:70729",
+        "label": "ChemicalSubstance",
+        "name": "Ceftaroline"
+      },
+      {
+        "id": "InterPro:IPR001460",
+        "label": "GeneFamily",
+        "name": "Penicillin-binding protein, transpeptidase"
+      },
+      {
+        "id": "GO:0018104",
+        "label": "BiologicalProcess",
+        "name": "Cross-linking of the peptidoglycan"
+      },
+      {
+        "id": "GO:0009273",
+        "label": "BiologicalProcess",
+        "name": "Peptidoglycan-based cell wall biogenesis"
+      },
+      {
+        "id": "GO:0005618",
+        "label": "CellularComponent",
+        "name": "Cell wall"
+      },
+      {
+        "id": "NCBITaxon:1280",
+        "label": "OrganismTaxon",
+        "name": "Staphylococcus aureus"
+      },
+      {
+        "id": "MESH:D013203",
+        "label": "Disease",
+        "name": "Infection due to Staphylococcus aureus"
+      }
+    ],
+    "reference": [
+      "https://go.drugbank.com/drugs/DB06590",
+      "https://en.wikipedia.org/wiki/Ceftaroline_fosamil#Chemistry"
+    ]
+  },
+  {
+    "directed": true,
+    "graph": {
+      "_id": "DB06590_MESH_D012226_1",
+      "disease": "Rhinoscleroma",
+      "disease_mesh": "MESH:D012226",
+      "drug": "Ceftaroline fosamil",
+      "drug_mesh": "MESH:C515501",
+      "drugbank": "DB:DB06590"
+    },
+    "links": [
+      {
+        "key": "has metabolite",
+        "source": "MESH:C515501",
+        "target": "CHEBI:70729"
+      },
+      {
+        "key": "decreases activity of",
+        "source": "CHEBI:70729",
+        "target": "InterPro:IPR001460"
+      },
+      {
+        "key": "positively regulates",
+        "source": "InterPro:IPR001460",
+        "target": "GO:0018104"
+      },
+      {
+        "key": "positively regulates",
+        "source": "GO:0018104",
+        "target": "GO:0009273"
+      },
+      {
+        "key": "has output",
+        "source": "GO:0009273",
+        "target": "GO:0005618"
+      },
+      {
+        "key": "occurs in",
+        "source": "GO:0005618",
+        "target": "NCBITaxon:39831"
+      },
+      {
+        "key": "causes",
+        "source": "NCBITaxon:39831",
+        "target": "MESH:D012226"
+      }
+    ],
+    "multigraph": true,
+    "nodes": [
+      {
+        "id": "MESH:C515501",
+        "label": "Drug",
+        "name": "Ceftaroline fosamil"
+      },
+      {
+        "id": "CHEBI:70729",
+        "label": "ChemicalSubstance",
+        "name": "Ceftaroline"
+      },
+      {
+        "id": "InterPro:IPR001460",
+        "label": "GeneFamily",
+        "name": "Penicillin-binding protein, transpeptidase"
+      },
+      {
+        "id": "GO:0018104",
+        "label": "BiologicalProcess",
+        "name": "Cross-linking of the peptidoglycan"
+      },
+      {
+        "id": "GO:0009273",
+        "label": "BiologicalProcess",
+        "name": "Peptidoglycan-based cell wall biogenesis"
+      },
+      {
+        "id": "GO:0005618",
+        "label": "CellularComponent",
+        "name": "Cell wall"
+      },
+      {
+        "id": "NCBITaxon:39831",
+        "label": "OrganismTaxon",
+        "name": "Klebsiella pneumoniae subsp. rhinoscleromatis"
+      },
+      {
+        "id": "MESH:D012226",
+        "label": "Disease",
+        "name": "Rhinoscleroma"
+      }
+    ],
+    "reference": [
+      "https://go.drugbank.com/drugs/DB06590",
+      "https://en.wikipedia.org/wiki/Ceftaroline_fosamil#Chemistry",
+      "https://en.wikipedia.org/wiki/Rhinoscleroma"
+    ]
+  },
+  {
+    "directed": true,
+    "graph": {
+      "_id": "DB06590_MESH_D004927_1",
+      "disease": "Infection due to Escherichia coli",
+      "disease_mesh": "MESH:D004927",
+      "drug": "Ceftaroline fosamil",
+      "drug_mesh": "MESH:C515501",
+      "drugbank": "DB:DB06590"
+    },
+    "links": [
+      {
+        "key": "has metabolite",
+        "source": "MESH:C515501",
+        "target": "CHEBI:70729"
+      },
+      {
+        "key": "decreases activity of",
+        "source": "CHEBI:70729",
+        "target": "InterPro:IPR001460"
+      },
+      {
+        "key": "positively regulates",
+        "source": "InterPro:IPR001460",
+        "target": "GO:0018104"
+      },
+      {
+        "key": "positively regulates",
+        "source": "GO:0018104",
+        "target": "GO:0009273"
+      },
+      {
+        "key": "has output",
+        "source": "GO:0009273",
+        "target": "GO:0005618"
+      },
+      {
+        "key": "occurs in",
+        "source": "GO:0005618",
+        "target": "NCBITaxon:562"
+      },
+      {
+        "key": "causes",
+        "source": "NCBITaxon:562",
+        "target": "MESH:D004927"
+      }
+    ],
+    "multigraph": true,
+    "nodes": [
+      {
+        "id": "MESH:C515501",
+        "label": "Drug",
+        "name": "Ceftaroline fosamil"
+      },
+      {
+        "id": "CHEBI:70729",
+        "label": "ChemicalSubstance",
+        "name": "Ceftaroline"
+      },
+      {
+        "id": "InterPro:IPR001460",
+        "label": "GeneFamily",
+        "name": "Penicillin-binding protein, transpeptidase"
+      },
+      {
+        "id": "GO:0018104",
+        "label": "BiologicalProcess",
+        "name": "Cross-linking of the peptidoglycan"
+      },
+      {
+        "id": "GO:0009273",
+        "label": "BiologicalProcess",
+        "name": "Peptidoglycan-based cell wall biogenesis"
+      },
+      {
+        "id": "GO:0005618",
+        "label": "CellularComponent",
+        "name": "Cell wall"
+      },
+      {
+        "id": "NCBITaxon:562",
+        "label": "OrganismTaxon",
+        "name": "Escherichia coli"
+      },
+      {
+        "id": "MESH:D004927",
+        "label": "Disease",
+        "name": "Infection due to Escherichia coli"
+      }
+    ],
+    "reference": [
+      "https://go.drugbank.com/drugs/DB06590",
+      "https://en.wikipedia.org/wiki/Ceftaroline_fosamil#Chemistry",
+      "https://en.wikipedia.org/wiki/Rhinoscleroma"
+    ]
+  },
+  {
+    "directed": true,
+    "graph": {
+      "_id": "DB06590_MESH_D013290_1",
+      "disease": "Streptococcus pyogenes infection",
+      "disease_mesh": "MESH:D013290",
+      "drug": "Ceftaroline fosamil",
+      "drug_mesh": "MESH:C515501",
+      "drugbank": "DB:DB06590"
+    },
+    "links": [
+      {
+        "key": "has metabolite",
+        "source": "MESH:C515501",
+        "target": "CHEBI:70729"
+      },
+      {
+        "key": "decreases activity of",
+        "source": "CHEBI:70729",
+        "target": "InterPro:IPR001460"
+      },
+      {
+        "key": "positively regulates",
+        "source": "InterPro:IPR001460",
+        "target": "GO:0018104"
+      },
+      {
+        "key": "positively regulates",
+        "source": "GO:0018104",
+        "target": "GO:0009273"
+      },
+      {
+        "key": "has output",
+        "source": "GO:0009273",
+        "target": "GO:0005618"
+      },
+      {
+        "key": "occurs in",
+        "source": "GO:0005618",
+        "target": "NCBITaxon:1314"
+      },
+      {
+        "key": "causes",
+        "source": "NCBITaxon:1314",
+        "target": "MESH:D013290"
+      }
+    ],
+    "multigraph": true,
+    "nodes": [
+      {
+        "id": "MESH:C515501",
+        "label": "Drug",
+        "name": "Ceftaroline fosamil"
+      },
+      {
+        "id": "CHEBI:70729",
+        "label": "ChemicalSubstance",
+        "name": "Ceftaroline"
+      },
+      {
+        "id": "InterPro:IPR001460",
+        "label": "GeneFamily",
+        "name": "Penicillin-binding protein, transpeptidase"
+      },
+      {
+        "id": "GO:0018104",
+        "label": "BiologicalProcess",
+        "name": "Cross-linking of the peptidoglycan"
+      },
+      {
+        "id": "GO:0009273",
+        "label": "BiologicalProcess",
+        "name": "Peptidoglycan-based cell wall biogenesis"
+      },
+      {
+        "id": "GO:0005618",
+        "label": "CellularComponent",
+        "name": "Cell wall"
+      },
+      {
+        "id": "NCBITaxon:1314",
+        "label": "OrganismTaxon",
+        "name": "Streptococcus pyogenes"
+      },
+      {
+        "id": "MESH:D013290",
+        "label": "Disease",
+        "name": "Streptococcus pyogenes infection"
+      }
+    ],
+    "reference": [
+      "https://go.drugbank.com/drugs/DB06590",
+      "https://en.wikipedia.org/wiki/Ceftaroline_fosamil#Chemistry"
+    ]
+  },
+  {
+    "directed": true,
+    "graph": {
+      "_id": "DB08816_MESH_D054058_1",
+      "disease": "Acute coronary syndrome",
+      "disease_mesh": "MESH:D054058",
+      "drug": "ticagrelor",
+      "drug_mesh": "MESH:C503700",
+      "drugbank": "DB:DB08816"
+    },
+    "links": [
+      {
+        "key": "decreases activity of",
+        "source": "MESH:C503700",
+        "target": "UniProt:Q9H244"
+      },
+      {
+        "key": "positively regulates",
+        "source": "UniProt:Q9H244",
+        "target": "GO:0007193"
+      },
+      {
+        "key": "positively regulates",
+        "source": "GO:0007193",
+        "target": "GO:0070527"
+      },
+      {
+        "key": "positively correlated with",
+        "source": "GO:0070527",
+        "target": "GO:0072378"
+      },
+      {
+        "key": "contributes to",
+        "source": "GO:0072378",
+        "target": "MESH:D054058"
+      }
+    ],
+    "multigraph": true,
+    "nodes": [
+      {
+        "id": "MESH:C503700",
+        "label": "Drug",
+        "name": "Ticagrelor"
+      },
+      {
+        "id": "UniProt:Q9H244",
+        "label": "Protein",
+        "name": "P2Y purinoceptor 12"
+      },
+      {
+        "id": "GO:0007193",
+        "label": "BiologicalProcess",
+        "name": "Adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway"
+      },
+      {
+        "id": "GO:0070527",
+        "label": "BiologicalProcess",
+        "name": "Platelet aggregation"
+      },
+      {
+        "id": "GO:0072378",
+        "label": "BiologicalProcess",
+        "name": "Blood coagulation, fibrin clot formation"
+      },
+      {
+        "id": "MESH:D054058",
+        "label": "Disease",
+        "name": "Acute coronary syndrome"
+      }
+    ],
+    "reference": [
+      "https://go.drugbank.com/drugs/DB08816#BE0000110"
+    ]
+  },
+  {
+    "directed": true,
+    "graph": {
+      "_id": "DB08816_MESH_D016491_1",
+      "disease": "Peripheral vascular disease",
+      "disease_mesh": "MESH:D016491",
+      "drug": "ticagrelor",
+      "drug_mesh": "MESH:C503700",
+      "drugbank": "DB:DB08816"
+    },
+    "links": [
+      {
+        "key": "decreases activity of",
+        "source": "MESH:C503700",
+        "target": "UniProt:Q9H244"
+      },
+      {
+        "key": "positively regulates",
+        "source": "UniProt:Q9H244",
+        "target": "GO:0007193"
+      },
+      {
+        "key": "positively regulates",
+        "source": "GO:0007193",
+        "target": "GO:0070527"
+      },
+      {
+        "key": "positively correlated with",
+        "source": "GO:0070527",
+        "target": "GO:0072378"
+      },
+      {
+        "key": "contributes to",
+        "source": "GO:0072378",
+        "target": "MESH:D016491"
+      }
+    ],
+    "multigraph": true,
+    "nodes": [
+      {
+        "id": "MESH:C503700",
+        "label": "Drug",
+        "name": "Ticagrelor"
+      },
+      {
+        "id": "UniProt:Q9H244",
+        "label": "Protein",
+        "name": "P2Y purinoceptor 12"
+      },
+      {
+        "id": "GO:0007193",
+        "label": "BiologicalProcess",
+        "name": "Adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway"
+      },
+      {
+        "id": "GO:0070527",
+        "label": "BiologicalProcess",
+        "name": "Platelet aggregation"
+      },
+      {
+        "id": "GO:0072378",
+        "label": "BiologicalProcess",
+        "name": "Blood coagulation, fibrin clot formation"
+      },
+      {
+        "id": "MESH:D016491",
+        "label": "Disease",
+        "name": "Peripheral vascular disease"
+      }
+    ],
+    "reference": [
+      "https://go.drugbank.com/drugs/DB08816#BE0000110"
+    ]
+  },
+  {
+    "directed": true,
+    "graph": {
+      "_id": "DB09113_MESH_D012127_1",
+      "disease": "Respiratory distress syndrome in the newborn",
+      "disease_mesh": "MESH:D012127",
+      "drug": "poractant alfa",
+      "drug_mesh": "MESH:C068291",
+      "drugbank": "DB:DB09113"
+    },
+    "links": [
+      {
+        "key": "positively regulates",
+        "source": "MESH:C068291",
+        "target": "GO:0043129"
+      },
+      {
+        "key": "negatively correlated with",
+        "source": "GO:0043129",
+        "target": "MESH:D012127"
+      }
+    ],
+    "multigraph": true,
+    "nodes": [
+      {
+        "id": "MESH:C068291",
+        "label": "Drug",
+        "name": "Poractant alfa"
+      },
+      {
+        "id": "GO:0043129",
+        "label": "BiologicalProcess",
+        "name": "Surfactant homeostasis"
+      },
+      {
+        "id": "MESH:D012127",
+        "label": "Disease",
+        "name": "Respiratory distress syndrome in the newborn"
+      }
+    ],
+    "reference": [
+      "https://en.wikipedia.org/wiki/Infant_respiratory_distress_syndrome",
+      "https://go.drugbank.com/drugs/DB09113"
+    ]
+  },
+  {
+    "directed": true,
+    "graph": {
+      "_id": "DB13064_MESH_D006255_1",
+      "disease": "Seasonal allergic rhinitis",
+      "disease_mesh": "MESH:D006255",
+      "drug": "tramazoline",
+      "drug_mesh": "MESH:C005370",
+      "drugbank": "DB:DB13064"
+    },
+    "links": [
+      {
+        "key": "increases activity of",
+        "source": "MESH:C005370",
+        "target": "UniProt:P08913"
+      },
+      {
+        "key": "positively regulates",
+        "source": "UniProt:P08913",
+        "target": "GO:0042310"
+      },
+      {
+        "key": "negatively correlated with",
+        "source": "GO:0042310",
+        "target": "HP:0001742"
+      },
+      {
+        "key": "positively correlated with",
+        "source": "HP:0001742",
+        "target": "MESH:D006255"
+      }
+    ],
+    "multigraph": true,
+    "nodes": [
+      {
+        "id": "MESH:C005370",
+        "label": "Drug",
+        "name": "Tramazoline"
+      },
+      {
+        "id": "UniProt:P08913",
+        "label": "Protein",
+        "name": "Alpha-2A adrenergic receptor"
+      },
+      {
+        "id": "GO:0042310",
+        "label": "BiologicalProcess",
+        "name": "Vasoconstriction"
+      },
+      {
+        "id": "HP:0001742",
+        "label": "PhenotypicFeature",
+        "name": "Nasal obstruction"
+      },
+      {
+        "id": "MESH:D006255",
+        "label": "Disease",
+        "name": "Seasonal allergic rhinitis"
+      }
+    ],
+    "reference": [
+      "https://go.drugbank.com/drugs/DB06711#BE0000501",
+      "https://drugs.ncats.io/drug/4DG710Q678",
+      "https://pubmed.ncbi.nlm.nih.gov/16809058/"
+    ]
+  },
+  {
+    "directed": true,
+    "graph": {
+      "_id": "DB13064_MESH_D065631_1",
+      "disease": "Allergic rhinitis",
+      "disease_mesh": "MESH:D065631",
+      "drug": "tramazoline",
+      "drug_mesh": "MESH:C005370",
+      "drugbank": "DB:DB13064"
+    },
+    "links": [
+      {
+        "key": "increases activity of",
+        "source": "MESH:C005370",
+        "target": "UniProt:P08913"
+      },
+      {
+        "key": "positively regulates",
+        "source": "UniProt:P08913",
+        "target": "GO:0042310"
+      },
+      {
+        "key": "negatively correlated with",
+        "source": "GO:0042310",
+        "target": "HP:0001742"
+      },
+      {
+        "key": "positively correlated with",
+        "source": "HP:0001742",
+        "target": "MESH:D065631"
+      }
+    ],
+    "multigraph": true,
+    "nodes": [
+      {
+        "id": "MESH:C005370",
+        "label": "Drug",
+        "name": "Tramazoline"
+      },
+      {
+        "id": "UniProt:P08913",
+        "label": "Protein",
+        "name": "Alpha-2A adrenergic receptor"
+      },
+      {
+        "id": "GO:0042310",
+        "label": "BiologicalProcess",
+        "name": "Vasoconstriction"
+      },
+      {
+        "id": "HP:0001742",
+        "label": "PhenotypicFeature",
+        "name": "Nasal obstruction"
+      },
+      {
+        "id": "MESH:D065631",
+        "label": "Disease",
+        "name": "Allergic rhinitis"
+      }
+    ],
+    "reference": [
+      "https://go.drugbank.com/drugs/DB06711#BE0000501",
+      "https://drugs.ncats.io/drug/4DG710Q678",
+      "https://pubmed.ncbi.nlm.nih.gov/16809058/"
+    ]
+  },
+  {
+    "directed": true,
+    "graph": {
+      "_id": "DB13064_MESH_D003233_1",
+      "disease": "Allergic conjunctivitis",
+      "disease_mesh": "MESH:D003233",
+      "drug": "tramazoline",
+      "drug_mesh": "MESH:C005370",
+      "drugbank": "DB:DB13064"
+    },
+    "links": [
+      {
+        "key": "increases activity of",
+        "source": "MESH:C005370",
+        "target": "UniProt:P08913"
+      },
+      {
+        "key": "positively regulates",
+        "source": "UniProt:P08913",
+        "target": "GO:0042310"
+      },
+      {
+        "key": "negatively correlated with",
+        "source": "GO:0042310",
+        "target": "HP:0010783"
+      },
+      {
+        "key": "positively correlated with",
+        "source": "HP:0010783",
+        "target": "MESH:D003233"
+      }
+    ],
+    "multigraph": true,
+    "nodes": [
+      {
+        "id": "MESH:C005370",
+        "label": "Drug",
+        "name": "Tramazoline"
+      },
+      {
+        "id": "UniProt:P08913",
+        "label": "Protein",
+        "name": "Alpha-2A adrenergic receptor"
+      },
+      {
+        "id": "GO:0042310",
+        "label": "BiologicalProcess",
+        "name": "Vasoconstriction"
+      },
+      {
+        "id": "HP:0010783",
+        "label": "PhenotypicFeature",
+        "name": "Erythema"
+      },
+      {
+        "id": "MESH:D003233",
+        "label": "Disease",
+        "name": "Allergic conjunctivitis"
+      }
+    ],
+    "reference": [
+      "https://go.drugbank.com/drugs/DB06711#BE0000501",
+      "https://drugs.ncats.io/drug/4DG710Q678",
+      "https://pubmed.ncbi.nlm.nih.gov/16809058/"
+    ]
+  },
+  {
+    "directed": true,
+    "graph": {
+      "_id": "DB13064_MESH_D012912_1",
+      "disease": "Sneezing",
+      "disease_mesh": "MESH:D012912",
+      "drug": "tramazoline",
+      "drug_mesh": "MESH:C005370",
+      "drugbank": "DB:DB13064"
+    },
+    "links": [
+      {
+        "key": "increases activity of",
+        "source": "MESH:C005370",
+        "target": "UniProt:P08913"
+      },
+      {
+        "key": "positively regulates",
+        "source": "UniProt:P08913",
+        "target": "GO:0042310"
+      },
+      {
+        "key": "negatively correlated with",
+        "source": "GO:0042310",
+        "target": "HP:0001742"
+      },
+      {
+        "key": "positively correlated with",
+        "source": "HP:0001742",
+        "target": "MESH:D012220"
+      },
+      {
+        "key": "positively correlated with",
+        "source": "MESH:D012220",
+        "target": "MESH:D012912"
+      }
+    ],
+    "multigraph": true,
+    "nodes": [
+      {
+        "id": "MESH:C005370",
+        "label": "Drug",
+        "name": "Tramazoline"
+      },
+      {
+        "id": "UniProt:P08913",
+        "label": "Protein",
+        "name": "Alpha-2A adrenergic receptor"
+      },
+      {
+        "id": "GO:0042310",
+        "label": "BiologicalProcess",
+        "name": "Vasoconstriction"
+      },
+      {
+        "id": "HP:0001742",
+        "label": "PhenotypicFeature",
+        "name": "Nasal obstruction"
+      },
+      {
+        "id": "MESH:D012220",
+        "label": "Disease",
+        "name": "Rhinitis"
+      },
+      {
+        "id": "MESH:D012912",
+        "label": "Disease",
+        "name": "Sneezing"
+      }
+    ],
+    "reference": [
+      "https://go.drugbank.com/drugs/DB06711#BE0000501",
+      "https://drugs.ncats.io/drug/4DG710Q678",
+      "https://pubmed.ncbi.nlm.nih.gov/16809058/"
+    ]
+  },
+  {
+    "directed": true,
+    "graph": {
+      "_id": "DB13064_MESH_D012223_1",
+      "disease": "Vasomotor rhinitis",
+      "disease_mesh": "MESH:D012223",
+      "drug": "tramazoline",
+      "drug_mesh": "MESH:C005370",
+      "drugbank": "DB:DB13064"
+    },
+    "links": [
+      {
+        "key": "increases activity of",
+        "source": "MESH:C005370",
+        "target": "UniProt:P08913"
+      },
+      {
+        "key": "positively regulates",
+        "source": "UniProt:P08913",
+        "target": "GO:0042310"
+      },
+      {
+        "key": "negatively correlated with",
+        "source": "GO:0042310",
+        "target": "HP:0001742"
+      },
+      {
+        "key": "positively correlated with",
+        "source": "HP:0001742",
+        "target": "MESH:D012223"
+      }
+    ],
+    "multigraph": true,
+    "nodes": [
+      {
+        "id": "MESH:C005370",
+        "label": "Drug",
+        "name": "Tramazoline"
+      },
+      {
+        "id": "UniProt:P08913",
+        "label": "Protein",
+        "name": "Alpha-2A adrenergic receptor"
+      },
+      {
+        "id": "GO:0042310",
+        "label": "BiologicalProcess",
+        "name": "Vasoconstriction"
+      },
+      {
+        "id": "HP:0001742",
+        "label": "PhenotypicFeature",
+        "name": "Nasal obstruction"
+      },
+      {
+        "id": "MESH:D012223",
+        "label": "Disease",
+        "name": "Vasomotor rhinitis"
+      }
+    ],
+    "reference": [
+      "https://go.drugbank.com/drugs/DB06711#BE0000501",
+      "https://drugs.ncats.io/drug/4DG710Q678",
+      "https://pubmed.ncbi.nlm.nih.gov/16809058/"
+    ]
+  },
+  {
+    "directed": true,
+    "graph": {
+      "_id": "DB13064_MESH_D003139_1",
+      "disease": "Common cold",
+      "disease_mesh": "MESH:D003139",
+      "drug": "tramazoline",
+      "drug_mesh": "MESH:C005370",
+      "drugbank": "DB:DB13064"
+    },
+    "links": [
+      {
+        "key": "increases activity of",
+        "source": "MESH:C005370",
+        "target": "UniProt:P08913"
+      },
+      {
+        "key": "positively regulates",
+        "source": "UniProt:P08913",
+        "target": "GO:0042310"
+      },
+      {
+        "key": "negatively correlated with",
+        "source": "GO:0042310",
+        "target": "HP:0001742"
+      },
+      {
+        "key": "occurs in",
+        "source": "HP:0001742",
+        "target": "MESH:D003139"
+      }
+    ],
+    "multigraph": true,
+    "nodes": [
+      {
+        "id": "MESH:C005370",
+        "label": "Drug",
+        "name": "Tramazoline"
+      },
+      {
+        "id": "UniProt:P08913",
+        "label": "Protein",
+        "name": "Alpha-2A adrenergic receptor"
+      },
+      {
+        "id": "GO:0042310",
+        "label": "BiologicalProcess",
+        "name": "Vasoconstriction"
+      },
+      {
+        "id": "HP:0001742",
+        "label": "PhenotypicFeature",
+        "name": "Nasal obstruction"
+      },
+      {
+        "id": "MESH:D003139",
+        "label": "Disease",
+        "name": "Common cold"
+      }
+    ],
+    "reference": [
+      "https://go.drugbank.com/drugs/DB06711#BE0000501",
+      "https://drugs.ncats.io/drug/4DG710Q678",
+      "https://pubmed.ncbi.nlm.nih.gov/16809058/"
+    ]
   }
 ]
\ No newline at end of file
diff --git a/indication_paths.yaml b/indication_paths.yaml
index cf14e12c7..02a30173b 100644
--- a/indication_paths.yaml
+++ b/indication_paths.yaml
@@ -64549,8 +64549,7 @@
     - https://en.wikipedia.org/wiki/Brimonidine#Mechanism_of_action
     - https://en.wikipedia.org/wiki/Rosacea#Medications
     - https://pubmed.ncbi.nlm.nih.gov/26566370/
--   comments: MESH:C000608451 may have been deprecated; no longer in MESH.
-    directed: true
+-   directed: true
     graph:
         _id: DB09087_MESH_D010437_1
         disease: Peptic ulcer
@@ -64559,23 +64558,17 @@
         drug_mesh: MESH:D000534
         drugbank: DB:DB09087
     links:
-    -   key: subclass of
-        source: MESH:D000534
-        target: MESH:D000891
-    -   key: subclass of
+    -   key: negatively regulates
         source: MESH:D000534
-        target: MESH:D001252
-    -   key: negatively correlated with
-        source: MESH:D000891
         target: GO:0006954
-    -   key: negatively correlated with
-        source: MESH:D001252
-        target: MESH:D005744
+    -   key: negatively regulates
+        source: MESH:D000534
+        target: GO:0001696
     -   key: positively correlated with
         source: GO:0006954
         target: MESH:D010437
     -   key: positively correlated with
-        source: MESH:D005744
+        source: GO:0001696
         target: MESH:D010437
     multigraph: true
     nodes:
@@ -64584,15 +64577,9 @@
         id: MESH:D000534
         label: Drug
         name: alum
-    -   id: MESH:D000891
-        label: ChemicalSubstance
-        name: Anti-Infective Agents, Local
-    -   id: MESH:D001252
-        label: ChemicalSubstance
-        name: Astringents
-    -   id: MESH:D005744
-        label: ChemicalSubstance
-        name: Gastric Acid
+    -   id: GO:0001696
+        label: BiologicalProcess
+        name: gastric acid secretion
     -   id: GO:0006954
         label: BiologicalProcess
         name: inflammatory response
@@ -64602,11 +64589,10 @@
     reference:
     - https://go.drugbank.com/drugs/DB09087#pharmacodynamics
     - https://en.wikipedia.org/wiki/Potassium_alum#Medicine_and_cosmetics
--   comments: MESH:C000608451 may have been deprecated; no longer in MESH. The disease
-        is denotated as Indigestion in the original file before curation. Note that
-        the majority of cases no cause can be attributed to leading to the disease.
-        When a cause can indeed be determined, the majority of cases will be due to
-        gastroesophageal reflux and gastritis (https://en.wikipedia.org/wiki/Indigestion#Cause).
+-   comment: The disease is also known as Indigestion as per in the original file
+        before curation. Note that in the majority of cases no cause can be attributed
+        to leading to the disease. When a cause can indeed be determined, the majority
+        of cases will be due to gastroesophageal reflux and gastritis (https://en.wikipedia.org/wiki/Indigestion#Cause).
     directed: true
     graph:
         _id: DB09087_MESH_D004415_1
@@ -64616,28 +64602,22 @@
         drug_mesh: MESH:D000534
         drugbank: DB:DB09087
     links:
-    -   key: subclass of
-        source: MESH:D000534
-        target: MESH:D000891
-    -   key: subclass of
+    -   key: negatively regulates
         source: MESH:D000534
-        target: MESH:D001252
-    -   key: negatively correlated with
-        source: MESH:D000891
         target: GO:0006954
-    -   key: negatively correlated with
-        source: MESH:D001252
-        target: MESH:D005744
+    -   key: negatively regulates
+        source: MESH:D000534
+        target: GO:0001696
     -   key: positively correlated with
         source: GO:0006954
         target: HP:0005263
     -   key: positively correlated with
-        source: MESH:D005744
+        source: GO:0001696
         target: HP:0002020
-    -   key: positively correlated with
+    -   key: manifestation of
         source: HP:0002020
         target: MESH:D004415
-    -   key: positively correlated with
+    -   key: manifestation of
         source: HP:0005263
         target: MESH:D004415
     multigraph: true
@@ -64647,15 +64627,9 @@
         id: MESH:D000534
         label: Drug
         name: alum
-    -   id: MESH:D000891
-        label: ChemicalSubstance
-        name: Anti-Infective Agents, Local
-    -   id: MESH:D001252
-        label: ChemicalSubstance
-        name: Astringents
-    -   id: MESH:D005744
-        label: ChemicalSubstance
-        name: Gastric Acid
+    -   id: GO:0001696
+        label: BiologicalProcess
+        name: gastric acid secretion
     -   id: HP:0005263
         label: PhenotypicFeature
         name: Gastritis
@@ -64765,7 +64739,7 @@
     - https://go.drugbank.com/drugs/DB09087#pharmacodynamics
     - https://en.wikipedia.org/wiki/Potassium_alum#Medicine_and_cosmetics
     - https://en.wikipedia.org/wiki/Gastroesophageal_reflux_disease#Antacids
--   comments: Esomeprazole is the s-isomer of Omeprazole, both are a proton pump inhibitor
+-   comment: Esomeprazole is the s-isomer of Omeprazole, both are a proton pump inhibitor
         class of drug and the mechanism of action for both is similar. Weve annotated
         the path for the S isomer only as it seems this isomer is metabolized more
         slowly than omeprazole and therefore it will act for longer and more effectively
@@ -64824,7 +64798,7 @@
     - https://go.drugbank.com/drugs/DB00736#mechanism-of-action
     - https://en.wikipedia.org/wiki/Esomeprazole
     - https://en.wikipedia.org/wiki/Omeprazole#Mechanism_of_action
--   comments: Esomeprazole is the s-isomer of Omeprazole, both are a proton pump inhibitor
+-   comment: Esomeprazole is the s-isomer of Omeprazole, both are a proton pump inhibitor
         class of drug and the mechanism of action for both is similar. Weve annotated
         the path for the S isomer only as it seems this isomer is metabolized more
         slowly than omeprazole and therefore it will act for longer and more effectively
@@ -64854,7 +64828,7 @@
     -   key: positively correlated with
         source: GO:0001696
         target: HP:0002020
-    -   key: positively correlated with
+    -   key: manifestation of
         source: HP:0004791
         target: MESH:D004942
     -   key: manifestation of
@@ -64889,7 +64863,7 @@
     - https://en.wikipedia.org/wiki/Omeprazole#Mechanism_of_action
     - https://en.wikipedia.org/wiki/Esophagitis#Causes
     - https://en.wikipedia.org/wiki/Esophagitis#Medications
--   comments: Esomeprazole is the s-isomer of Omeprazole, both are a proton pump inhibitor
+-   comment: Esomeprazole is the s-isomer of Omeprazole, both are a proton pump inhibitor
         class of drug and the mechanism of action for both is similar. Weve annotated
         the path for the S isomer only as it seems this isomer is metabolized more
         slowly than omeprazole and therefore it will act for longer and more effectively
@@ -64919,10 +64893,10 @@
     -   key: positively correlated with
         source: GO:0001696
         target: HP:0002588
-    -   key: positively correlated with
+    -   key: manifestation of
         source: HP:0002588
         target: MESH:D015043
-    -   key: positively correlated with
+    -   key: manifestation of
         source: HP:0004398
         target: MESH:D015043
     multigraph: true
@@ -64956,7 +64930,7 @@
     - https://en.wikipedia.org/wiki/Esophagitis#Medications
     - https://en.wikipedia.org/wiki/Zollinger%E2%80%93Ellison_syndrome#Treatment
     - https://en.wikipedia.org/wiki/Zollinger%E2%80%93Ellison_syndrome#Pathophysiology
--   comments: Esomeprazole is the s-isomer of Omeprazole, both are a proton pump inhibitor
+-   comment: Esomeprazole is the s-isomer of Omeprazole, both are a proton pump inhibitor
         class of drug and the mechanism of action for both is similar. Weve annotated
         the path for the S isomer only as it seems this isomer is metabolized more
         slowly than omeprazole and therefore it will act for longer and more effectively
@@ -65004,10 +64978,6 @@
     - https://go.drugbank.com/drugs/DB00736#mechanism-of-action
     - https://en.wikipedia.org/wiki/Esomeprazole
     - https://en.wikipedia.org/wiki/Omeprazole#Mechanism_of_action
-    - https://en.wikipedia.org/wiki/Esophagitis#Causes
-    - https://en.wikipedia.org/wiki/Esophagitis#Medications
-    - https://en.wikipedia.org/wiki/Zollinger%E2%80%93Ellison_syndrome#Treatment
-    - https://en.wikipedia.org/wiki/Zollinger%E2%80%93Ellison_syndrome#Pathophysiology
 -   directed: true
     graph:
         _id: DB01048_MESH_D015658_2
@@ -65061,7 +65031,8 @@
     reference:
     - https://go.drugbank.com/drugs/DB01048#mechanism-of-action
     - https://en.wikipedia.org/wiki/Abacavir#Mechanism_of_action
--   comments: The disease is denoted as Sore throat symptom in the original file.
+-   comment: The disease is also known as Sore throat symptom as per the original
+        file.
     directed: true
     graph:
         _id: DB06742_MESH_D010612_1
@@ -65071,24 +65042,21 @@
         drug_mesh: MESH:D000551
         drugbank: DB:DB06742
     links:
-    -   key: increases abundance of
-        source: MESH:D000551
-        target: MESH:D011663
-    -   key: produced by
-        source: MESH:D011663
-        target: MESH:D056809
-    -   key: part of
-        source: MESH:D056809
-        target: UBERON:0000065
-    -   key: location of
-        source: UBERON:0000065
-        target: MESH:D010612
     -   key: negatively regulates
         source: MESH:D000551
         target: GO:0038060
     -   key: positively correlated with
         source: GO:0038060
-        target: MESH:D007249
+        target: GO:0006954
+    -   key: positively correlated with
+        source: GO:0006954
+        target: HP:0033050
+    -   key: negatively regulates
+        source: MESH:D000551
+        target: Pfam:PF06512
+    -   key: positively correlated with
+        source: Pfam:PF06512
+        target: GO:0006954
     -   key: increases abundance of
         source: GO:0038060
         target: UBERON:0016552
@@ -65098,22 +65066,13 @@
     -   key: positively correlated with
         source: HP:0031602
         target: HP:0033050
-    -   key: negatively regulates
-        source: MESH:D000551
-        target: Pfam:PF06512
-    -   key: positively correlated with
-        source: Pfam:PF06512
-        target: MESH:D010146
     -   key: positively correlated with
         source: Pfam:PF06512
-        target: MESH:D007249
-    -   key: positively correlated with
-        source: MESH:D010146
-        target: HP:0033050
+        target: HP:0012531
     -   key: positively correlated with
-        source: MESH:D007249
+        source: HP:0012531
         target: HP:0033050
-    -   key: positively correlated with
+    -   key: manifestation of
         source: HP:0033050
         target: MESH:D010612
     multigraph: true
@@ -65121,20 +65080,11 @@
     -   id: MESH:D000551
         label: Drug
         name: ambroxol
-    -   id: MESH:D011663
-        label: ChemicalSubstance
-        name: Pulmonary Surfactants
-    -   id: MESH:D056809
-        label: Cell
-        name: Alveolar Epithelial Cells
-    -   id: UBERON:0000065
-        label: GrossAnatomicalStructure
-        name: respiratory tract
     -   id: GO:0038060
         label: BiologicalProcess
         name: nitric oxide-cGMP-mediated signaling pathway
-    -   id: MESH:D010146
-        label: BiologicalProcess
+    -   id: HP:0012531
+        label: PhenotypicFeature
         name: Pain
     -   id: UBERON:0016552
         label: GrossAnatomicalStructure
@@ -65145,11 +65095,11 @@
     -   id: Pfam:PF06512
         label: GeneFamily
         name: Sodium ion transport-associated
-    -   id: MESH:D007249
-        label: PhenotypicFeature
-        name: Inflammation
-    -   id: HP:0033050
+    -   id: GO:0006954
         label: BiologicalProcess
+        name: inflammatory response
+    -   id: HP:0033050
+        label: PhenotypicFeature
         name: Pharyngalgia
     -   id: MESH:D010612
         label: Disease
@@ -65159,7 +65109,7 @@
     - https://go.drugbank.com/drugs/DB06742#mechanism-of-action
     - https://pubmed.ncbi.nlm.nih.gov/28937232/
     - https://en.wikipedia.org/wiki/Sore_throat#Diagnosis
--   comments: Tolvaptan is also known as aquaretic (https://en.wikipedia.org/wiki/Aquaretic).
+-   comment: Tolvaptan is also known as aquaretic (https://en.wikipedia.org/wiki/Aquaretic).
         Note that hyponatremia corresponds to the state where water content is relatively
         large for the sodium content available (https://pubmed.ncbi.nlm.nih.gov/19322975/),
         which is possibly due to increased water reabsorption. There are different
@@ -65207,8 +65157,8 @@
     - https://go.drugbank.com/drugs/DB06212#mechanism-of-action
     - https://pubmed.ncbi.nlm.nih.gov/20868352/
     - https://en.wikipedia.org/wiki/Vasopressin_receptor_antagonist
--   comments: This disease is denoted as Syndrome of inappropriate vasopressin secretion
-        in the original file. Tolvaptan is also known as aquaretic (https://en.wikipedia.org/wiki/Aquaretic).
+-   comment: This disease is also known as Syndrome of inappropriate vasopressin secretion
+        as per the original file. Tolvaptan is also known as aquaretic (https://en.wikipedia.org/wiki/Aquaretic).
         Note that hyponatremia corresponds to the state where water content is relatively
         large for the sodium content available (https://pubmed.ncbi.nlm.nih.gov/19322975/),
         which is possibly due to increased water reabsorption.
@@ -65257,8 +65207,8 @@
     - https://pubmed.ncbi.nlm.nih.gov/20868352/
     - https://en.wikipedia.org/wiki/Vasopressin_receptor_antagonist
     - https://en.wikipedia.org/wiki/Syndrome_of_inappropriate_antidiuretic_hormone_secretion#Treatment
--   comments: This disease is denoted as Polycystic kidney disease adult type in the
-        original file. Tolvaptan is also known as aquaretic (https://en.wikipedia.org/wiki/Aquaretic).
+-   comment: This disease is also known as Polycystic kidney disease adult type as
+        per the original file. Tolvaptan is also known as aquaretic (https://en.wikipedia.org/wiki/Aquaretic).
         Note that hyponatremia corresponds to the state where water content is relatively
         large for the sodium content available (https://pubmed.ncbi.nlm.nih.gov/19322975/),
         which is possibly due to increased water reabsorption.
@@ -65286,7 +65236,7 @@
     -   key: positively correlated with
         source: CHEBI:17489
         target: HP:0000107
-    -   key: positively correlated with
+    -   key: manifestation of
         source: HP:0000107
         target: MESH:D016891
     -   key: positively correlated with
@@ -65362,7 +65312,7 @@
     - https://en.wikipedia.org/wiki/Aminolevulinic_acid#Medical_uses
     - https://en.wikipedia.org/wiki/Actinic_keratosis#Procedures
     - https://en.wikipedia.org/wiki/Photodynamic_therapy#Photosensitizers
--   comments: In Parkinson's disease, there is imbalance between levels of acetylcholine
+-   comment: In Parkinson's disease, there is imbalance between levels of acetylcholine
         and dopamine, where increased levels of acetylcholine and degeneration of
         dopaminergic pathways are observed. Therefore, muscarinic antagonists such
         as biperiden block central cholinergic activity and balancing out neurotransmitters
@@ -65386,6 +65336,9 @@
         target: GO:0007271
     -   key: positively correlated with
         source: GO:0007271
+        target: HP:0100022
+    -   key: manifestation of
+        source: HP:0100022
         target: MESH:D010300
     multigraph: true
     nodes:
@@ -65400,12 +65353,15 @@
     -   id: GO:0007271
         label: BiologicalProcess
         name: synaptic transmission, cholinergic
+    -   id: HP:0100022
+        label: PhenotypicFeature
+        name: Abnormality of movement
     -   id: MESH:D010300
         label: Disease
         name: Parkinson's disease
     reference:
     - https://go.drugbank.com/drugs/DB00810#mechanism-of-action
--   comments: The disease is denoted as Postencephalitic parkinsonism in the original
+-   comment: The disease is denoted as Postencephalitic parkinsonism in the original
         file. This disease is believed to be caused by a viral infection, leading
         to clinical parkinsonism (https://en.wikipedia.org/wiki/Postencephalitic_parkinsonism)
         and anti-Parkinson drugs may be helpful in treating the symptoms (https://en.wikipedia.org/wiki/Encephalitis_lethargica).
@@ -65431,7 +65387,7 @@
     -   key: positively correlated with
         source: GO:0007271
         target: HP:0100022
-    -   key: manifestation of
+    -   key: positively correlated with
         source: HP:0100022
         target: HP:0001300
     -   key: manifestation of
@@ -65461,7 +65417,7 @@
         name: Parkinson Disease, Postencephalitic
     reference:
     - https://go.drugbank.com/drugs/DB00810#mechanism-of-action
--   comments: The disease is denoted as Parkinsonism in the original file. Muscarinic
+-   comment: The disease is also known as Parkinsonism as per the original file. Muscarinic
         antagonists can allow dopamine levels to rebalance, which can help relieve
         some Parkinsonian symptoms e.g. involuntary movements. Anticholinergic drugs
         may also be prescribed to improve bladder dysfunction (https://pubmed.ncbi.nlm.nih.gov/20370804/).
@@ -65508,7 +65464,8 @@
     reference:
     - https://go.drugbank.com/drugs/DB00810#mechanism-of-action
     - https://en.wikipedia.org/wiki/Muscarinic_antagonist#Effects
--   comments: The disease is denoted as Extrapyramidal disease in the original file.
+-   comment: The disease is also known as Extrapyramidal disease as per the original
+        file.
     directed: true
     graph:
         _id: DB00810_MESH_D001480_1
@@ -69453,7 +69410,7 @@
         name: Urinary tract infectious disease
     reference:
     - https://go.drugbank.com/drugs/DB00827#mechanism-of-action
--   comments: The drug is no longer FDA approved (https://en.wikipedia.org/wiki/Tocolytic#Types_of_agents).
+-   comment: The drug is no longer FDA approved (https://en.wikipedia.org/wiki/Tocolytic#Types_of_agents).
     directed: true
     graph:
         _id: DB00867_MESH_D007752_1
@@ -69751,7 +69708,7 @@
     - https://go.drugbank.com/drugs/DB09265
     - https://en.wikipedia.org/wiki/Lixisenatide#Mechanism_of_action
     - https://en.wikipedia.org/wiki/Glucagon-like_peptide-1_receptor#Function_and_therapeutic_potential
--   comments: There seems to be no evidence linking sulfacetamide as treatment for
+-   comment: There seems to be no evidence linking sulfacetamide as treatment for
         Amebic infection. Sulfacetamide is an antibacterial type of drug (https://www.kegg.jp/entry/D05947)
         and it seems the drug has some anti-inflammatory role. Since the disease could
         lead to inflammation and ulceration of the colon perhaps there could be an
@@ -69770,26 +69727,26 @@
         drug_mesh: MESH:D013409
         drugbank: DB:DB00634
     links:
-    -   key: decreases activity of
+    -   key: negatively regulates
         source: MESH:D013409
-        target: MESH:D007249
-    -   key: positively correlated with
-        source: MESH:D007249
+        target: GO:0006954
+    -   key: caused by
+        source: GO:0006954
         target: MESH:D000562
     multigraph: true
     nodes:
     -   id: MESH:D013409
         label: Drug
         name: sulfacetamide
-    -   id: MESH:D007249
+    -   id: GO:0006954
         label: BiologicalProcess
-        name: Inflammation
+        name: inflammatory response
     -   id: MESH:D000562
         label: Disease
         name: Amebic infection
     reference:
     - https://go.drugbank.com/drugs/DB00634#mechanism-of-action
--   comments: The action of the drug on 5-HT2 receptors is of an inverse agonist (https://en.wikipedia.org/wiki/Inverse_agonist).
+-   comment: The action of the drug on 5-HT2 receptors is of an inverse agonist (https://en.wikipedia.org/wiki/Inverse_agonist).
         The dopamine neurons are located in the mesolimbic dopaminergic system (BTO:0005591),
         which is a component pathway of the medial forebrain bundle (UBERON:0001910)(https://en.wikipedia.org/wiki/Medial_forebrain_bundle#Anatomy).
     directed: true
@@ -69858,19 +69815,19 @@
     -   key: correlated with
         source: UBERON:0009834
         target: HP:0000741
-    -   key: positively correlated with
+    -   key: manifestation of
         source: HP:0100543
         target: MESH:D012559
-    -   key: positively correlated with
+    -   key: manifestation of
         source: HP:0030213
         target: MESH:D012559
-    -   key: positively correlated with
+    -   key: manifestation of
         source: HP:0012154
         target: MESH:D012559
-    -   key: positively correlated with
+    -   key: manifestation of
         source: HP:0002465
         target: MESH:D012559
-    -   key: positively correlated with
+    -   key: manifestation of
         source: HP:0000741
         target: MESH:D012559
     -   key: manifestation of
@@ -72305,8 +72262,8 @@
         name: Glaucoma
     reference:
     - https://go.drugbank.com/drugs/DB08808#mechanism-of-action
--   comments: Disease is denoted Infection by Onchocerca volvulus in the original
-        file.
+-   comment: Disease is also known as Infection by Onchocerca volvulus as per the
+        original file.
     directed: true
     graph:
         _id: DB00602_MESH_D009855_2
@@ -72325,8 +72282,11 @@
     -   key: positively correlated with
         source: GO:0005254
         target: GO:0060081
-    -   key: in taxon
+    -   key: negatively regulates
         source: GO:0060081
+        target: GO:0099565
+    -   key: in taxon
+        source: GO:0099565
         target: NCBITaxon:6282
     -   key: causes
         source: NCBITaxon:6282
@@ -72345,6 +72305,9 @@
     -   id: GO:0060081
         label: BiologicalProcess
         name: membrane hyperpolarization
+    -   id: GO:0099565
+        label: BiologicalProcess
+        name: chemical synaptic transmission, postsynaptic
     -   id: NCBITaxon:6282
         label: OrganismTaxon
         name: Onchocerca volvulus
@@ -72354,8 +72317,8 @@
     reference:
     - https://en.wikipedia.org/wiki/Ivermectin#Mechanism_of_action
     - https://go.drugbank.com/drugs/DB00602#mechanism-of-action
-    - https://en.wikipedia.org/wiki/Strongyloidiasis#Treatment
--   comments: Disease is denoted Infection by Strongyloides in the original file.
+    - https://en.wikipedia.org/wiki/Onchocerciasis#Ivermectin
+-   comment: Disease is denoted Infection by Strongyloides in the original file.
     directed: true
     graph:
         _id: DB00602_MESH_D013322_1
@@ -72374,8 +72337,11 @@
     -   key: positively correlated with
         source: GO:0005254
         target: GO:0060081
-    -   key: in taxon
+    -   key: negatively regulates
         source: GO:0060081
+        target: GO:0099565
+    -   key: in taxon
+        source: GO:0099565
         target: NCBITaxon:6248
     -   key: causes
         source: NCBITaxon:6248
@@ -72394,6 +72360,9 @@
     -   id: GO:0060081
         label: BiologicalProcess
         name: membrane hyperpolarization
+    -   id: GO:0099565
+        label: BiologicalProcess
+        name: chemical synaptic transmission, postsynaptic
     -   id: NCBITaxon:6248
         label: OrganismTaxon
         name: Strongyloides stercoralis
@@ -72404,7 +72373,7 @@
     - https://en.wikipedia.org/wiki/Ivermectin#Mechanism_of_action
     - https://go.drugbank.com/drugs/DB00602#mechanism-of-action
     - https://en.wikipedia.org/wiki/Strongyloidiasis#Treatment
--   comments: Balsalazide is a prodrug and it releases mesalazine in the large intestine,
+-   comment: Balsalazide is a prodrug and it releases mesalazine in the large intestine,
         the active site of ulcerative colitis (https://en.wikipedia.org/wiki/Balsalazide
         https://en.wikipedia.org/wiki/Mesalazine#Chemistry).
     directed: true
@@ -72416,12 +72385,15 @@
         drug_mesh: MESH:C038637
         drugbank: DB:DB01014
     links:
-    -   key: produces
+    -   key: has metabolite
         source: MESH:C038637
         target: MESH:D019804
     -   key: decreases activity of
         source: MESH:D019804
-        target: MESH:D011451
+        target: UniProt:P35354
+    -   key: decreases activity of
+        source: MESH:D019804
+        target: UniProt:P23219
     -   key: decreases activity of
         source: MESH:D019804
         target: UniProt:O15111
@@ -72436,7 +72408,7 @@
         target: GO:0007249
     -   key: positively correlated with
         source: GO:0007249
-        target: MESH:D007249
+        target: GO:0006954
     -   key: decreases activity of
         source: MESH:D019804
         target: UniProt:P09917
@@ -72448,30 +72420,27 @@
         target: REACT:R-HSA-1169091
     -   key: positively correlated with
         source: REACT:R-HSA-1169091
-        target: MESH:D007249
-    -   key: positively regulates
-        source: UniProt:P37231
-        target: GO:0060249
-    -   key: located in
-        source: GO:0060249
-        target: UBERON:0001155
+        target: GO:0006954
     -   key: participates in
         source: UniProt:P09917
         target: REACT:R-HSA-2142691
     -   key: participates in
-        source: MESH:D011451
+        source: UniProt:P35354
+        target: REACT:R-HSA-2162123
+    -   key: participates in
+        source: UniProt:P23219
         target: REACT:R-HSA-2162123
     -   key: positively correlated with
         source: REACT:R-HSA-2162123
-        target: MESH:D007249
+        target: GO:0006954
     -   key: positively correlated with
         source: REACT:R-HSA-2142691
-        target: MESH:D007249
+        target: GO:0006954
     -   key: located in
-        source: MESH:D007249
+        source: GO:0006954
         target: UBERON:0001052
     -   key: located in
-        source: MESH:D007249
+        source: GO:0006954
         target: UBERON:0001155
     -   key: location of
         source: UBERON:0001052
@@ -72485,11 +72454,14 @@
         label: Drug
         name: balsalazide
     -   id: MESH:D019804
-        label: Drug
+        label: ChemicalSubstance
         name: Mesalamine
-    -   id: MESH:D011451
-        label: GeneFamily
-        name: Prostaglandin-Endoperoxide Synthases
+    -   id: UniProt:P23219
+        label: Protein
+        name: Prostaglandin G/H synthase 1
+    -   id: UniProt:P35354
+        label: Protein
+        name: Prostaglandin G/H synthase 2
     -   id: UniProt:P09917
         label: Protein
         name: Polyunsaturated fatty acid 5-lipoxygenase
@@ -72505,9 +72477,6 @@
     -   id: GO:0007249
         label: BiologicalProcess
         name: I-kappaB kinase/NF-kappaB signaling
-    -   id: GO:0060249
-        label: BiologicalProcess
-        name: anatomical structure homeostasis
     -   id: REACT:R-HSA-2142691
         label: Pathway
         name: Synthesis of Leukotrienes (LT) and Eoxins (EX)
@@ -72517,9 +72486,9 @@
     -   id: REACT:R-HSA-1169091
         label: Pathway
         name: Activation of NF-kappaB in B cells
-    -   id: MESH:D007249
+    -   id: GO:0006954
         label: BiologicalProcess
-        name: Inflammation
+        name: inflammatory response
     -   id: UBERON:0001052
         label: GrossAnatomicalStructure
         name: rectum
@@ -72650,7 +72619,7 @@
     - https://go.drugbank.com/drugs/DB01224#mechanism-of-action
     - https://go.drugbank.com/drugs/DB01224#BE0000451
     - https://go.drugbank.com/drugs/DB01224#BE0000756
--   comments: Imatinib also modulates other protein targets and is an indication for
+-   comment: Imatinib also modulates other protein targets and is an indication for
         other malignancies (https://en.wikipedia.org/wiki/Imatinib#Medical_uses).
     directed: true
     graph:
@@ -72759,8 +72728,8 @@
     - https://www.cancer.gov/publications/dictionaries/cancer-drug/def/imatinib-mesylate
     - https://en.wikipedia.org/wiki/Leukocytosis#Causes
     - https://en.wikipedia.org/wiki/Chronic_myelogenous_leukemia#Chronic_phase_2
--   comments: The disease is denoted Chronic eosinophilic leukemia in the original
-        file. The malignancy is driven by FIP1L1-PDGFRA fusion genes (https://en.wikipedia.org/wiki/FIP1L1#FIP1L1-PDGFRA_fusion_genes).
+-   comment: The disease is also known as Chronic eosinophilic leukemia as per the
+        original file. The malignancy is driven by FIP1L1-PDGFRA fusion genes (https://en.wikipedia.org/wiki/FIP1L1#FIP1L1-PDGFRA_fusion_genes).
     directed: true
     graph:
         _id: DB00619_MESH_C580364_1
@@ -72772,9 +72741,9 @@
     links:
     -   key: decreases activity of
         source: MESH:D000068877
-        target: MESH:D017479
+        target: UniProt:P16234
     -   key: positively regulates
-        source: MESH:D017479
+        source: UniProt:P16234
         target: GO:0048008
     -   key: positively correlated with
         source: GO:0048008
@@ -72790,9 +72759,9 @@
     -   id: MESH:D000068877
         label: Drug
         name: imatinib
-    -   id: MESH:D017479
-        label: GeneFamily
-        name: Receptors, Platelet-Derived Growth Factor
+    -   id: UniProt:P16234
+        label: Protein
+        name: Platelet-derived growth factor receptor alpha
     -   id: GO:0048008
         label: BiologicalProcess
         name: platelet-derived growth factor receptor signaling pathway
@@ -72812,10 +72781,11 @@
     - https://en.wikipedia.org/wiki/Chronic_eosinophilic_leukemia
     - https://en.wikipedia.org/wiki/Eosinophilia#Chronic_eosinophilic_leukemia_(NOS)
     - https://en.wikipedia.org/wiki/Imatinib#Other
--   comments: The disease is denoted Idiopathic hypereosinophilic syndrome in the
-        original file. Treatment with imatinib is indicated for patients who have
-        a tyrosine kinase fusion protein (https://en.wikipedia.org/wiki/Hypereosinophilic_syndrome#Diagnosis),
-        a PDGFRA-FIP1L1 chimera, where PDGR is an oncogene (https://en.wikipedia.org/wiki/Oncogene#Classification).
+-   comment: The disease is also known as Idiopathic hypereosinophilic syndrome as
+        per the original file. Treatment with imatinib is indicated for patients who
+        have a PDGFRA-FIP1L1 chimera, where PDGR, a tyrosine kinase (https://en.wikipedia.org/wiki/Hypereosinophilic_syndrome#Diagnosis)
+        and an oncogene (https://en.wikipedia.org/wiki/Oncogene#Classification) is
+        fused with FIP1L1, giving rise to a PDGFRA-FIP1L1 chimera.
     directed: true
     graph:
         _id: DB00619_MESH_D017681_1
@@ -72827,9 +72797,6 @@
     links:
     -   key: decreases activity of
         source: MESH:D000068877
-        target: MESH:D015514
-    -   key: derives from
-        source: MESH:D015514
         target: UniProt:P16234
     -   key: positively regulates
         source: UniProt:P16234
@@ -72845,9 +72812,6 @@
     -   id: MESH:D000068877
         label: Drug
         name: imatinib
-    -   id: MESH:D015514
-        label: GeneFamily
-        name: Oncogene Proteins, Fusion
     -   id: UniProt:P16234
         label: Protein
         name: Platelet-derived growth factor receptor alpha
@@ -72865,7 +72829,7 @@
     - https://go.drugbank.com/drugs/DB00619#BE0000205
     - https://go.drugbank.com/drugs/DB00619#BE0000852
     - https://en.wikipedia.org/wiki/Imatinib#Other
--   comments: The majority of Gastrointestinal stromal tumor patients have mutations
+-   comment: The majority of Gastrointestinal stromal tumor patients have mutations
         on the KIT or PDGFRA genes (95% of all patients).
     directed: true
     graph:
@@ -72946,9 +72910,10 @@
     - https://en.wikipedia.org/wiki/Imatinib#Gastrointestinal_stromal_tumors
     - https://go.drugbank.com/drugs/DB00619#BE0000453
     - https://go.drugbank.com/drugs/DB00619#BE0000852
--   comments: The majority of Dermatofibrosarcoma tumours have two genes fused due
-        to a translocation involving the collagen gene (COL1A1) and platelet-derived
-        growth factor (PDGF) genes.
+-   comment: The majority of dermatofibrosarcoma tumours have two genes fused due
+        to a translocation involving the collagen gene (COL1A1) and the platelet-derived
+        growth factor (PDGF). The latter can be further subdivided giving rise to
+        PDGFA, for example, which is an oncogene.
     directed: true
     graph:
         _id: DB00619_MESH_D018223_1
@@ -72960,18 +72925,15 @@
     links:
     -   key: decreases activity of
         source: MESH:D000068877
-        target: MESH:D050506
-    -   key: derives from
-        source: MESH:D050506
-        target: MESH:D010982
+        target: UniProt:P16234
     -   key: positively regulates
-        source: MESH:D010982
+        source: UniProt:P16234
         target: GO:0030154
     -   key: positively regulates
-        source: MESH:D010982
+        source: UniProt:P16234
         target: GO:0008283
     -   key: positively regulates
-        source: MESH:D010982
+        source: UniProt:P16234
         target: MESH:D002470
     -   key: positively correlated with
         source: GO:0008283
@@ -72987,12 +72949,9 @@
     -   id: MESH:D000068877
         label: Drug
         name: imatinib
-    -   id: MESH:D050506
-        label: GeneFamily
-        name: Mutant Chimeric Proteins
-    -   id: MESH:D010982
-        label: GeneFamily
-        name: Platelet-Derived Growth Factor
+    -   id: UniProt:P16234
+        label: Protein
+        name: Platelet-derived growth factor receptor alpha
     -   id: GO:0030154
         label: BiologicalProcess
         name: cell differentiation
@@ -73086,9 +73045,9 @@
     links:
     -   key: decreases activity of
         source: MESH:D014700
-        target: MESH:D020746
+        target: UniProt:Q13936
     -   key: positively regulates
-        source: MESH:D020746
+        source: UniProt:Q13936
         target: GO:0060402
     -   key: positively correlated with
         source: GO:0060402
@@ -73096,7 +73055,7 @@
     -   key: positively correlated with
         source: GO:0042310
         target: HP:0033533
-    -   key: positively correlated with
+    -   key: affects risk for
         source: HP:0033533
         target: HP:0032263
     -   key: manifestation of
@@ -73107,9 +73066,9 @@
     -   id: MESH:D014700
         label: Drug
         name: verapamil
-    -   id: MESH:D020746
-        label: GeneFamily
-        name: Calcium Channels, L-Type
+    -   id: UniProt:Q13936
+        label: Protein
+        name: Voltage-dependent L-type calcium channel subunit alpha-1C
     -   id: GO:0060402
         label: BiologicalProcess
         name: calcium ion transport into cytosol
@@ -73141,15 +73100,15 @@
     links:
     -   key: decreases activity of
         source: MESH:D014700
-        target: MESH:D020746
+        target: UniProt:Q13936
     -   key: positively regulates
-        source: MESH:D020746
+        source: UniProt:Q13936
         target: GO:0061337
     -   key: positively correlated with
         source: GO:0061337
-        target: MESH:D006339
+        target: GO:0060047
     -   key: positively correlated with
-        source: MESH:D006339
+        source: GO:0060047
         target: HP:0001692
     -   key: manifestation of
         source: HP:0001692
@@ -73159,15 +73118,15 @@
     -   id: MESH:D014700
         label: Drug
         name: verapamil
-    -   id: MESH:D020746
-        label: GeneFamily
-        name: Calcium Channels, L-Type
+    -   id: UniProt:Q13936
+        label: Protein
+        name: Voltage-dependent L-type calcium channel subunit alpha-1C
     -   id: GO:0061337
         label: BiologicalProcess
         name: cardiac conduction
-    -   id: MESH:D006339
+    -   id: GO:0060047
         label: BiologicalProcess
-        name: Heart Rate
+        name: heart contraction
     -   id: HP:0001692
         label: PhenotypicFeature
         name: Atrial arrhythmia
@@ -73191,36 +73150,36 @@
     links:
     -   key: decreases activity of
         source: MESH:D014700
-        target: MESH:D020746
+        target: UniProt:Q13936
     -   key: positively regulates
-        source: MESH:D020746
+        source: UniProt:Q13936
         target: GO:0060402
     -   key: positively correlated with
         source: GO:0060402
         target: GO:0042310
     -   key: positively correlated with
         source: GO:0042310
-        target: MESH:D017202
-    -   key: positively correlated with
-        source: MESH:D017202
+        target: HP:0033401
+    -   key: manifestation of
+        source: HP:0033401
         target: MESH:D054058
     multigraph: true
     nodes:
     -   id: MESH:D014700
         label: Drug
         name: verapamil
-    -   id: MESH:D020746
-        label: GeneFamily
-        name: Calcium Channels, L-Type
+    -   id: UniProt:Q13936
+        label: Protein
+        name: Voltage-dependent L-type calcium channel subunit alpha-1C
     -   id: GO:0060402
         label: BiologicalProcess
         name: calcium ion transport into cytosol
     -   id: GO:0042310
         label: BiologicalProcess
         name: vasoconstriction
-    -   id: MESH:D017202
+    -   id: HP:0033401
         label: PhenotypicFeature
-        name: Myocardial Ischemia
+        name: Tissue ischemia
     -   id: MESH:D054058
         label: Disease
         name: Acute coronary syndrome
@@ -73240,36 +73199,36 @@
     links:
     -   key: decreases activity of
         source: MESH:D014700
-        target: MESH:D020746
+        target: UniProt:Q13936
     -   key: positively regulates
-        source: MESH:D020746
+        source: UniProt:Q13936
         target: GO:0060402
     -   key: positively correlated with
         source: GO:0060402
         target: GO:0042310
     -   key: positively correlated with
         source: GO:0042310
-        target: MESH:D017202
-    -   key: positively correlated with
-        source: MESH:D017202
+        target: HP:0033401
+    -   key: manifestation of
+        source: HP:0033401
         target: MESH:D000787
     multigraph: true
     nodes:
     -   id: MESH:D014700
         label: Drug
         name: verapamil
-    -   id: MESH:D020746
-        label: GeneFamily
-        name: Calcium Channels, L-Type
+    -   id: UniProt:Q13936
+        label: Protein
+        name: Voltage-dependent L-type calcium channel subunit alpha-1C
     -   id: GO:0060402
         label: BiologicalProcess
         name: calcium ion transport into cytosol
     -   id: GO:0042310
         label: BiologicalProcess
         name: vasoconstriction
-    -   id: MESH:D017202
+    -   id: HP:0033401
         label: PhenotypicFeature
-        name: Myocardial Ischemia
+        name: Tissue ischemia
     -   id: MESH:D000787
         label: Disease
         name: Angina pectoris
@@ -73279,7 +73238,7 @@
     - https://en.wikipedia.org/wiki/Verapamil#Mechanism_of_action
     - https://en.wikipedia.org/wiki/Antiarrhythmic_agent#Class_IV_agents
     - https://en.wikipedia.org/wiki/Angina#Treatment
--   comments: The disease is denoted as Prinzmetal angina in the original file.
+-   comment: The disease is also known as Prinzmetal angina as per the original file.
     directed: true
     graph:
         _id: DB00661_MESH_D000788_1
@@ -73291,36 +73250,36 @@
     links:
     -   key: decreases activity of
         source: MESH:D014700
-        target: MESH:D020746
+        target: UniProt:Q13936
     -   key: positively regulates
-        source: MESH:D020746
+        source: UniProt:Q13936
         target: GO:0060402
     -   key: positively correlated with
         source: GO:0060402
         target: GO:0042310
     -   key: positively correlated with
         source: GO:0042310
-        target: MESH:D017202
-    -   key: positively correlated with
-        source: MESH:D017202
+        target: HP:0033401
+    -   key: manifestation of
+        source: HP:0033401
         target: MESH:D000788
     multigraph: true
     nodes:
     -   id: MESH:D014700
         label: Drug
         name: verapamil
-    -   id: MESH:D020746
-        label: GeneFamily
-        name: Calcium Channels, L-Type
+    -   id: UniProt:Q13936
+        label: Protein
+        name: Voltage-dependent L-type calcium channel subunit alpha-1C
     -   id: GO:0060402
         label: BiologicalProcess
         name: calcium ion transport into cytosol
     -   id: GO:0042310
         label: BiologicalProcess
         name: vasoconstriction
-    -   id: MESH:D017202
+    -   id: HP:0033401
         label: PhenotypicFeature
-        name: Myocardial Ischemia
+        name: Tissue ischemia
     -   id: MESH:D000788
         label: Disease
         name: Angina Pectoris, Variant
@@ -138815,3 +138774,976 @@
     - https://go.drugbank.com/drugs/DB09109
     - https://en.wikipedia.org/wiki/Factor_VIII
     - https://en.wikipedia.org/wiki/Coagulation
+-   comment: Withdrawn. Tridihexethyl is no longer available in the US market.
+    directed: true
+    graph:
+        _id: DB00505_MESH_D010437_1
+        disease: Peptic ulcer
+        disease_mesh: MESH:D010437
+        drug: Tridihexethyl
+        drug_mesh: MESH:C005386
+        drugbank: DB:DB00505
+    links:
+    -   key: decreases activity of
+        source: MESH:C005386
+        target: UniProt:P20309
+    -   key: participates in
+        source: UniProt:P20309
+        target: GO:0001699
+    -   key: increases abundance of
+        source: GO:0001699
+        target: MESH:D005744
+    -   key: positively regulates
+        source: MESH:D005744
+        target: InterPro:IPR034162
+    -   key: positively correlated with
+        source: InterPro:IPR034162
+        target: MESH:D010437
+    multigraph: true
+    nodes:
+    -   id: MESH:C005386
+        label: Drug
+        name: Tridihexethyl
+    -   id: UniProt:P20309
+        label: Protein
+        name: Muscarinic acetylcholine receptor M3
+    -   id: GO:0001699
+        label: BiologicalProcess
+        name: Acetylcholine-induced gastric acid secretion
+    -   id: MESH:D005744
+        label: ChemicalSubstance
+        name: Gastric acid
+    -   id: InterPro:IPR034162
+        label: GeneFamily
+        name: Pepsin catalytic domain
+    -   id: MESH:D010437
+        label: Disease
+        name: Peptic ulcer
+    reference:
+    - https://go.drugbank.com/drugs/DB00505
+-   comment: Withdrawn. Tridihexethyl is no longer available in the US market.
+    directed: true
+    graph:
+        _id: DB00505_MESH_D013276_1
+        disease: Gastric ulcer
+        disease_mesh: MESH:D013276
+        drug: Tridihexethyl
+        drug_mesh: MESH:C005386
+        drugbank: DB:DB00505
+    links:
+    -   key: decreases activity of
+        source: MESH:C005386
+        target: UniProt:P20309
+    -   key: participates in
+        source: UniProt:P20309
+        target: GO:0001699
+    -   key: increases abundance of
+        source: GO:0001699
+        target: MESH:D005744
+    -   key: positively regulates
+        source: MESH:D005744
+        target: InterPro:IPR034162
+    -   key: positively correlated with
+        source: InterPro:IPR034162
+        target: MESH:D013276
+    multigraph: true
+    nodes:
+    -   id: MESH:C005386
+        label: Drug
+        name: Tridihexethyl
+    -   id: UniProt:P20309
+        label: Protein
+        name: Muscarinic acetylcholine receptor M3
+    -   id: GO:0001699
+        label: BiologicalProcess
+        name: Acetylcholine-induced gastric acid secretion
+    -   id: MESH:D005744
+        label: ChemicalSubstance
+        name: Gastric acid
+    -   id: InterPro:IPR034162
+        label: GeneFamily
+        name: Pepsin catalytic domain
+    -   id: MESH:D013276
+        label: Disease
+        name: Gastric ulcer
+    reference:
+    - https://go.drugbank.com/drugs/DB00505
+-   directed: true
+    graph:
+        _id: DB00733_MESH_D062025_1
+        disease: Organophosphate poisoning
+        disease_mesh: MESH:D062025
+        drug: pralidoxime
+        drug_mesh: MESH:C028797
+        drugbank: DB:DB00733
+    links:
+    -   key: increases activity of
+        source: MESH:C028797
+        target: UniProt:P22303
+    -   key: positively regulates
+        source: UniProt:P22303
+        target: GO:0006581
+    -   key: decreases abundance of
+        source: GO:0006581
+        target: MESH:D000109
+    -   key: contributes to
+        source: MESH:D000109
+        target: GO:0032224
+    -   key: occurs in
+        source: GO:0032224
+        target: MESH:D062025
+    multigraph: true
+    nodes:
+    -   id: MESH:C028797
+        label: Drug
+        name: Pralidoxime
+    -   id: UniProt:P22303
+        label: Protein
+        name: Acetylcholinesterase
+    -   id: GO:0006581
+        label: BiologicalProcess
+        name: Acetylcholine catabolic process
+    -   id: MESH:D000109
+        label: ChemicalSubstance
+        name: Acetylcholine
+    -   id: GO:0032224
+        label: BiologicalProcess
+        name: Positive regulation of synaptic transmission, cholinergic
+    -   id: MESH:D062025
+        label: Disease
+        name: Organophosphate poisoning
+    reference:
+    - https://go.drugbank.com/drugs/DB00733
+    - https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1420/
+    - https://en.wikipedia.org/wiki/Organophosphate_poisoning#Signs_and_symptoms
+-   comment: Trioxsalen is a psoralen derivative that has been used in combination
+        with UV light to treat vitiligo, but has been discontinued by its manufacturer.
+    directed: true
+    graph:
+        _id: DB04571_MESH_D014820_1
+        disease: Vitiligo
+        disease_mesh: MESH:D014820
+        drug: trioxsalen
+        drug_mesh: MESH:D014307
+        drugbank: DB:DB04571
+    links:
+    -   key: disrupts
+        source: MESH:D014307
+        target: MESH:D004247
+    -   key: participates in
+        source: MESH:D004247
+        target: GO:0006915
+    -   key: treats
+        source: GO:0006915
+        target: MESH:D014820
+    multigraph: true
+    nodes:
+    -   id: MESH:D014307
+        label: Drug
+        name: Trioxsalen
+    -   id: MESH:D004247
+        label: ChemicalSubstance
+        name: DNA
+    -   id: GO:0006915
+        label: BiologicalProcess
+        name: Apoptotic process
+    -   id: MESH:D014820
+        label: Disease
+        name: Vitiligo
+    reference:
+    - https://go.drugbank.com/drugs/DB04571
+    - https://en.wikipedia.org/wiki/Vitiligo
+-   comment: The exact mechanism of action of ingenol mebutate in actinic keratosis
+        is unknown.
+    directed: true
+    graph:
+        _id: DB05013_MESH_D055623_1
+        disease: Actinic keratosis
+        disease_mesh: MESH:D055623
+        drug: ingenol mebutate
+        drug_mesh: MESH:C486592
+        drugbank: DB:DB05013
+    links:
+    -   key: increases activity of
+        source: MESH:C486592
+        target: UniProt:Q05655
+    -   key: positively correlated with
+        source: UniProt:Q05655
+        target: GO:0004697
+    -   key: increases activity of
+        source: MESH:C486592
+        target: UniProt:P17252
+    -   key: positively correlated with
+        source: UniProt:P17252
+        target: GO:0004697
+    -   key: positively regulates
+        source: GO:0004697
+        target: GO:0070265
+    -   key: positively regulates
+        source: GO:0004697
+        target: GO:0001788
+    -   key: treats
+        source: GO:0070265
+        target: MESH:D055623
+    -   key: treats
+        source: GO:0001788
+        target: MESH:D055623
+    multigraph: true
+    nodes:
+    -   id: MESH:C486592
+        label: Drug
+        name: Ingenol mebutate
+    -   id: UniProt:Q05655
+        label: Protein
+        name: Protein kinase C delta type
+    -   id: GO:0004697
+        label: MolecularActivity
+        name: Protein kinase C activity
+    -   id: UniProt:P17252
+        label: Protein
+        name: Protein kinase C alpha type
+    -   id: GO:0070265
+        label: BiologicalProcess
+        name: Necrotic cell death
+    -   id: GO:0001788
+        label: BiologicalProcess
+        name: Antibody-dependent cellular cytotoxicity
+    -   id: MESH:D055623
+        label: Disease
+        name: Actinic keratosis
+    reference:
+    - https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4257954/
+    - https://en.wikipedia.org/wiki/Actinic_keratosis
+    - https://go.drugbank.com/drugs/DB05013
+-   directed: true
+    graph:
+        _id: DB05311_MESH_D054179_1
+        disease: Hereditary angioneurotic edema
+        disease_mesh: MESH:D054179
+        drug: ecallantide
+        drug_mesh: MESH:C511194
+        drugbank: DB:DB05311
+    links:
+    -   key: decreases activity of
+        source: MESH:C511194
+        target: UniProt:P03952
+    -   key: increases abundance of
+        source: UniProt:P03952
+        target: MESH:D001920
+    -   key: contributes to
+        source: MESH:D001920
+        target: GO:0043117
+    -   key: contributes to
+        source: MESH:D001920
+        target: GO:0006954
+    -   key: contributes to
+        source: GO:0043117
+        target: HP:0000969
+    -   key: contributes to
+        source: GO:0006954
+        target: HP:0012531
+    -   key: manifestation of
+        source: HP:0000969
+        target: MESH:D054179
+    -   key: manifestation of
+        source: HP:0012531
+        target: MESH:D054179
+    multigraph: true
+    nodes:
+    -   id: MESH:C511194
+        label: Drug
+        name: Ecallantide
+    -   id: UniProt:P03952
+        label: Protein
+        name: Plasma kallikrein
+    -   id: MESH:D001920
+        label: ChemicalSubstance
+        name: Bradykinin
+    -   id: GO:0043117
+        label: BiologicalProcess
+        name: Positive regulation of vascular permeability
+    -   id: GO:0006954
+        label: BiologicalProcess
+        name: Inflammatory response
+    -   id: HP:0000969
+        label: PhenotypicFeature
+        name: Edema
+    -   id: HP:0012531
+        label: PhenotypicFeature
+        name: Pain
+    -   id: MESH:D054179
+        label: Disease
+        name: Hereditary angioneurotic edema
+    reference:
+    - https://go.drugbank.com/drugs/DB05311#BE0002440
+    - https://en.wikipedia.org/wiki/Kinin%E2%80%93kallikrein_system
+-   directed: true
+    graph:
+        _id: DB06590_MESH_D011018_1
+        disease: Pneumococcal pneumonia
+        disease_mesh: MESH:D011018
+        drug: ceftaroline fosamil
+        drug_mesh: MESH:C515501
+        drugbank: DB:DB06590
+    links:
+    -   key: has metabolite
+        source: MESH:C515501
+        target: CHEBI:70729
+    -   key: decreases activity of
+        source: CHEBI:70729
+        target: InterPro:IPR001460
+    -   key: positively regulates
+        source: InterPro:IPR001460
+        target: GO:0009252
+    -   key: contributes to
+        source: GO:0009252
+        target: GO:0009273
+    -   key: in taxon
+        source: GO:0009273
+        target: NCBITaxon:1313
+    -   key: causes
+        source: NCBITaxon:1313
+        target: MESH:D011018
+    multigraph: true
+    nodes:
+    -   id: MESH:C515501
+        label: Drug
+        name: Ceftaroline fosamil
+    -   id: CHEBI:70729
+        label: ChemicalSubstance
+        name: Ceftaroline
+    -   id: InterPro:IPR001460
+        label: GeneFamily
+        name: Penicillin-binding protein, transpeptidase
+    -   id: GO:0009252
+        label: BiologicalProcess
+        name: Peptidoglycan biosynthetic process
+    -   id: GO:0009273
+        label: BiologicalProcess
+        name: Peptidoglycan-based cell wall biogenesis
+    -   id: NCBITaxon:1313
+        label: OrganismTaxon
+        name: Streptococcus pneumoniae
+    -   id: MESH:D011018
+        label: Disease
+        name: Pneumococcal pneumonia
+    reference:
+    - https://go.drugbank.com/drugs/DB06590
+    - https://en.wikipedia.org/wiki/Ceftaroline_fosamil#Chemistry
+-   directed: true
+    graph:
+        _id: DB06590_MESH_D013203_1
+        disease: Infection due to Staphylococcus aureus
+        disease_mesh: MESH:D013203
+        drug: Ceftaroline fosamil
+        drug_mesh: MESH:C515501
+        drugbank: DB:DB06590
+    links:
+    -   key: has metabolite
+        source: MESH:C515501
+        target: CHEBI:70729
+    -   key: decreases activity of
+        source: CHEBI:70729
+        target: InterPro:IPR001460
+    -   key: positively regulates
+        source: InterPro:IPR001460
+        target: GO:0018104
+    -   key: positively regulates
+        source: GO:0018104
+        target: GO:0009273
+    -   key: has output
+        source: GO:0009273
+        target: GO:0005618
+    -   key: occurs in
+        source: GO:0005618
+        target: NCBITaxon:1280
+    -   key: causes
+        source: NCBITaxon:1280
+        target: MESH:D013203
+    multigraph: true
+    nodes:
+    -   id: MESH:C515501
+        label: Drug
+        name: Ceftaroline fosamil
+    -   id: CHEBI:70729
+        label: ChemicalSubstance
+        name: Ceftaroline
+    -   id: InterPro:IPR001460
+        label: GeneFamily
+        name: Penicillin-binding protein, transpeptidase
+    -   id: GO:0018104
+        label: BiologicalProcess
+        name: Cross-linking of the peptidoglycan
+    -   id: GO:0009273
+        label: BiologicalProcess
+        name: Peptidoglycan-based cell wall biogenesis
+    -   id: GO:0005618
+        label: CellularComponent
+        name: Cell wall
+    -   id: NCBITaxon:1280
+        label: OrganismTaxon
+        name: Staphylococcus aureus
+    -   id: MESH:D013203
+        label: Disease
+        name: Infection due to Staphylococcus aureus
+    reference:
+    - https://go.drugbank.com/drugs/DB06590
+    - https://en.wikipedia.org/wiki/Ceftaroline_fosamil#Chemistry
+-   directed: true
+    graph:
+        _id: DB06590_MESH_D012226_1
+        disease: Rhinoscleroma
+        disease_mesh: MESH:D012226
+        drug: Ceftaroline fosamil
+        drug_mesh: MESH:C515501
+        drugbank: DB:DB06590
+    links:
+    -   key: has metabolite
+        source: MESH:C515501
+        target: CHEBI:70729
+    -   key: decreases activity of
+        source: CHEBI:70729
+        target: InterPro:IPR001460
+    -   key: positively regulates
+        source: InterPro:IPR001460
+        target: GO:0018104
+    -   key: positively regulates
+        source: GO:0018104
+        target: GO:0009273
+    -   key: has output
+        source: GO:0009273
+        target: GO:0005618
+    -   key: occurs in
+        source: GO:0005618
+        target: NCBITaxon:39831
+    -   key: causes
+        source: NCBITaxon:39831
+        target: MESH:D012226
+    multigraph: true
+    nodes:
+    -   id: MESH:C515501
+        label: Drug
+        name: Ceftaroline fosamil
+    -   id: CHEBI:70729
+        label: ChemicalSubstance
+        name: Ceftaroline
+    -   id: InterPro:IPR001460
+        label: GeneFamily
+        name: Penicillin-binding protein, transpeptidase
+    -   id: GO:0018104
+        label: BiologicalProcess
+        name: Cross-linking of the peptidoglycan
+    -   id: GO:0009273
+        label: BiologicalProcess
+        name: Peptidoglycan-based cell wall biogenesis
+    -   id: GO:0005618
+        label: CellularComponent
+        name: Cell wall
+    -   id: NCBITaxon:39831
+        label: OrganismTaxon
+        name: Klebsiella pneumoniae subsp. rhinoscleromatis
+    -   id: MESH:D012226
+        label: Disease
+        name: Rhinoscleroma
+    reference:
+    - https://go.drugbank.com/drugs/DB06590
+    - https://en.wikipedia.org/wiki/Ceftaroline_fosamil#Chemistry
+    - https://en.wikipedia.org/wiki/Rhinoscleroma
+-   directed: true
+    graph:
+        _id: DB06590_MESH_D004927_1
+        disease: Infection due to Escherichia coli
+        disease_mesh: MESH:D004927
+        drug: Ceftaroline fosamil
+        drug_mesh: MESH:C515501
+        drugbank: DB:DB06590
+    links:
+    -   key: has metabolite
+        source: MESH:C515501
+        target: CHEBI:70729
+    -   key: decreases activity of
+        source: CHEBI:70729
+        target: InterPro:IPR001460
+    -   key: positively regulates
+        source: InterPro:IPR001460
+        target: GO:0018104
+    -   key: positively regulates
+        source: GO:0018104
+        target: GO:0009273
+    -   key: has output
+        source: GO:0009273
+        target: GO:0005618
+    -   key: occurs in
+        source: GO:0005618
+        target: NCBITaxon:562
+    -   key: causes
+        source: NCBITaxon:562
+        target: MESH:D004927
+    multigraph: true
+    nodes:
+    -   id: MESH:C515501
+        label: Drug
+        name: Ceftaroline fosamil
+    -   id: CHEBI:70729
+        label: ChemicalSubstance
+        name: Ceftaroline
+    -   id: InterPro:IPR001460
+        label: GeneFamily
+        name: Penicillin-binding protein, transpeptidase
+    -   id: GO:0018104
+        label: BiologicalProcess
+        name: Cross-linking of the peptidoglycan
+    -   id: GO:0009273
+        label: BiologicalProcess
+        name: Peptidoglycan-based cell wall biogenesis
+    -   id: GO:0005618
+        label: CellularComponent
+        name: Cell wall
+    -   id: NCBITaxon:562
+        label: OrganismTaxon
+        name: Escherichia coli
+    -   id: MESH:D004927
+        label: Disease
+        name: Infection due to Escherichia coli
+    reference:
+    - https://go.drugbank.com/drugs/DB06590
+    - https://en.wikipedia.org/wiki/Ceftaroline_fosamil#Chemistry
+    - https://en.wikipedia.org/wiki/Rhinoscleroma
+-   directed: true
+    graph:
+        _id: DB06590_MESH_D013290_1
+        disease: Streptococcus pyogenes infection
+        disease_mesh: MESH:D013290
+        drug: Ceftaroline fosamil
+        drug_mesh: MESH:C515501
+        drugbank: DB:DB06590
+    links:
+    -   key: has metabolite
+        source: MESH:C515501
+        target: CHEBI:70729
+    -   key: decreases activity of
+        source: CHEBI:70729
+        target: InterPro:IPR001460
+    -   key: positively regulates
+        source: InterPro:IPR001460
+        target: GO:0018104
+    -   key: positively regulates
+        source: GO:0018104
+        target: GO:0009273
+    -   key: has output
+        source: GO:0009273
+        target: GO:0005618
+    -   key: occurs in
+        source: GO:0005618
+        target: NCBITaxon:1314
+    -   key: causes
+        source: NCBITaxon:1314
+        target: MESH:D013290
+    multigraph: true
+    nodes:
+    -   id: MESH:C515501
+        label: Drug
+        name: Ceftaroline fosamil
+    -   id: CHEBI:70729
+        label: ChemicalSubstance
+        name: Ceftaroline
+    -   id: InterPro:IPR001460
+        label: GeneFamily
+        name: Penicillin-binding protein, transpeptidase
+    -   id: GO:0018104
+        label: BiologicalProcess
+        name: Cross-linking of the peptidoglycan
+    -   id: GO:0009273
+        label: BiologicalProcess
+        name: Peptidoglycan-based cell wall biogenesis
+    -   id: GO:0005618
+        label: CellularComponent
+        name: Cell wall
+    -   id: NCBITaxon:1314
+        label: OrganismTaxon
+        name: Streptococcus pyogenes
+    -   id: MESH:D013290
+        label: Disease
+        name: Streptococcus pyogenes infection
+    reference:
+    - https://go.drugbank.com/drugs/DB06590
+    - https://en.wikipedia.org/wiki/Ceftaroline_fosamil#Chemistry
+-   directed: true
+    graph:
+        _id: DB08816_MESH_D054058_1
+        disease: Acute coronary syndrome
+        disease_mesh: MESH:D054058
+        drug: ticagrelor
+        drug_mesh: MESH:C503700
+        drugbank: DB:DB08816
+    links:
+    -   key: decreases activity of
+        source: MESH:C503700
+        target: UniProt:Q9H244
+    -   key: positively regulates
+        source: UniProt:Q9H244
+        target: GO:0007193
+    -   key: positively regulates
+        source: GO:0007193
+        target: GO:0070527
+    -   key: positively correlated with
+        source: GO:0070527
+        target: GO:0072378
+    -   key: contributes to
+        source: GO:0072378
+        target: MESH:D054058
+    multigraph: true
+    nodes:
+    -   id: MESH:C503700
+        label: Drug
+        name: Ticagrelor
+    -   id: UniProt:Q9H244
+        label: Protein
+        name: P2Y purinoceptor 12
+    -   id: GO:0007193
+        label: BiologicalProcess
+        name: Adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway
+    -   id: GO:0070527
+        label: BiologicalProcess
+        name: Platelet aggregation
+    -   id: GO:0072378
+        label: BiologicalProcess
+        name: Blood coagulation, fibrin clot formation
+    -   id: MESH:D054058
+        label: Disease
+        name: Acute coronary syndrome
+    reference:
+    - https://go.drugbank.com/drugs/DB08816#BE0000110
+-   directed: true
+    graph:
+        _id: DB08816_MESH_D016491_1
+        disease: Peripheral vascular disease
+        disease_mesh: MESH:D016491
+        drug: ticagrelor
+        drug_mesh: MESH:C503700
+        drugbank: DB:DB08816
+    links:
+    -   key: decreases activity of
+        source: MESH:C503700
+        target: UniProt:Q9H244
+    -   key: positively regulates
+        source: UniProt:Q9H244
+        target: GO:0007193
+    -   key: positively regulates
+        source: GO:0007193
+        target: GO:0070527
+    -   key: positively correlated with
+        source: GO:0070527
+        target: GO:0072378
+    -   key: contributes to
+        source: GO:0072378
+        target: MESH:D016491
+    multigraph: true
+    nodes:
+    -   id: MESH:C503700
+        label: Drug
+        name: Ticagrelor
+    -   id: UniProt:Q9H244
+        label: Protein
+        name: P2Y purinoceptor 12
+    -   id: GO:0007193
+        label: BiologicalProcess
+        name: Adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway
+    -   id: GO:0070527
+        label: BiologicalProcess
+        name: Platelet aggregation
+    -   id: GO:0072378
+        label: BiologicalProcess
+        name: Blood coagulation, fibrin clot formation
+    -   id: MESH:D016491
+        label: Disease
+        name: Peripheral vascular disease
+    reference:
+    - https://go.drugbank.com/drugs/DB08816#BE0000110
+-   directed: true
+    graph:
+        _id: DB09113_MESH_D012127_1
+        disease: Respiratory distress syndrome in the newborn
+        disease_mesh: MESH:D012127
+        drug: poractant alfa
+        drug_mesh: MESH:C068291
+        drugbank: DB:DB09113
+    links:
+    -   key: positively regulates
+        source: MESH:C068291
+        target: GO:0043129
+    -   key: negatively correlated with
+        source: GO:0043129
+        target: MESH:D012127
+    multigraph: true
+    nodes:
+    -   id: MESH:C068291
+        label: Drug
+        name: Poractant alfa
+    -   id: GO:0043129
+        label: BiologicalProcess
+        name: Surfactant homeostasis
+    -   id: MESH:D012127
+        label: Disease
+        name: Respiratory distress syndrome in the newborn
+    reference:
+    - https://en.wikipedia.org/wiki/Infant_respiratory_distress_syndrome
+    - https://go.drugbank.com/drugs/DB09113
+-   directed: true
+    graph:
+        _id: DB13064_MESH_D006255_1
+        disease: Seasonal allergic rhinitis
+        disease_mesh: MESH:D006255
+        drug: tramazoline
+        drug_mesh: MESH:C005370
+        drugbank: DB:DB13064
+    links:
+    -   key: increases activity of
+        source: MESH:C005370
+        target: UniProt:P08913
+    -   key: positively regulates
+        source: UniProt:P08913
+        target: GO:0042310
+    -   key: negatively correlated with
+        source: GO:0042310
+        target: HP:0001742
+    -   key: positively correlated with
+        source: HP:0001742
+        target: MESH:D006255
+    multigraph: true
+    nodes:
+    -   id: MESH:C005370
+        label: Drug
+        name: Tramazoline
+    -   id: UniProt:P08913
+        label: Protein
+        name: Alpha-2A adrenergic receptor
+    -   id: GO:0042310
+        label: BiologicalProcess
+        name: Vasoconstriction
+    -   id: HP:0001742
+        label: PhenotypicFeature
+        name: Nasal obstruction
+    -   id: MESH:D006255
+        label: Disease
+        name: Seasonal allergic rhinitis
+    reference:
+    - https://go.drugbank.com/drugs/DB06711#BE0000501
+    - https://drugs.ncats.io/drug/4DG710Q678
+    - https://pubmed.ncbi.nlm.nih.gov/16809058/
+-   directed: true
+    graph:
+        _id: DB13064_MESH_D065631_1
+        disease: Allergic rhinitis
+        disease_mesh: MESH:D065631
+        drug: tramazoline
+        drug_mesh: MESH:C005370
+        drugbank: DB:DB13064
+    links:
+    -   key: increases activity of
+        source: MESH:C005370
+        target: UniProt:P08913
+    -   key: positively regulates
+        source: UniProt:P08913
+        target: GO:0042310
+    -   key: negatively correlated with
+        source: GO:0042310
+        target: HP:0001742
+    -   key: positively correlated with
+        source: HP:0001742
+        target: MESH:D065631
+    multigraph: true
+    nodes:
+    -   id: MESH:C005370
+        label: Drug
+        name: Tramazoline
+    -   id: UniProt:P08913
+        label: Protein
+        name: Alpha-2A adrenergic receptor
+    -   id: GO:0042310
+        label: BiologicalProcess
+        name: Vasoconstriction
+    -   id: HP:0001742
+        label: PhenotypicFeature
+        name: Nasal obstruction
+    -   id: MESH:D065631
+        label: Disease
+        name: Allergic rhinitis
+    reference:
+    - https://go.drugbank.com/drugs/DB06711#BE0000501
+    - https://drugs.ncats.io/drug/4DG710Q678
+    - https://pubmed.ncbi.nlm.nih.gov/16809058/
+-   directed: true
+    graph:
+        _id: DB13064_MESH_D003233_1
+        disease: Allergic conjunctivitis
+        disease_mesh: MESH:D003233
+        drug: tramazoline
+        drug_mesh: MESH:C005370
+        drugbank: DB:DB13064
+    links:
+    -   key: increases activity of
+        source: MESH:C005370
+        target: UniProt:P08913
+    -   key: positively regulates
+        source: UniProt:P08913
+        target: GO:0042310
+    -   key: negatively correlated with
+        source: GO:0042310
+        target: HP:0010783
+    -   key: positively correlated with
+        source: HP:0010783
+        target: MESH:D003233
+    multigraph: true
+    nodes:
+    -   id: MESH:C005370
+        label: Drug
+        name: Tramazoline
+    -   id: UniProt:P08913
+        label: Protein
+        name: Alpha-2A adrenergic receptor
+    -   id: GO:0042310
+        label: BiologicalProcess
+        name: Vasoconstriction
+    -   id: HP:0010783
+        label: PhenotypicFeature
+        name: Erythema
+    -   id: MESH:D003233
+        label: Disease
+        name: Allergic conjunctivitis
+    reference:
+    - https://go.drugbank.com/drugs/DB06711#BE0000501
+    - https://drugs.ncats.io/drug/4DG710Q678
+    - https://pubmed.ncbi.nlm.nih.gov/16809058/
+-   directed: true
+    graph:
+        _id: DB13064_MESH_D012912_1
+        disease: Sneezing
+        disease_mesh: MESH:D012912
+        drug: tramazoline
+        drug_mesh: MESH:C005370
+        drugbank: DB:DB13064
+    links:
+    -   key: increases activity of
+        source: MESH:C005370
+        target: UniProt:P08913
+    -   key: positively regulates
+        source: UniProt:P08913
+        target: GO:0042310
+    -   key: negatively correlated with
+        source: GO:0042310
+        target: HP:0001742
+    -   key: positively correlated with
+        source: HP:0001742
+        target: MESH:D012220
+    -   key: positively correlated with
+        source: MESH:D012220
+        target: MESH:D012912
+    multigraph: true
+    nodes:
+    -   id: MESH:C005370
+        label: Drug
+        name: Tramazoline
+    -   id: UniProt:P08913
+        label: Protein
+        name: Alpha-2A adrenergic receptor
+    -   id: GO:0042310
+        label: BiologicalProcess
+        name: Vasoconstriction
+    -   id: HP:0001742
+        label: PhenotypicFeature
+        name: Nasal obstruction
+    -   id: MESH:D012220
+        label: Disease
+        name: Rhinitis
+    -   id: MESH:D012912
+        label: Disease
+        name: Sneezing
+    reference:
+    - https://go.drugbank.com/drugs/DB06711#BE0000501
+    - https://drugs.ncats.io/drug/4DG710Q678
+    - https://pubmed.ncbi.nlm.nih.gov/16809058/
+-   directed: true
+    graph:
+        _id: DB13064_MESH_D012223_1
+        disease: Vasomotor rhinitis
+        disease_mesh: MESH:D012223
+        drug: tramazoline
+        drug_mesh: MESH:C005370
+        drugbank: DB:DB13064
+    links:
+    -   key: increases activity of
+        source: MESH:C005370
+        target: UniProt:P08913
+    -   key: positively regulates
+        source: UniProt:P08913
+        target: GO:0042310
+    -   key: negatively correlated with
+        source: GO:0042310
+        target: HP:0001742
+    -   key: positively correlated with
+        source: HP:0001742
+        target: MESH:D012223
+    multigraph: true
+    nodes:
+    -   id: MESH:C005370
+        label: Drug
+        name: Tramazoline
+    -   id: UniProt:P08913
+        label: Protein
+        name: Alpha-2A adrenergic receptor
+    -   id: GO:0042310
+        label: BiologicalProcess
+        name: Vasoconstriction
+    -   id: HP:0001742
+        label: PhenotypicFeature
+        name: Nasal obstruction
+    -   id: MESH:D012223
+        label: Disease
+        name: Vasomotor rhinitis
+    reference:
+    - https://go.drugbank.com/drugs/DB06711#BE0000501
+    - https://drugs.ncats.io/drug/4DG710Q678
+    - https://pubmed.ncbi.nlm.nih.gov/16809058/
+-   directed: true
+    graph:
+        _id: DB13064_MESH_D003139_1
+        disease: Common cold
+        disease_mesh: MESH:D003139
+        drug: tramazoline
+        drug_mesh: MESH:C005370
+        drugbank: DB:DB13064
+    links:
+    -   key: increases activity of
+        source: MESH:C005370
+        target: UniProt:P08913
+    -   key: positively regulates
+        source: UniProt:P08913
+        target: GO:0042310
+    -   key: negatively correlated with
+        source: GO:0042310
+        target: HP:0001742
+    -   key: occurs in
+        source: HP:0001742
+        target: MESH:D003139
+    multigraph: true
+    nodes:
+    -   id: MESH:C005370
+        label: Drug
+        name: Tramazoline
+    -   id: UniProt:P08913
+        label: Protein
+        name: Alpha-2A adrenergic receptor
+    -   id: GO:0042310
+        label: BiologicalProcess
+        name: Vasoconstriction
+    -   id: HP:0001742
+        label: PhenotypicFeature
+        name: Nasal obstruction
+    -   id: MESH:D003139
+        label: Disease
+        name: Common cold
+    reference:
+    - https://go.drugbank.com/drugs/DB06711#BE0000501
+    - https://drugs.ncats.io/drug/4DG710Q678
+    - https://pubmed.ncbi.nlm.nih.gov/16809058/
diff --git a/submission.yaml b/submission.yaml
index 87d093df5..8b1378917 100644
--- a/submission.yaml
+++ b/submission.yaml
@@ -1,1841 +1 @@
-- directed: true
-  graph:
-    _id: DB09087_MESH_D010437_1
-    disease: Peptic ulcer
-    disease_mesh: MESH:D010437
-    drug: alum
-    drug_mesh: MESH:D000534
-    drugbank: DB:DB09087
-  links:
-    - key: negatively regulates
-      source: MESH:D000534
-      target: GO:0006954
-    - key: negatively regulates
-      source: MESH:D000534
-      target: GO:0001696
-    - key: positively correlated with
-      source: GO:0006954
-      target: MESH:D010437
-    - key: positively correlated with
-      source: GO:0001696
-      target: MESH:D010437
-  multigraph: true
-  nodes:
-    - id: MESH:D000534
-      label: Drug
-      name: alum
-      alt_ids:
-         - MESH:C041524
-    - id: GO:0001696
-      label: BiologicalProcess
-      name: gastric acid secretion
-    - id: GO:0006954
-      label: BiologicalProcess
-      name: inflammatory response
-    - id: MESH:D010437
-      label: Disease
-      name: Peptic ulcer
-  reference:
-    - https://go.drugbank.com/drugs/DB09087#pharmacodynamics
-    - https://en.wikipedia.org/wiki/Potassium_alum#Medicine_and_cosmetics
-- directed: true
-  graph:
-    _id: DB09087_MESH_D004415_1
-    disease: Dyspepsia
-    disease_mesh: MESH:D004415
-    drug: alum
-    drug_mesh: MESH:D000534
-    drugbank: DB:DB09087
-  links:
-    - key: negatively regulates
-      source: MESH:D000534
-      target: GO:0006954
-    - key: negatively regulates
-      source: MESH:D000534
-      target: GO:0001696
-    - key: positively correlated with
-      source: GO:0006954
-      target: HP:0005263
-    - key: positively correlated with
-      source: GO:0001696
-      target: HP:0002020
-    - key: manifestation of
-      source: HP:0002020
-      target: MESH:D004415
-    - key: manifestation of
-      source: HP:0005263
-      target: MESH:D004415
-  multigraph: true
-  nodes:
-    - id: MESH:D000534
-      label: Drug
-      name: alum
-      alt_ids:
-         - MESH:C041524
-    - id: GO:0001696
-      label: BiologicalProcess
-      name: gastric acid secretion
-    - id: HP:0005263
-      label: PhenotypicFeature
-      name: Gastritis
-    - id: GO:0006954
-      label: BiologicalProcess
-      name: inflammatory response
-    - id: HP:0002020
-      label: PhenotypicFeature
-      name: Gastroesophageal reflux
-    - id: MESH:D004415
-      label: Disease
-      name: Dyspepsia
-  reference:
-    - https://go.drugbank.com/drugs/DB09087#pharmacodynamics
-    - https://en.wikipedia.org/wiki/Potassium_alum#Medicine_and_cosmetics
-  comment: The disease is also known as Indigestion as per in the original file before curation. Note that in the majority of cases no cause can be attributed to leading to the disease. When a cause can indeed be determined, the majority of cases will be due to gastroesophageal reflux and gastritis (https://en.wikipedia.org/wiki/Indigestion#Cause).
-- directed: true
-  graph:
-    _id: DB00736_MESH_D005764_1
-    disease: Gastroesophageal reflux disease
-    disease_mesh: MESH:D005764
-    drug: esomeprazole
-    drug_mesh: MESH:D064098
-    drugbank: DB:DB00736
-  links:
-    - key: decreases activity of
-      source: MESH:D064098
-      target: UniProt:P20648
-    - key: positively correlated with
-      source: UniProt:P20648
-      target: GO:0008900
-    - key: located in
-      source: GO:0008900
-      target: UBERON:0000325
-    - key: positively correlated with
-      source: UBERON:0000325
-      target: GO:0001696
-    - key: positively correlated with
-      source: GO:0001696
-      target: MESH:D006356
-    - key: manifestation of
-      source: MESH:D006356
-      target: MESH:D005764
-  multigraph: true
-  nodes:
-    - id: MESH:D064098
-      label: Drug
-      name: esomeprazole
-    - id: UniProt:P20648
-      label: Protein
-      name: Potassium-transporting ATPase alpha chain 1
-    - id: GO:0008900
-      label: MolecularActivity
-      name: P-type potassium:proton transporter activity
-    - id: UBERON:0000325
-      label: GrossAnatomicalStructure
-      name: gastric gland
-    - id: GO:0001696
-      label: BiologicalProcess
-      name: gastric acid secretion
-    - id: MESH:D006356
-      label: PhenotypicFeature
-      name: Heartburn
-    - id: MESH:D005764
-      label: Disease
-      name: Gastroesophageal reflux disease
-  reference:
-    - https://go.drugbank.com/drugs/DB00736#mechanism-of-action
-    - https://en.wikipedia.org/wiki/Esomeprazole
-    - https://en.wikipedia.org/wiki/Omeprazole#Mechanism_of_action
-  comment: Esomeprazole is the s-isomer of Omeprazole, both are a proton pump inhibitor class of drug and the mechanism of action for both is similar. Weve annotated the path for the S isomer only as it seems this isomer is metabolized more slowly than omeprazole and therefore it will act for longer and more effectively (https://onlinelibrary.wiley.com/doi/pdf/10.1046/j.1365-2036.17.s1.1.x).
-- directed: true
-  graph:
-    _id: DB00736_MESH_D004942_1
-    disease: Esophagitis, Peptic
-    disease_mesh: MESH:D004942
-    drug: esomeprazole
-    drug_mesh: MESH:D064098
-    drugbank: DB:DB00736
-  links:
-    - key: decreases activity of
-      source: MESH:D064098
-      target: UniProt:P20648
-    - key: positively correlated with
-      source: UniProt:P20648
-      target: GO:0008900
-    - key: positively correlated with
-      source: GO:0008900
-      target: GO:0001696
-    - key: positively correlated with
-      source: GO:0001696
-      target: HP:0004791
-    - key: positively correlated with
-      source: GO:0001696
-      target: HP:0002020
-    - key: manifestation of
-      source: HP:0004791
-      target: MESH:D004942
-    - key: manifestation of
-      source: HP:0002020
-      target: MESH:D004942
-  multigraph: true
-  nodes:
-    - id: MESH:D064098
-      label: Drug
-      name: esomeprazole
-    - id: UniProt:P20648
-      label: Protein
-      name: Potassium-transporting ATPase alpha chain 1
-    - id: GO:0008900
-      label: MolecularActivity
-      name: P-type potassium:proton transporter activity
-    - id: GO:0001696
-      label: BiologicalProcess
-      name: gastric acid secretion
-    - id: HP:0004791
-      label: PhenotypicFeature
-      name: Esophageal ulceration
-    - id: HP:0002020
-      label: PhenotypicFeature
-      name: Gastroesophageal reflux
-    - id: MESH:D004942
-      label: Disease
-      name: Esophagitis, Peptic
-  reference:
-    - https://go.drugbank.com/drugs/DB00736#mechanism-of-action
-    - https://en.wikipedia.org/wiki/Esomeprazole
-    - https://en.wikipedia.org/wiki/Omeprazole#Mechanism_of_action
-    - https://en.wikipedia.org/wiki/Esophagitis#Causes
-    - https://en.wikipedia.org/wiki/Esophagitis#Medications
-  comment: Esomeprazole is the s-isomer of Omeprazole, both are a proton pump inhibitor class of drug and the mechanism of action for both is similar. Weve annotated the path for the S isomer only as it seems this isomer is metabolized more slowly than omeprazole and therefore it will act for longer and more effectively (https://onlinelibrary.wiley.com/doi/pdf/10.1046/j.1365-2036.17.s1.1.x). This disease is denoted as Peptic reflux disease in the original file.
-- directed: true
-  graph:
-    _id: DB00736_MESH_D015043_1
-    disease: Zollinger-Ellison syndrome
-    disease_mesh: MESH:D015043
-    drug: esomeprazole
-    drug_mesh: MESH:D064098
-    drugbank: DB:DB00736
-  links:
-    - key: decreases activity of
-      source: MESH:D064098
-      target: UniProt:P20648
-    - key: positively correlated with
-      source: UniProt:P20648
-      target: GO:0008900
-    - key: positively correlated with
-      source: GO:0008900
-      target: GO:0001696
-    - key: positively correlated with
-      source: GO:0001696
-      target: HP:0004398
-    - key: positively correlated with
-      source: GO:0001696
-      target: HP:0002588
-    - key: manifestation of
-      source: HP:0002588
-      target: MESH:D015043
-    - key: manifestation of
-      source: HP:0004398
-      target: MESH:D015043
-  multigraph: true
-  nodes:
-    - id: MESH:D064098
-      label: Drug
-      name: esomeprazole
-    - id: UniProt:P20648
-      label: Protein
-      name: Potassium-transporting ATPase alpha chain 1
-    - id: GO:0008900
-      label: MolecularActivity
-      name: P-type potassium:proton transporter activity
-    - id: GO:0001696
-      label: BiologicalProcess
-      name: gastric acid secretion
-    - id: HP:0002588
-      label: PhenotypicFeature
-      name: Duodenal ulcer
-    - id: HP:0004398
-      label: PhenotypicFeature
-      name: Peptic Ulcer
-    - id: MESH:D015043
-      label: Disease
-      name: Zollinger-Ellison syndrome
-  reference:
-    - https://go.drugbank.com/drugs/DB00736#mechanism-of-action
-    - https://en.wikipedia.org/wiki/Esomeprazole
-    - https://en.wikipedia.org/wiki/Omeprazole#Mechanism_of_action
-    - https://en.wikipedia.org/wiki/Esophagitis#Causes
-    - https://en.wikipedia.org/wiki/Esophagitis#Medications
-    - https://en.wikipedia.org/wiki/Zollinger%E2%80%93Ellison_syndrome#Treatment
-    - https://en.wikipedia.org/wiki/Zollinger%E2%80%93Ellison_syndrome#Pathophysiology
-  comment: Esomeprazole is the s-isomer of Omeprazole, both are a proton pump inhibitor class of drug and the mechanism of action for both is similar. Weve annotated the path for the S isomer only as it seems this isomer is metabolized more slowly than omeprazole and therefore it will act for longer and more effectively (https://onlinelibrary.wiley.com/doi/pdf/10.1046/j.1365-2036.17.s1.1.x). This disease is denoted as Peptic reflux disease in the original file.
-- directed: true
-  graph:
-    _id: DB00736_MESH_D010437_1
-    disease: Peptic ulcer
-    disease_mesh: MESH:D010437
-    drug: esomeprazole
-    drug_mesh: MESH:D064098
-    drugbank: DB:DB00736
-  links:
-    - key: decreases activity of
-      source: MESH:D064098
-      target: UniProt:P20648
-    - key: positively correlated with
-      source: UniProt:P20648
-      target: GO:0008900
-    - key: positively correlated with
-      source: GO:0008900
-      target: GO:0001696
-    - key: positively correlated with
-      source: GO:0001696
-      target: MESH:D010437
-  multigraph: true
-  nodes:
-    - id: MESH:D064098
-      label: Drug
-      name: esomeprazole
-    - id: UniProt:P20648
-      label: Protein
-      name: Potassium-transporting ATPase alpha chain 1
-    - id: GO:0008900
-      label: MolecularActivity
-      name: P-type potassium:proton transporter activity
-    - id: GO:0001696
-      label: BiologicalProcess
-      name: gastric acid secretion
-    - id: MESH:D010437
-      label: Disease
-      name: Peptic ulcer
-  reference:
-    - https://go.drugbank.com/drugs/DB00736#mechanism-of-action
-    - https://en.wikipedia.org/wiki/Esomeprazole
-    - https://en.wikipedia.org/wiki/Omeprazole#Mechanism_of_action
-  comment: Esomeprazole is the s-isomer of Omeprazole, both are a proton pump inhibitor class of drug and the mechanism of action for both is similar. Weve annotated the path for the S isomer only as it seems this isomer is metabolized more slowly than omeprazole and therefore it will act for longer and more effectively (https://onlinelibrary.wiley.com/doi/pdf/10.1046/j.1365-2036.17.s1.1.x). This disease is denoted as Peptic reflux disease in the original file.
-- directed: true
-  graph:
-    _id: DB06742_MESH_D010612_1
-    disease: Pharyngitis
-    disease_mesh: MESH:D010612
-    drug: ambroxol
-    drug_mesh: MESH:D000551
-    drugbank: DB:DB06742
-  links:
-    - key: negatively regulates
-      source: MESH:D000551
-      target: GO:0038060
-    - key: positively correlated with
-      source: GO:0038060
-      target: GO:0006954
-    - key: positively correlated with
-      source: GO:0006954
-      target: HP:0033050
-    - key: negatively regulates
-      source: MESH:D000551
-      target: Pfam:PF06512
-    - key: positively correlated with
-      source: Pfam:PF06512
-      target: GO:0006954
-    - key: increases abundance of
-      source: GO:0038060
-      target: UBERON:0016552
-    - key: positively correlated with
-      source: UBERON:0016552
-      target: HP:0031602
-    - key: positively correlated with
-      source: HP:0031602
-      target: HP:0033050
-    - key: positively correlated with
-      source: Pfam:PF06512
-      target: HP:0012531
-    - key: positively correlated with
-      source: HP:0012531
-      target: HP:0033050
-    - key: manifestation of
-      source: HP:0033050
-      target: MESH:D010612
-  multigraph: true
-  nodes:
-    - id: MESH:D000551
-      label: Drug
-      name: ambroxol
-    - id: GO:0038060
-      label: BiologicalProcess
-      name: nitric oxide-cGMP-mediated signaling pathway
-    - id: HP:0012531
-      label: PhenotypicFeature
-      name: Pain
-    - id: UBERON:0016552
-      label: GrossAnatomicalStructure
-      name: phlegm
-    - id: HP:0031602
-      label: PhenotypicFeature
-      name: Abnormal mucociliary clearance
-    - id: Pfam:PF06512
-      label: GeneFamily
-      name: Sodium ion transport-associated
-    - id: GO:0006954
-      label: BiologicalProcess
-      name: inflammatory response
-    - id: HP:0033050
-      label: PhenotypicFeature
-      name: Pharyngalgia
-    - id: MESH:D010612
-      label: Disease
-      name: Pharyngitis
-  reference:
-    - https://en.wikipedia.org/wiki/Ambroxol#Mechanism_of_action
-    - https://go.drugbank.com/drugs/DB06742#mechanism-of-action
-    - https://pubmed.ncbi.nlm.nih.gov/28937232/
-    - https://en.wikipedia.org/wiki/Sore_throat#Diagnosis
-  comment: The disease is also known as Sore throat symptom as per the original file.
-- directed: true
-  graph:
-    _id: DB06212_MESH_D007010_1
-    disease: Hyponatremia
-    disease_mesh: MESH:D007010
-    drug: tolvaptan
-    drug_mesh: MESH:C116664
-    drugbank: DB:DB06212
-  links:
-    - key: negatively regulates
-      source: MESH:C116664
-      target: UniProt:P30518
-    - key: participates in
-      source: UniProt:P30518
-      target: REACT:R-HSA-432040
-    - key: positively regulates
-      source: REACT:R-HSA-432040
-      target: GO:0070295
-    - key: positively correlated with
-      source: GO:0070295
-      target: MESH:D007010
-  multigraph: true
-  nodes:
-    - id: MESH:C116664
-      label: Drug
-      name: tolvaptan
-    - id: UniProt:P30518
-      label: Protein
-      name: Vasopressin V2 receptor
-    - id: REACT:R-HSA-432040
-      label: Pathway
-      name: Vasopressin regulates renal water homeostasis via Aquaporins
-    - id: GO:0070295
-      label: BiologicalProcess
-      name: renal water absorption
-    - id: MESH:D007010
-      label: Disease
-      name: Hyponatremia
-  reference:
-    - https://go.drugbank.com/drugs/DB06212#mechanism-of-action
-    - https://pubmed.ncbi.nlm.nih.gov/20868352/
-    - https://en.wikipedia.org/wiki/Vasopressin_receptor_antagonist
-  comment: Tolvaptan is also known as aquaretic (https://en.wikipedia.org/wiki/Aquaretic). Note that hyponatremia corresponds to the state where water content is relatively large for the sodium content available (https://pubmed.ncbi.nlm.nih.gov/19322975/), which is possibly due to increased water reabsorption. There are different types of hyponatremia, and medications like tolvaptan should only be used in those patients with high volume or normal volume hyponatremia (https://en.wikipedia.org/wiki/Hyponatremia#Medications).
-- directed: true
-  graph:
-    _id: DB06212_MESH_D007177_1
-    disease: Inappropriate ADH Syndrome
-    disease_mesh: MESH:D007177
-    drug: tolvaptan
-    drug_mesh: MESH:C116664
-    drugbank: DB:DB06212
-  links:
-    - key: negatively regulates
-      source: MESH:C116664
-      target: UniProt:P30518
-    - key: participates in
-      source: UniProt:P30518
-      target: REACT:R-HSA-432040
-    - key: positively regulates
-      source: REACT:R-HSA-432040
-      target: GO:0070295
-    - key: positively correlated with
-      source: GO:0070295
-      target: MESH:D007177
-  multigraph: true
-  nodes:
-    - id: MESH:C116664
-      label: Drug
-      name: tolvaptan
-    - id: UniProt:P30518
-      label: Protein
-      name: Vasopressin V2 receptor
-    - id: REACT:R-HSA-432040
-      label: Pathway
-      name: Vasopressin regulates renal water homeostasis via Aquaporins
-    - id: GO:0070295
-      label: BiologicalProcess
-      name: renal water absorption
-    - id: MESH:D007177
-      label: Disease
-      name: Inappropriate ADH Syndrome
-      alt_names:
-        - Syndrome of Inappropriate ADH Secretion, SIADH
-  reference:
-    - https://go.drugbank.com/drugs/DB06212#mechanism-of-action
-    - https://pubmed.ncbi.nlm.nih.gov/20868352/
-    - https://en.wikipedia.org/wiki/Vasopressin_receptor_antagonist
-    - https://en.wikipedia.org/wiki/Syndrome_of_inappropriate_antidiuretic_hormone_secretion#Treatment
-  comment: This disease is also known as Syndrome of inappropriate vasopressin secretion as per the original file. Tolvaptan is also known as aquaretic (https://en.wikipedia.org/wiki/Aquaretic). Note that hyponatremia corresponds to the state where water content is relatively large for the sodium content available (https://pubmed.ncbi.nlm.nih.gov/19322975/), which is possibly due to increased water reabsorption.
-- directed: true
-  graph:
-    _id: DB06212_MESH_D016891_1
-    disease: Polycystic Kidney, Autosomal Dominant
-    disease_mesh: MESH:D016891
-    drug: tolvaptan
-    drug_mesh: MESH:C116664
-    drugbank: DB:DB06212
-  links:
-    - key: negatively regulates
-      source: MESH:C116664
-      target: UniProt:P30518
-    - key: participates in
-      source: UniProt:P30518
-      target: REACT:R-HSA-418555
-    - key: increases abundance of
-      source: REACT:R-HSA-418555
-      target: CHEBI:17489
-    - key: positively correlated with
-      source: CHEBI:17489
-      target: GO:0008283
-    - key: positively correlated with
-      source: CHEBI:17489
-      target: HP:0000107
-    - key: manifestation of
-      source: HP:0000107
-      target: MESH:D016891
-    - key: positively correlated with
-      source: GO:0008283
-      target: MESH:D016891
-  multigraph: true
-  nodes:
-    - id: MESH:C116664
-      label: Drug
-      name: tolvaptan
-    - id: UniProt:P30518
-      label: Protein
-      name: Vasopressin V2 receptor
-    - id: REACT:R-HSA-418555
-      label: Pathway
-      name: G alpha (s) signalling events
-    - id: CHEBI:17489
-      label: ChemicalSubstance
-      name: 3,5-cyclic AMP
-    - id: HP:0000107
-      label: PhenotypicFeature
-      name: Renal cyst
-    - id: GO:0008283
-      label: BiologicalProcess
-      name: cell population proliferation
-    - id: MESH:D016891
-      label: Disease
-      name: Polycystic Kidney, Autosomal Dominant
-  reference:
-    - https://go.drugbank.com/drugs/DB06212#mechanism-of-action
-    - https://pubmed.ncbi.nlm.nih.gov/20868352/
-    - https://en.wikipedia.org/wiki/Autosomal_dominant_polycystic_kidney_disease#Aquaretic_medication
-    - https://en.wikipedia.org/wiki/Vasopressin_receptor_antagonist#Polycystic_kidney_disease
-  comment: This disease is also known as Polycystic kidney disease adult type as per the original file. Tolvaptan is also known as aquaretic (https://en.wikipedia.org/wiki/Aquaretic). Note that hyponatremia corresponds to the state where water content is relatively large for the sodium content available (https://pubmed.ncbi.nlm.nih.gov/19322975/), which is possibly due to increased water reabsorption.
-- directed: true
-  graph:
-    _id: DB00810_MESH_D010300_1
-    disease: Parkinson's disease
-    disease_mesh: MESH:D010300
-    drug: biperiden
-    drug_mesh: MESH:D001712
-    drugbank: DB:DB00810
-  links:
-    - key: negatively regulates
-      source: MESH:D001712
-      target: UniProt:P11229
-    - key: positively regulates
-      source: UniProt:P11229
-      target: GO:0007271
-    - key: positively correlated with
-      source: GO:0007271
-      target: HP:0100022
-    - key: manifestation of
-      source: HP:0100022
-      target: MESH:D010300
-  multigraph: true
-  nodes:
-    - id: MESH:D001712
-      label: Drug
-      name: biperiden
-      alt_ids:
-        - MESH:C036432
-    - id: UniProt:P11229
-      label: Protein
-      name: Muscarinic acetylcholine receptor M1
-    - id: GO:0007271
-      label: BiologicalProcess
-      name: synaptic transmission, cholinergic
-    - id: HP:0100022
-      label: PhenotypicFeature
-      name: Abnormality of movement
-    - id: MESH:D010300
-      label: Disease
-      name: Parkinson's disease
-  reference: https://go.drugbank.com/drugs/DB00810#mechanism-of-action
-  comment: In Parkinson's disease, there is imbalance between levels of acetylcholine and dopamine, where increased levels of acetylcholine and degeneration of dopaminergic pathways are observed. Therefore, muscarinic antagonists such as biperiden block central cholinergic activity and balancing out neurotransmitters in the brain (https://en.wikipedia.org/wiki/Muscarinic_antagonist#Effects). Anticholinergic drugs may also be prescribed to improve bladder dysfunction (https://pubmed.ncbi.nlm.nih.gov/20370804/).
-- directed: true
-  graph:
-    _id: DB00810_MESH_D010301_1
-    disease: Parkinson Disease, Postencephalitic
-    disease_mesh: MESH:D010301
-    drug: biperiden
-    drug_mesh: MESH:D001712
-    drugbank: DB:DB00810
-  links:
-    - key: negatively regulates
-      source: MESH:D001712
-      target: UniProt:P11229
-    - key: positively regulates
-      source: UniProt:P11229
-      target: GO:0007271
-    - key: positively correlated with
-      source: GO:0007271
-      target: HP:0100022
-    - key: positively correlated with
-      source: HP:0100022
-      target: HP:0001300
-    - key: manifestation of
-      source: HP:0001300
-      target: MESH:D010301
-  multigraph: true
-  nodes:
-    - id: MESH:D001712
-      label: Drug
-      name: biperiden
-      alt_ids:
-        - MESH:C036432
-    - id: UniProt:P11229
-      label: Protein
-      name: Muscarinic acetylcholine receptor M1
-    - id: GO:0007271
-      label: BiologicalProcess
-      name: synaptic transmission, cholinergic
-    - id: HP:0100022
-      label: PhenotypicFeature
-      name: Abnormality of movement
-    - id: HP:0001300
-      label: PhenotypicFeature
-      name: Parkinsonism
-    - id: MESH:D010301
-      label: Disease
-      name: Parkinson Disease, Postencephalitic
-  reference: https://go.drugbank.com/drugs/DB00810#mechanism-of-action
-  comment: The disease is denoted as Postencephalitic parkinsonism in the original file. This disease is believed to be caused by a viral infection, leading to clinical parkinsonism (https://en.wikipedia.org/wiki/Postencephalitic_parkinsonism) and anti-Parkinson drugs may be helpful in treating the symptoms (https://en.wikipedia.org/wiki/Encephalitis_lethargica). For example, muscarinic antagonists can allow dopamine levels to rebalance, which can help relieve some Parkinsonian symptoms e.g. involuntary movements. Anticholinergic drugs may also be prescribed to improve bladder dysfunction (https://pubmed.ncbi.nlm.nih.gov/20370804/).
-- directed: true
-  graph:
-    _id: DB00810_MESH_D020734_1
-    disease: Parkinsonian Disorders
-    disease_mesh: MESH:D020734
-    drug: biperiden
-    drug_mesh: MESH:D001712
-    drugbank: DB:DB00810
-  links:
-    - key: negatively regulates
-      source: MESH:D001712
-      target: UniProt:P11229
-    - key: positively regulates
-      source: UniProt:P11229
-      target: GO:0007271
-    - key: positively correlated with
-      source: GO:0007271
-      target: HP:0100022
-    - key: manifestation of
-      source: HP:0100022
-      target: MESH:D020734
-  multigraph: true
-  nodes:
-    - id: MESH:D001712
-      label: Drug
-      name: biperiden
-      alt_ids:
-        - MESH:C036432
-    - id: UniProt:P11229
-      label: Protein
-      name: Muscarinic acetylcholine receptor M1
-    - id: GO:0007271
-      label: BiologicalProcess
-      name: synaptic transmission, cholinergic
-    - id: HP:0100022
-      label: PhenotypicFeature
-      name: Abnormality of movement
-    - id: MESH:D020734
-      label: Disease
-      name: Parkinsonian Disorders
-  reference:
-    - https://go.drugbank.com/drugs/DB00810#mechanism-of-action
-    - https://en.wikipedia.org/wiki/Muscarinic_antagonist#Effects
-  comment: The disease is also known as Parkinsonism as per the original file. Muscarinic antagonists can allow dopamine levels to rebalance, which can help relieve some Parkinsonian symptoms e.g. involuntary movements. Anticholinergic drugs may also be prescribed to improve bladder dysfunction (https://pubmed.ncbi.nlm.nih.gov/20370804/).
-- directed: true
-  graph:
-    _id: DB00810_MESH_D001480_1
-    disease: Basal Ganglia Diseases
-    disease_mesh: MESH:D001480
-    drug: biperiden
-    drug_mesh: MESH:D001712
-    drugbank: DB:DB00810
-  links:
-    - key: negatively regulates
-      source: MESH:D001712
-      target: UniProt:P11229
-    - key: positively regulates
-      source: UniProt:P11229
-      target: GO:0007271
-    - key: positively correlated with
-      source: GO:0007271
-      target: HP:0002071
-    - key: manifestation of
-      source: HP:0002071
-      target: MESH:D001480
-  multigraph: true
-  nodes:
-    - id: MESH:D001712
-      label: Drug
-      name: biperiden
-      alt_ids:
-        - MESH:C036432
-    - id: UniProt:P11229
-      label: Protein
-      name: Muscarinic acetylcholine receptor M1
-    - id: GO:0007271
-      label: BiologicalProcess
-      name: synaptic transmission, cholinergic
-    - id: HP:0002071
-      label: PhenotypicFeature
-      name: Abnormality of extrapyramidal motor function
-    - id: MESH:D001480
-      label: Disease
-      name: Basal Ganglia Diseases
-  reference:
-    - https://go.drugbank.com/drugs/DB00810#mechanism-of-action
-    - https://en.wikipedia.org/wiki/Muscarinic_antagonist#Effects
-    - https://en.wikipedia.org/wiki/Extrapyramidal_symptoms#Treatment
-  comment: The disease is also known as Extrapyramidal disease as per the original file.
-- directed: true
-  graph:
-    _id: DB00205_MESH_D008288_1
-    disease: Malaria
-    disease_mesh: MESH:D008288
-    drug: pyrimethamine
-    drug_mesh: MESH:D011739
-    drugbank: DB:DB00205
-  links:
-    - key: negatively regulates
-      source: MESH:D011739
-      target: UniProt:P13922
-    - key: positively regulates
-      source: UniProt:P13922
-      target: GO:0046654
-    - key: positively correlated with
-      source: GO:0046654
-      target: GO:0006221
-    - key: positively correlated with
-      source: GO:0046654
-      target: GO:0019363
-    - key: positively correlated with
-      source: GO:0006221
-      target: GO:0000280
-    - key: positively correlated with
-      source: GO:0019363
-      target: GO:0000280
-    - key: in taxon
-      source: GO:0000280
-      target: NCBITaxon:5839
-    - key: causes
-      source: NCBITaxon:5839
-      target: MESH:D008288
-  multigraph: true
-  nodes:
-    - id: MESH:D011739
-      label: Drug
-      name: pyrimethamine
-    - id: UniProt:P13922
-      label: Protein
-      name: Bifunctional dihydrofolate reductase-thymidylate synthase
-    - id: GO:0046654
-      label: BiologicalProcess
-      name: tetrahydrofolate biosynthetic process
-    - id: GO:0006221
-      label: BiologicalProcess
-      name: pyrimidine nucleotide biosynthetic process
-    - id: GO:0019363
-      label: BiologicalProcess
-      name: pyridine nucleotide biosynthetic process
-    - id: GO:0000280
-      label: BiologicalProcess
-      name: nuclear division
-    - id: NCBITaxon:5839
-      label: OrganismTaxon
-      name: Plasmodium falciparum K1
-    - id: MESH:D008288
-      label: Disease
-      name: Malaria
-  reference:
-    - https://go.drugbank.com/drugs/DB00205#mechanism-of-action
-    - https://www.ebi.ac.uk/chembl/target_report_card/CHEMBL1939/
-- directed: true
-  graph:
-    _id: DB00205_MESH_D014123_1
-    disease: Toxoplasmosis
-    disease_mesh: MESH:D014123
-    drug: pyrimethamine
-    drug_mesh: MESH:D011739
-    drugbank: DB:DB00205
-  links:
-    - key: negatively regulates
-      source: MESH:D011739
-      target: Pfam:PF00186
-    - key: positively regulates
-      source: Pfam:PF00186
-      target: GO:0046654
-    - key: positively correlated with
-      source: GO:0046654
-      target: GO:0006221
-    - key: positively correlated with
-      source: GO:0046654
-      target: GO:0019363
-    - key: positively correlated with
-      source: GO:0006221
-      target: GO:0000280
-    - key: positively correlated with
-      source: GO:0019363
-      target: GO:0000280
-    - key: in taxon
-      source: GO:0000280
-      target: NCBITaxon:5811
-    - key: causes
-      source: NCBITaxon:5811
-      target: MESH:D014123
-  multigraph: true
-  nodes:
-    - id: MESH:D011739
-      label: Drug
-      name: pyrimethamine
-    - id: Pfam:PF00186
-      label: GeneFamily
-      name: Dihydrofolate reductase
-    - id: GO:0046654
-      label: BiologicalProcess
-      name: tetrahydrofolate biosynthetic process
-    - id: GO:0006221
-      label: BiologicalProcess
-      name: pyrimidine nucleotide biosynthetic process
-    - id: GO:0019363
-      label: BiologicalProcess
-      name: pyridine nucleotide biosynthetic process
-    - id: GO:0000280
-      label: BiologicalProcess
-      name: nuclear division
-    - id: NCBITaxon:5811
-      label: OrganismTaxon
-      name: Toxoplasma gondii
-    - id: MESH:D014123
-      label: Disease
-      name: Toxoplasmosis
-  reference:
-    - https://go.drugbank.com/drugs/DB00205#mechanism-of-action
-    - https://www.ebi.ac.uk/chembl/target_report_card/CHEMBL1939/
-- directed: true
-  graph:
-    _id: DB00867_MESH_D007752_1
-    disease: Premature labor
-    disease_mesh: MESH:D007752
-    drug: ritodrine
-    drug_mesh: MESH:D012312
-    drugbank: DB:DB00867
-  links:
-    - key: positively regulates
-      source: MESH:D012312
-      target: UniProt:P07550
-    - key: positively regulates
-      source: UniProt:P07550
-      target: GO:0044558
-    - key: negatively correlated with
-      source: GO:0044558
-      target: MESH:D007752
-  multigraph: true
-  nodes:
-    - id: MESH:D012312
-      label: Drug
-      name: ritodrine
-    - id: UniProt:P07550
-      label: Protein
-      name: Beta-2 adrenergic receptor
-    - id: GO:0044558
-      label: BiologicalProcess
-      name: uterine smooth muscle relaxation
-    - id: MESH:D007752
-      label: Disease
-      name: Premature labor
-  reference:
-    - https://go.drugbank.com/drugs/DB00867#mechanism-of-action
-    - https://en.wikipedia.org/wiki/Ritodrine
-  comment: The drug is no longer FDA approved (https://en.wikipedia.org/wiki/Tocolytic#Types_of_agents).
-- directed: true
-  graph:
-    _id: DB00634_MESH_D000562_1
-    disease: Amebic infection
-    disease_mesh: MESH:D000562
-    drug: sulfacetamide
-    drug_mesh: MESH:D013409
-    drugbank: DB:DB00634
-  links:
-    - key: negatively regulates
-      source: MESH:D013409
-      target: GO:0006954
-    - key: caused by
-      source: GO:0006954
-      target: MESH:D000562
-  multigraph: true
-  nodes:
-    - id: MESH:D013409
-      label: Drug
-      name: sulfacetamide
-    - id: GO:0006954
-      label: BiologicalProcess
-      name: inflammatory response
-    - id: MESH:D000562
-      label: Disease
-      name: Amebic infection
-  reference: https://go.drugbank.com/drugs/DB00634#mechanism-of-action
-  comment: There seems to be no evidence linking sulfacetamide as treatment for Amebic infection. Sulfacetamide is an antibacterial type of drug (https://www.kegg.jp/entry/D05947) and it seems the drug has some anti-inflammatory role. Since the disease could lead to inflammation and ulceration of the colon perhaps there could be an anti-inflammation hypothesis but the drug is mainly available as eye drops and lotions (https://en.wikipedia.org/wiki/Sulfacetamide#Available_forms), and therefore unavailable to treat the intestinal tract in such formats. Note there are few amoeba species that may cause skin or eye issues (https://en.wikipedia.org/wiki/Acanthamoeba_keratitis), in which case sulfacetamide could potentially be an indication, albeit no evidence to prove this assumption has been found in databases or literature.
-- directed: true
-  graph:
-    _id: DB08922_MESH_D012559_1
-    disease: Schizophrenia
-    disease_mesh: MESH:D012559
-    drug: perospirone
-    drug_mesh: MESH:C065533
-    drugbank: DB:DB08922
-  links:
-    - key: increases activity of
-      source: MESH:C065533
-      target: UniProt:P08908
-    - key: decreases activity of
-      source: MESH:C065533
-      target: UniProt:P14416
-    - key: decreases activity of
-      source: MESH:C065533
-      target: UniProt:P28223
-    - key: negatively correlated with
-      source: UniProt:P08908
-      target: HP:0000739
-    - key: positively regulates
-      source: UniProt:P28223
-      target: GO:0014046
-    - key: positively regulates
-      source: UniProt:P28223
-      target: GO:0014047
-    - key: positively correlated with
-      source: GO:0014047
-      target: GO:0004952
-    - key: positively correlated with
-      source: GO:0004952
-      target: HP:0000709
-    - key: positively regulates
-      source: UniProt:P14416
-      target: GO:0014046
-    - key: increases abundance of
-      source: GO:0014046
-      target: CHEBI:18243
-    - key: located in
-      source: CHEBI:18243
-      target: UBERON:0001910
-    - key: correlated with
-      source: UBERON:0001910
-      target: HP:0000709
-    - key: positively correlated with
-      source: HP:0000709
-      target: MESH:D012559
-    - key: located in
-      source: CHEBI:18243
-      target: UBERON:0009834
-    - key: correlated with
-      source: UBERON:0009834
-      target: HP:0100543
-    - key: correlated with
-      source: UBERON:0009834
-      target: HP:0030213
-    - key: correlated with
-      source: UBERON:0009834
-      target: HP:0012154
-    - key: correlated with
-      source: UBERON:0009834
-      target: HP:0002465
-    - key: correlated with
-      source: UBERON:0009834
-      target: HP:0000741
-    - key: manifestation of
-      source: HP:0100543
-      target: MESH:D012559
-    - key: manifestation of
-      source: HP:0030213
-      target: MESH:D012559
-    - key: manifestation of
-      source: HP:0012154
-      target: MESH:D012559
-    - key: manifestation of
-      source: HP:0002465
-      target: MESH:D012559
-    - key: manifestation of
-      source: HP:0000741
-      target: MESH:D012559
-    - key: manifestation of
-      source: HP:0000739
-      target: MESH:D012559
-  multigraph: true
-  nodes:
-    - id: MESH:C065533
-      label: Drug
-      name: perospirone
-    - id: UniProt:P28223
-      label: Protein
-      name: 5-hydroxytryptamine receptor 2A
-    - id: UniProt:P14416
-      label: Protein
-      name: D(2) dopamine receptor
-    - id: UniProt:P08908
-      label: Protein
-      name: 5-hydroxytryptamine receptor 1A
-    - id: GO:0014046
-      label: BiologicalProcess
-      name: dopamine secretion
-    - id: GO:0014047
-      label: BiologicalProcess
-      name: glutamate secretion
-    - id: GO:0004952
-      label: MolecularActivity
-      name: dopamine neurotransmitter receptor activity
-    - id: CHEBI:18243
-      label: ChemicalSubstance
-      name: dopamine
-    - id: UBERON:0009834
-      label: GrossAnatomicalStructure
-      name: dorsolateral prefrontal cortex
-    - id: UBERON:0001910
-      label: GrossAnatomicalStructure
-      name: medial forebrain bundle
-    - id: HP:0100543
-      label: PhenotypicFeature
-      name: Cognitive impairment
-    - id: HP:0030213
-      label: PhenotypicFeature
-      name: Emotional blunting
-    - id: HP:0012154
-      label: PhenotypicFeature
-      name: Anhedonia
-    - id: HP:0002465
-      label: PhenotypicFeature
-      name: Poor speech
-    - id: HP:0000741
-      label: PhenotypicFeature
-      name: Apathy
-    - id: HP:0000709
-      label: PhenotypicFeature
-      name: Psychosis
-    - id: HP:0000739
-      label: PhenotypicFeature
-      name: Anxiety
-    - id: MESH:D012559
-      label: Disease
-      name: Schizophrenia
-  reference:
-    - https://go.drugbank.com/drugs/DB08922#mechanism-of-action
-    - https://en.wikipedia.org/wiki/Antipsychotic#Mechanism_of_action
-    - https://en.wikipedia.org/wiki/Mesolimbic_pathway#Relation_to_neurological_and_psychological_disorders
-    - https://en.wikipedia.org/wiki/Schizophrenia#Signs_and_symptoms
-    - https://en.wikipedia.org/wiki/Dopaminergic_pathways#Pathways
-    - https://en.wikipedia.org/wiki/Mesocortical_pathway
-    - https://en.wikipedia.org/wiki/Dopamine_hypothesis_of_schizophrenia#Introduction
-    - https://en.wikipedia.org/wiki/Atypical_antipsychotic#Pharmacology
-    - https://en.wikipedia.org/wiki/5-HT1A_receptor#Function
-  comment: The action of the drug on 5-HT2 receptors is of an inverse agonist (https://en.wikipedia.org/wiki/Inverse_agonist). The dopamine neurons are located in the mesolimbic dopaminergic system (BTO:0005591), which is a component pathway of the medial forebrain bundle (UBERON:0001910)(https://en.wikipedia.org/wiki/Medial_forebrain_bundle#Anatomy).
-- directed: true
-  graph:
-    _id: DB00602_MESH_D009855_2
-    disease: Onchocerciasis
-    disease_mesh: MESH:D009855
-    drug: ivermectin
-    drug_mesh: MESH:D007559
-    drugbank: DB:DB00602
-  links:
-    - key: increases activity of
-      source: MESH:D007559
-      target: InterPro:IPR015680
-    - key: positively regulates
-      source: InterPro:IPR015680
-      target: GO:0005254
-    - key: positively correlated with
-      source: GO:0005254
-      target: GO:0060081
-    - key: negatively regulates
-      source: GO:0060081
-      target: GO:0099565
-    - key: in taxon
-      source: GO:0099565
-      target: NCBITaxon:6282
-    - key: causes
-      source: NCBITaxon:6282
-      target: MESH:D009855
-  multigraph: true
-  nodes:
-    - id: MESH:D007559
-      label: Drug
-      name: ivermectin
-    - id: InterPro:IPR015680
-      label: GeneFamily
-      name: Glutamate-Gated Chloride Channel
-    - id: GO:0005254
-      label: MolecularActivity
-      name: chloride channel activity
-    - id: GO:0060081
-      label: BiologicalProcess
-      name: membrane hyperpolarization
-    - id: GO:0099565
-      label: BiologicalProcess
-      name: chemical synaptic transmission, postsynaptic
-    - id: NCBITaxon:6282
-      label: OrganismTaxon
-      name: Onchocerca volvulus
-    - id: MESH:D009855
-      label: Disease
-      name: Onchocerciasis
-  reference:
-    - https://en.wikipedia.org/wiki/Ivermectin#Mechanism_of_action
-    - https://go.drugbank.com/drugs/DB00602#mechanism-of-action
-    - https://en.wikipedia.org/wiki/Onchocerciasis#Ivermectin
-  comment: Disease is also known as Infection by Onchocerca volvulus as per the original file.
-- directed: true
-  graph:
-    _id: DB00602_MESH_D013322_1
-    disease: Strongyloidiasis
-    disease_mesh: MESH:D013322
-    drug: ivermectin
-    drug_mesh: MESH:D007559
-    drugbank: DB:DB00602
-  links:
-    - key: increases activity of
-      source: MESH:D007559
-      target: InterPro:IPR015680
-    - key: positively regulates
-      source: InterPro:IPR015680
-      target: GO:0005254
-    - key: positively correlated with
-      source: GO:0005254
-      target: GO:0060081
-    - key: negatively regulates
-      source: GO:0060081
-      target: GO:0099565
-    - key: in taxon
-      source: GO:0099565
-      target: NCBITaxon:6248
-    - key: causes
-      source: NCBITaxon:6248
-      target: MESH:D013322
-  multigraph: true
-  nodes:
-    - id: MESH:D007559
-      label: Drug
-      name: ivermectin
-    - id: InterPro:IPR015680
-      label: GeneFamily
-      name: Glutamate-Gated Chloride Channel
-    - id: GO:0005254
-      label: MolecularActivity
-      name: chloride channel activity
-    - id: GO:0060081
-      label: BiologicalProcess
-      name: membrane hyperpolarization
-    - id: GO:0099565
-      label: BiologicalProcess
-      name: chemical synaptic transmission, postsynaptic
-    - id: NCBITaxon:6248
-      label: OrganismTaxon
-      name: Strongyloides stercoralis
-    - id: MESH:D013322
-      label: Disease
-      name: Strongyloidiasis
-  reference:
-    - https://en.wikipedia.org/wiki/Ivermectin#Mechanism_of_action
-    - https://go.drugbank.com/drugs/DB00602#mechanism-of-action
-    - https://en.wikipedia.org/wiki/Strongyloidiasis#Treatment
-  comment: Disease is denoted Infection by Strongyloides in the original file.
-- directed: true
-  graph:
-    _id: DB01014_MESH_D003093_1
-    disease: Ulcerative colitis
-    disease_mesh: MESH:D003093
-    drug: balsalazide
-    drug_mesh: MESH:C038637
-    drugbank: DB:DB01014
-  links:
-    - key: has metabolite
-      source: MESH:C038637
-      target: MESH:D019804
-    - key: decreases activity of
-      source: MESH:D019804
-      target: UniProt:P35354
-    - key: decreases activity of
-      source: MESH:D019804
-      target: UniProt:P23219
-    - key: decreases activity of
-      source: MESH:D019804
-      target: UniProt:O15111
-    - key: decreases activity of
-      source: MESH:D019804
-      target: UniProt:O14920
-    - key: positively regulates
-      source: UniProt:O14920
-      target: GO:0007249
-    - key: positively regulates
-      source: UniProt:O15111
-      target: GO:0007249
-    - key: positively correlated with
-      source: GO:0007249
-      target: GO:0006954
-    - key: decreases activity of
-      source: MESH:D019804
-      target: UniProt:P09917
-    - key: increases activity of
-      source: MESH:D019804
-      target: UniProt:P37231
-    - key: negatively correlated with
-      source: UniProt:P37231
-      target: REACT:R-HSA-1169091
-    - key: positively correlated with
-      source: REACT:R-HSA-1169091
-      target: GO:0006954
-    - key: participates in
-      source: UniProt:P09917
-      target: REACT:R-HSA-2142691
-    - key: participates in
-      source: UniProt:P35354
-      target: REACT:R-HSA-2162123
-    - key: participates in
-      source: UniProt:P23219
-      target: REACT:R-HSA-2162123
-    - key: positively correlated with
-      source: REACT:R-HSA-2162123
-      target: GO:0006954
-    - key: positively correlated with
-      source: REACT:R-HSA-2142691
-      target: GO:0006954
-    - key: located in
-      source: GO:0006954
-      target: UBERON:0001052
-    - key: located in
-      source: GO:0006954
-      target: UBERON:0001155
-    - key: location of
-      source: UBERON:0001052
-      target: MESH:D003093
-    - key: location of
-      source: UBERON:0001155
-      target: MESH:D003093
-  multigraph: true
-  nodes:
-    - id: MESH:C038637
-      label: Drug
-      name: balsalazide
-    - id: MESH:D019804
-      label: ChemicalSubstance
-      name: Mesalamine
-    - id: UniProt:P23219
-      label: Protein
-      name: Prostaglandin G/H synthase 1
-    - id: UniProt:P35354
-      label: Protein
-      name: Prostaglandin G/H synthase 2
-    - id: UniProt:P09917
-      label: Protein
-      name: Polyunsaturated fatty acid 5-lipoxygenase
-    - id: UniProt:P37231
-      label: Protein
-      name: Peroxisome proliferator-activated receptor gamma
-    - id: UniProt:O15111
-      label: Protein
-      name: Inhibitor of nuclear factor kappa-B kinase subunit alpha
-    - id: UniProt:O14920
-      label: Protein
-      name: Inhibitor of nuclear factor kappa-B kinase subunit beta
-    - id: GO:0007249
-      label: BiologicalProcess
-      name: I-kappaB kinase/NF-kappaB signaling
-    - id: REACT:R-HSA-2142691
-      label: Pathway
-      name: Synthesis of Leukotrienes (LT) and Eoxins (EX)
-    - id: REACT:R-HSA-2162123
-      label: Pathway
-      name: Synthesis of Prostaglandins (PG) and Thromboxanes (TX)
-    - id: REACT:R-HSA-1169091
-      label: Pathway
-      name: Activation of NF-kappaB in B cells
-    - id: GO:0006954
-      label: BiologicalProcess
-      name: inflammatory response
-    - id: UBERON:0001052
-      label: GrossAnatomicalStructure
-      name: rectum
-    - id: UBERON:0001155
-      label: GrossAnatomicalStructure
-      name: colon
-    - id: MESH:D003093
-      label: Disease
-      name: Ulcerative colitis
-  reference:
-    - https://go.drugbank.com/drugs/DB01014#mechanism-of-action
-    - https://go.drugbank.com/drugs/DB00244#mechanism-of-action
-    - https://pubmed.ncbi.nlm.nih.gov/20151072/
-    - https://go.drugbank.com/drugs/DB00244#BE0004655
-    - https://en.wikipedia.org/wiki/CHUK#Clinical_significance
-    - https://en.wikipedia.org/wiki/IKK2#Clinical_significance
-  comment: Balsalazide is a prodrug and it releases mesalazine in the large intestine, the active site of ulcerative colitis (https://en.wikipedia.org/wiki/Balsalazide https://en.wikipedia.org/wiki/Mesalazine#Chemistry).
-- directed: true
-  graph:
-    _id: DB00619_MESH_D015466_1
-    disease: Chronic phase chronic myeloid leukemia
-    disease_mesh: MESH:D015466
-    drug: imatinib
-    drug_mesh: MESH:D000068877
-    drugbank: DB:DB00619
-  links:
-    - key: decreases activity of
-      source: MESH:D000068877
-      target: MESH:D016044
-    - key: positively regulates
-      source: MESH:D016044
-      target: GO:0004674
-    - key: positively correlated with
-      source: GO:0004674
-      target: GO:0007266
-    - key: positively correlated with
-      source: GO:0007266
-      target: GO:0008283
-    - key: negatively correlated with
-      source: GO:0007266
-      target: GO:0006915
-    - key: positively correlated with
-      source: GO:0008283
-      target: MESH:D015466
-    - key: negatively correlated with
-      source: GO:0006915
-      target: MESH:D015466
-  multigraph: true
-  nodes:
-    - id: MESH:D000068877
-      label: Drug
-      name: imatinib
-    - id: MESH:D016044
-      label: Protein
-      name: Fusion Proteins, bcr-abl
-    - id: GO:0004674
-      label: MolecularActivity
-      name: protein serine/threonine kinase activity
-    - id: GO:0007266
-      label: BiologicalProcess
-      name: Rho protein signal transduction
-    - id: GO:0008283
-      label: BiologicalProcess
-      name: cell population proliferation
-    - id: GO:0006915
-      label: BiologicalProcess
-      name: apoptotic process
-    - id: MESH:D015466
-      label: Disease
-      name: Chronic phase chronic myeloid leukemia
-  reference:
-    - https://www.cancer.gov/publications/dictionaries/cancer-drug/def/imatinib-mesylate
-    - https://go.drugbank.com/drugs/DB00619#mechanism-of-action
-    - https://en.wikipedia.org/wiki/Imatinib#Chronic_myelogenous_leukemia
-  comment: Imatinib also modulates other protein targets and is an indication for other malignancies (https://en.wikipedia.org/wiki/Imatinib#Medical_uses).
-- directed: true
-  graph:
-    _id: DB00619_MESH_C580364_1
-    disease: Pdgfra-Associated Chronic Eosinophilic Leukemia
-    disease_mesh: MESH:C580364
-    drug: imatinib
-    drug_mesh: MESH:D000068877
-    drugbank: DB:DB00619
-  links:
-    - key: decreases activity of
-      source: MESH:D000068877
-      target: UniProt:P16234
-    - key: positively regulates
-      source: UniProt:P16234
-      target: GO:0048008
-    - key: positively correlated with
-      source: GO:0048008
-      target: GO:0008283
-    - key: positively correlated with
-      source: GO:0008283
-      target: HP:0001880
-    - key: manifestation of
-      source: HP:0001880
-      target: MESH:C580364
-  multigraph: true
-  nodes:
-    - id: MESH:D000068877
-      label: Drug
-      name: imatinib
-    - id: UniProt:P16234
-      label: Protein
-      name: Platelet-derived growth factor receptor alpha
-    - id: GO:0048008
-      label: BiologicalProcess
-      name: platelet-derived growth factor receptor signaling pathway
-    - id: GO:0008283
-      label: BiologicalProcess
-      name: cell population proliferation
-    - id: HP:0001880
-      label: PhenotypicFeature
-      name: Eosinophilia
-    - id: MESH:C580364
-      label: Disease
-      name: Pdgfra-Associated Chronic Eosinophilic Leukemia
-  reference:
-    - https://www.cancer.gov/publications/dictionaries/cancer-drug/def/imatinib-mesylate
-    - https://go.drugbank.com/drugs/DB00619#BE0000205
-    - https://go.drugbank.com/drugs/DB00619#BE0000852
-    - https://en.wikipedia.org/wiki/Chronic_eosinophilic_leukemia
-    - https://en.wikipedia.org/wiki/Eosinophilia#Chronic_eosinophilic_leukemia_(NOS)
-    - https://en.wikipedia.org/wiki/Imatinib#Other
-  comment: The disease is also known as Chronic eosinophilic leukemia as per the original file. The malignancy is driven by FIP1L1-PDGFRA fusion genes (https://en.wikipedia.org/wiki/FIP1L1#FIP1L1-PDGFRA_fusion_genes).
-- directed: true
-  graph:
-    _id: DB00619_MESH_D017681_1
-    disease: Hypereosinophilic Syndrome
-    disease_mesh: MESH:D017681
-    drug: imatinib
-    drug_mesh: MESH:D000068877
-    drugbank: DB:DB00619
-  links:
-    - key: decreases activity of
-      source: MESH:D000068877
-      target: UniProt:P16234
-    - key: positively regulates
-      source: UniProt:P16234
-      target: GO:0008283
-    - key: positively correlated with
-      source: GO:0008283
-      target: HP:0001880
-    - key: manifestation of
-      source: HP:0001880
-      target: MESH:D017681
-  multigraph: true
-  nodes:
-    - id: MESH:D000068877
-      label: Drug
-      name: imatinib
-    - id: UniProt:P16234
-      label: Protein
-      name: Platelet-derived growth factor receptor alpha
-    - id: GO:0008283
-      label: BiologicalProcess
-      name: cell population proliferation
-    - id: HP:0001880
-      label: PhenotypicFeature
-      name: Eosinophilia
-    - id: MESH:D017681
-      label: Disease
-      name: Hypereosinophilic Syndrome
-  reference:
-    - https://www.cancer.gov/publications/dictionaries/cancer-drug/def/imatinib-mesylate
-    - https://go.drugbank.com/drugs/DB00619#BE0000205
-    - https://go.drugbank.com/drugs/DB00619#BE0000852
-    - https://en.wikipedia.org/wiki/Imatinib#Other
-  comment: The disease is also known as Idiopathic hypereosinophilic syndrome as per the original file. Treatment with imatinib is indicated for patients who have a PDGFRA-FIP1L1 chimera, where PDGR, a tyrosine kinase (https://en.wikipedia.org/wiki/Hypereosinophilic_syndrome#Diagnosis) and an oncogene (https://en.wikipedia.org/wiki/Oncogene#Classification) is fused with FIP1L1, giving rise to a PDGFRA-FIP1L1 chimera.
-- directed: true
-  graph:
-    _id: DB00619_MESH_D046152_1
-    disease: Gastrointestinal stromal tumor
-    disease_mesh: MESH:D046152
-    drug: imatinib
-    drug_mesh: MESH:D000068877
-    drugbank: DB:DB00619
-  links:
-    - key: decreases activity of
-      source: MESH:D000068877
-      target: UniProt:P10721
-    - key: decreases activity of
-      source: MESH:D000068877
-      target: UniProt:P16234
-    - key: positively regulates
-      source: UniProt:P16234
-      target: GO:0035790
-    - key: positively correlated with
-      source: GO:0035790
-      target: GO:0008283
-    - key: positively correlated with
-      source: GO:0035790
-      target: MESH:D002470
-    - key: positively regulates
-      source: UniProt:P10721
-      target: GO:0038109
-    - key: positively correlated with
-      source: GO:0038109
-      target: GO:0008283
-    - key: positively correlated with
-      source: GO:0038109
-      target: MESH:D002470
-    - key: positively correlated with
-      source: GO:0038109
-      target: GO:0030154
-    - key: positively correlated with
-      source: GO:0008283
-      target: MESH:D046152
-    - key: positively correlated with
-      source: MESH:D002470
-      target: MESH:D046152
-    - key: positively correlated with
-      source: GO:0030154
-      target: MESH:D046152
-  multigraph: true
-  nodes:
-    - id: MESH:D000068877
-      label: Drug
-      name: imatinib
-    - id: UniProt:P10721
-      label: Protein
-      name: Mast/stem cell growth factor receptor Kit
-    - id: UniProt:P16234
-      label: Protein
-      name: Platelet-derived growth factor receptor alpha
-    - id: GO:0035790
-      label: BiologicalProcess
-      name: platelet-derived growth factor receptor-alpha signaling pathway
-    - id: GO:0038109
-      label: BiologicalProcess
-      name: Kit signaling pathway
-    - id: GO:0030154
-      label: BiologicalProcess
-      name: cell differentiation
-    - id: GO:0008283
-      label: BiologicalProcess
-      name: cell population proliferation
-    - id: MESH:D002470
-      label: BiologicalProcess
-      name: Cell Survival
-    - id: MESH:D046152
-      label: Disease
-      name: Gastrointestinal stromal tumor
-  reference:
-    - https://www.cancer.gov/publications/dictionaries/cancer-drug/def/imatinib-mesylate
-    - https://en.wikipedia.org/wiki/Imatinib#Gastrointestinal_stromal_tumors
-    - https://go.drugbank.com/drugs/DB00619#BE0000453
-    - https://go.drugbank.com/drugs/DB00619#BE0000852
-  comment: The majority of Gastrointestinal stromal tumor patients have mutations on the KIT or PDGFRA genes (95% of all patients).
-- directed: true
-  graph:
-    _id: DB00619_MESH_D018223_1
-    disease: Dermatofibrosarcoma
-    disease_mesh: MESH:D018223
-    drug: imatinib
-    drug_mesh: MESH:D000068877
-    drugbank: DB:DB00619
-  links:
-    - key: decreases activity of
-      source: MESH:D000068877
-      target: UniProt:P16234
-    - key: positively regulates
-      source: UniProt:P16234
-      target: GO:0030154
-    - key: positively regulates
-      source: UniProt:P16234
-      target: GO:0008283
-    - key: positively regulates
-      source: UniProt:P16234
-      target: MESH:D002470
-    - key: positively correlated with
-      source: GO:0008283
-      target: MESH:D018223
-    - key: positively correlated with
-      source: MESH:D002470
-      target: MESH:D018223
-    - key: positively correlated with
-      source: GO:0030154
-      target: MESH:D018223
-  multigraph: true
-  nodes:
-    - id: MESH:D000068877
-      label: Drug
-      name: imatinib
-    - id: UniProt:P16234
-      label: Protein
-      name: Platelet-derived growth factor receptor alpha
-    - id: GO:0030154
-      label: BiologicalProcess
-      name: cell differentiation
-    - id: GO:0008283
-      label: BiologicalProcess
-      name: cell population proliferation
-    - id: MESH:D002470
-      label: BiologicalProcess
-      name: Cell Survival
-    - id: MESH:D018223
-      label: Disease
-      name: Dermatofibrosarcoma
-  reference:
-    - https://www.cancer.gov/publications/dictionaries/cancer-drug/def/imatinib-mesylate
-    - https://en.wikipedia.org/wiki/Dermatofibrosarcoma_protuberans#Pathophysiology
-    - https://en.wikipedia.org/wiki/Imatinib#Dermatofibrosarcoma_protuberans_(DFSP)
-  comment: The majority of dermatofibrosarcoma tumours have two genes fused due to a translocation involving the collagen gene (COL1A1) and the platelet-derived growth factor (PDGF). The latter can be further subdivided giving rise to PDGFA, for example, which is an oncogene.
-- directed: true
-  graph:
-    _id: DB00661_MESH_D000788_1
-    disease: Angina Pectoris, Variant
-    disease_mesh: MESH:D000788
-    drug: verapamil
-    drug_mesh: MESH:D014700
-    drugbank: DB:DB00661
-  links:
-    - key: decreases activity of
-      source: MESH:D014700
-      target: UniProt:Q13936
-    - key: positively regulates
-      source: UniProt:Q13936
-      target: GO:0060402
-    - key: positively correlated with
-      source: GO:0060402
-      target: GO:0042310
-    - key: positively correlated with
-      source: GO:0042310
-      target: HP:0033401
-    - key: manifestation of
-      source: HP:0033401
-      target: MESH:D000788
-  multigraph: true
-  nodes:
-    - id: MESH:D014700
-      label: Drug
-      name: verapamil
-    - id: UniProt:Q13936
-      label: Protein
-      name: Voltage-dependent L-type calcium channel subunit alpha-1C
-    - id: GO:0060402
-      label: BiologicalProcess
-      name: calcium ion transport into cytosol
-    - id: GO:0042310
-      label: BiologicalProcess
-      name: vasoconstriction
-    - id: HP:0033401
-      label: PhenotypicFeature
-      name: Tissue ischemia
-    - id: MESH:D000788
-      label: Disease
-      name: Angina Pectoris, Variant
-  reference:
-    - https://go.drugbank.com/drugs/DB00661#mechanism-of-action
-    - https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL6966/
-    - https://en.wikipedia.org/wiki/Verapamil#Mechanism_of_action
-    - https://en.wikipedia.org/wiki/Antiarrhythmic_agent#Class_IV_agents
-    - https://en.wikipedia.org/wiki/Variant_angina#Maintenance
-  comment: The disease is also known as Prinzmetal angina as per the original file.
-- directed: true
-  graph:
-    _id: DB00661_MESH_D006973_1
-    disease: Hypertensive disorder
-    disease_mesh: MESH:D006973
-    drug: verapamil
-    drug_mesh: MESH:D014700
-    drugbank: DB:DB00661
-  links:
-    - key: decreases activity of
-      source: MESH:D014700
-      target: UniProt:Q13936
-    - key: positively regulates
-      source: UniProt:Q13936
-      target: GO:0060402
-    - key: positively correlated with
-      source: GO:0060402
-      target: GO:0042310
-    - key: positively correlated with
-      source: GO:0042310
-      target: HP:0033533
-    - key: affects risk for
-      source: HP:0033533
-      target: HP:0032263
-    - key: manifestation of
-      source: HP:0032263
-      target: MESH:D006973
-  multigraph: true
-  nodes:
-    - id: MESH:D014700
-      label: Drug
-      name: verapamil
-    - id: UniProt:Q13936
-      label: Protein
-      name: Voltage-dependent L-type calcium channel subunit alpha-1C
-    - id: GO:0060402
-      label: BiologicalProcess
-      name: calcium ion transport into cytosol
-    - id: GO:0042310
-      label: BiologicalProcess
-      name: vasoconstriction
-    - id: HP:0033533
-      label: PhenotypicFeature
-      name: Increased cardiac output
-    - id: HP:0032263
-      label: PhenotypicFeature
-      name: Increased blood pressure
-    - id: MESH:D006973
-      label: Disease
-      name: Hypertensive disorder
-  reference:
-    - https://go.drugbank.com/drugs/DB00661#mechanism-of-action
-    - https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL6966/
-    - https://en.wikipedia.org/wiki/Verapamil#Mechanism_of_action
-    - https://en.wikipedia.org/wiki/Antiarrhythmic_agent#Class_IV_agents
-- directed: true
-  graph:
-    _id: DB00661_MESH_D001281_1
-    disease: Atrial fibrillation
-    disease_mesh: MESH:D001281
-    drug: verapamil
-    drug_mesh: MESH:D014700
-    drugbank: DB:DB00661
-  links:
-    - key: decreases activity of
-      source: MESH:D014700
-      target: UniProt:Q13936
-    - key: positively regulates
-      source: UniProt:Q13936
-      target: GO:0061337
-    - key: positively correlated with
-      source: GO:0061337
-      target: GO:0060047
-    - key: positively correlated with
-      source: GO:0060047
-      target: HP:0001692
-    - key: manifestation of
-      source: HP:0001692
-      target: MESH:D001281
-  multigraph: true
-  nodes:
-    - id: MESH:D014700
-      label: Drug
-      name: verapamil
-    - id: UniProt:Q13936
-      label: Protein
-      name: Voltage-dependent L-type calcium channel subunit alpha-1C
-    - id: GO:0061337
-      label: BiologicalProcess
-      name: cardiac conduction
-    - id: GO:0060047
-      label: BiologicalProcess
-      name: heart contraction
-    - id: HP:0001692
-      label: PhenotypicFeature
-      name: Atrial arrhythmia
-    - id: MESH:D001281
-      label: Disease
-      name: Atrial fibrillation
-  reference:
-    - https://go.drugbank.com/drugs/DB00661#mechanism-of-action
-    - https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL6966/
-    - https://en.wikipedia.org/wiki/Verapamil#Mechanism_of_action
-    - https://en.wikipedia.org/wiki/Antiarrhythmic_agent#Class_IV_agents
-    - https://en.wikipedia.org/wiki/Atrial_fibrillation#Rate_control
-- directed: true
-  graph:
-    _id: DB00661_MESH_D054058_1
-    disease: Acute coronary syndrome
-    disease_mesh: MESH:D054058
-    drug: verapamil
-    drug_mesh: MESH:D014700
-    drugbank: DB:DB00661
-  links:
-    - key: decreases activity of
-      source: MESH:D014700
-      target: UniProt:Q13936
-    - key: positively regulates
-      source: UniProt:Q13936
-      target: GO:0060402
-    - key: positively correlated with
-      source: GO:0060402
-      target: GO:0042310
-    - key: positively correlated with
-      source: GO:0042310
-      target: HP:0033401
-    - key: manifestation of
-      source: HP:0033401
-      target: MESH:D054058
-  multigraph: true
-  nodes:
-    - id: MESH:D014700
-      label: Drug
-      name: verapamil
-    - id: UniProt:Q13936
-      label: Protein
-      name: Voltage-dependent L-type calcium channel subunit alpha-1C
-    - id: GO:0060402
-      label: BiologicalProcess
-      name: calcium ion transport into cytosol
-    - id: GO:0042310
-      label: BiologicalProcess
-      name: vasoconstriction
-    - id: HP:0033401
-      label: PhenotypicFeature
-      name: Tissue ischemia
-    - id: MESH:D054058
-      label: Disease
-      name: Acute coronary syndrome
-  reference:
-    - https://go.drugbank.com/drugs/DB00661#mechanism-of-action
-    - https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL6966/
-    - https://en.wikipedia.org/wiki/Verapamil#Mechanism_of_action
-    - https://en.wikipedia.org/wiki/Antiarrhythmic_agent#Class_IV_agents
-- directed: true
-  graph:
-    _id: DB00661_MESH_D000787_1
-    disease: Angina pectoris
-    disease_mesh: MESH:D000787
-    drug: verapamil
-    drug_mesh: MESH:D014700
-    drugbank: DB:DB00661
-  links:
-    - key: decreases activity of
-      source: MESH:D014700
-      target: UniProt:Q13936
-    - key: positively regulates
-      source: UniProt:Q13936
-      target: GO:0060402
-    - key: positively correlated with
-      source: GO:0060402
-      target: GO:0042310
-    - key: positively correlated with
-      source: GO:0042310
-      target: HP:0033401
-    - key: manifestation of
-      source: HP:0033401
-      target: MESH:D000787
-  multigraph: true
-  nodes:
-    - id: MESH:D014700
-      label: Drug
-      name: verapamil
-    - id: UniProt:Q13936
-      label: Protein
-      name: Voltage-dependent L-type calcium channel subunit alpha-1C
-    - id: GO:0060402
-      label: BiologicalProcess
-      name: calcium ion transport into cytosol
-    - id: GO:0042310
-      label: BiologicalProcess
-      name: vasoconstriction
-    - id: HP:0033401
-      label: PhenotypicFeature
-      name: Tissue ischemia
-    - id: MESH:D000787
-      label: Disease
-      name: Angina pectoris
-  reference:
-    - https://go.drugbank.com/drugs/DB00661#mechanism-of-action
-    - https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL6966/
-    - https://en.wikipedia.org/wiki/Verapamil#Mechanism_of_action
-    - https://en.wikipedia.org/wiki/Antiarrhythmic_agent#Class_IV_agents
-    - https://en.wikipedia.org/wiki/Angina#Treatment